Functional and Structural Characterization of Mesolimbic and Nigrostriatal Networks in Adult ADHD: Identifying Pathological Effects and Therapeutic Targets

Arjun Sethi

Thesis submitted to Brighton & Sussex Medical School

for the degree of Doctorate of Philosophy

June 2016

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) has been widely associated with abnormalities within the dopamine system. However, the nature of these changes, and how they are targeted by medication is unclear. For instance, though childhood ADHD is robustly associated with abnormal striatal morphology in voxel-based morphometry (VBM) studies, these changes are not necessarily observed in adulthood, which has been argued to reflect normalisation with treatment and maturation. However, findings for this hypothesis are inconsistent. Moreover, although dopaminergic signalling driven by the substantia nigra/ventral tegmental area (SN/VTA) is central to most theoretical accounts of ADHD, little research has examined how this structure and its subcomponents contribute to the disorder. Finally, although mesolimbic dopamine system abnormalities have been linked to altered reinforcement learning in ADHD, the mechanisms underpinning this are unclear. Recent advancements in MR and computational methodologies are well positioned to resolve these questions. This thesis employs several such methodological advancements to clarify the role of mesolimbic and nigrostriatal systems in ADHD. Firstly, I show that by using magnetisation transfer (MT) saturation maps optimised for subcortical contrast, striatal volumetric reductions are observed in VBM analyses of adults with ADHD. Moreover, I show that T1-weighted volumes used in previous studies are insensitive to these differences, and that prior assessments may have been confounded by other factors such as altered brain iron concentration. The second line of investigation uses diffusion MRI parcellation methods to provide the first microstructural assessment of SN/VTA subcomponents in ADHD, revealing distinct functional contributions. Specifically, microstructural differences in the nigrostriatal and mesolimbic SN/VTA appear to respectively underpin trait motivation and waiting impulsivity, and also appear to be differentially targeted by long term medication. The final study uses a temporal difference (TD) model to isolate computational parameters of reinforcement learning altered in ADHD. In doing so, this reveals impaired reward learning in ADHD that is ameliorated by stimulant medication, and several mechanisms underpinning this. Namely, stimulant medication appears to improve learning rates and reduce aberrant novelty processing within the SN/VTA in a manner specific to ADHD. Collectively these findings indicate the ongoing relevance of mesolimbic and nigrostriatal systems in adult ADHD. Moreover, this work shows that appropriate application of novel methodologies has the potential to answer previously unresolved questions in the literature, as well as offering a finer-grained understanding of how these systems contribute to the disorder.

Contents

Acronyms and Definitions

ADHD – Attention Deficit Hyperactivity Disorder

BDI – Becks Depression Inventory

CAARS – Connor's Adult ADHD Rating Scales

DAT – Dopamine transporter

FSIQ – Full scale intelligence quotient

MPQ – Multidimensional Personality Questionnaire

NAT – Noradrenaline transporter

NART – National Adult Reading Test

SN – Substantia nigra

SNpc – Substantia nigra pars compacta

SNpr – Substantia nigra pars reticulata

TD – Temporal Difference

TPQ - Tridimensional Personality Questionnaire

VTA – Ventral tegmental area

Acknowledgements

Massive love and thanks to all the patients and volunteers who took part in the study. Getting to know all of you was an absolute pleasure. Thank you to the radiographers of CISC, past and present. You kept me going through the dark mornings, button-box failures, and quenches. Thank you Mara. You've taught me so much there aren't enough words on a page to express my gratitude. You've been endlessly compassionate and inspiring, and reassured me that science can be light-hearted, friendly and apolitical. Neil, thank you for always pushing me to explore more, teaching me how to survive in academia, and showing me that sometimes it's just better to buy a new sofa-bed rather than trying to haul one down from London. Thank you Ella and Pat for being the bright smile that I've needed after a long commute. Kate, thank you for keeping me going through all of this. Sharing the excitement, anxieties and panics of research with you has meant so much. Finally, thank you to my Mum and Dad, and the rest of my family that extends far beyond conventional borders. Without your love and support I'm not sure how I would've survived this world. I would be nothing without you.

Declaration

I declare that the research contained in this thesis, unless otherwise formally indicated within the text, is the original work of the author. The thesis has not been previously submitted to this or any other university for a degree, and does not incorporate any material already submitted for a degree.

Signed:

Dated: 05/06/2016

1 Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is diagnostically categorised according to the presence of inattentive, hyperactive and impulsive symptom domains, and is the most common neurodevelopmental disorder, with an estimated prevalence of approximately 5% (Polanczyk et al. 2007). These symptoms persist into adulthood fully in around 15% of cases, and partially in 65% (Faraone et al. 2006), with a suggested prevalence of around 2.5% of the adult population (Simon et al. 2009). This persistence of symptoms can have highly deleterious consequences to both the individual and society, being associated with reduced employment, difficulty in interpersonal relationships, increased drug use, serious transport accidents and incarceration (Harpin 2005; Rösler et al. 2004; Chang et al. 2014). As acknowledgement of these issues, research into the neurobiology of ADHD in adulthood has been gaining momentum.

ADHD has largely been considered to be a disorder of the brain dopamine system. Whilst this was initially inferred from the efficacy of dopamine enhancing psychostimulants in the disorder, a wealth of genetic (Gizer et al. 2009; Franke et al. 2012) and molecular imaging studies (Volkow et al. 2007; Volkow et al. 2009; Volkow et al. 2012; Fusar-Poli et al. 2012; Volkow et al. 2011; Badgaiyan et al. 2015) now support this hypothesis. In spite of this, the precise nature of anatomical and functional abnormalities within the dopamine system, and how they are targeted by medication, remains unclear. Even some of the most widely reported findings in childhood such as differences in striatal morphology are poorly replicated in adulthood (Frodl & Skokauskas 2012; Nakao et al. 2011). This has led to suggestions that these anatomical abnormalities remit with development, even when symptoms persist. The question of whether these persistent cases reflect a dopaminergic deficit, or have some other neurobiological basis is unclear (del Campo et al. 2013).

Similarly, whilst there has been extensive work examining the morphology of networks modulated by dopaminergic signalling in ADHD, little is known of the role of the substantia nigra/ventral tegmental area (SN/VTA) which is at the heart of dopaminergic modulatory function. Though work has examined how reward networks are functionally altered in ADHD, the mechanisms underlying abnormal reward function, and its rescue by medication, is relatively poorly understood.

With the development of novel imaging methodologies and computational theories of dopaminergic function, identifying precise pathological and therapeutic targets of the brain dopamine system has become increasingly possible. The purpose of this work is to employ these advancements to resolve certain outstanding questions about the neurobiology and treatment of ADHD. This introductory segment will describe the neuroanatomical and functional context of these questions. Following this, three experimental chapters will introduce these problems and approaches in greater detail. In brief, these chapters will address:

i. The inadequacy of current imaging methods for visualising subcortical structures, and how updating these methodologies may shed light on previous conflicting reports about striatal abnormalities in ADHD

ii. How different subcomponents of the SN/VTA contribute to reward phenotypes observed in ADHD, namely reduced incentive motivation and increased waiting impulsivity, and how these subcomponents are altered by long term medication use

iii. How changes in computational mechanisms result in altered reward learning in ADHD, with a focus on stimulus novelty. This chapter will model these computational parameters against behaviour and functional imaging data, and assess how they are affected by acute treatment with stimulant medication

1.1   ADHD: Background

1.1.1   Diagnosis

ADHD is diagnosed according to the presence of clinically significant inattentive and/or hyperactive and impulsive symptom clusters that are observed in two or more settings (American Psychiatric Association 2013). ADHD is presently subcategorised into inattentive, hyperactive/impulsive and combined presentations (or 'subtypes', in DSM IV nomenclature) according to the presence of 6 or more symptoms of each respective domain (Table 1.1) in childhood, and 5 or more in adulthood. In response to a growing need to understand and treat the persistence of these symptoms in adulthood (Ginsberg et al. 2014), various changes from the DSM IV criteria have been adopted. In particular, reduced symptom count requirements in adults reflect the tendency for symptoms, particularly within hyperactive/impulsive domains, to reduce with age

(Biederman et al. 2000). The required presence of symptoms only before the age of 12 (rather than 7) also serves as a marked shift in recognising the prevalence of later onsets of the disorder. Additionally, the necessity for 'clinically significant impairment' in two or more settings has shifted to a requirement that symptoms 'interfere' with function and are 'present' in two more setting. Both DSM IV and V require that symptoms not be present exclusively during the course of schizophrenia or other psychotic disorder, or are not better explained by another disorder. The DSM V criteria removes the requirement that symptoms do not arise during another pervasive developmental disorder, allowing for joint diagnoses of ADHD and Autism Spectrum Disorders (ASD) that would not previously been permitted. Finally, the DSM V encourages more specific sub-threshold diagnoses in cases where full criteria are not met, but clinically significant impairments that warrant diagnoses and treatment are observed. In particular, the introduction of light, moderate and severe symptom ratings are intended to be used to descriptively supplement a diagnosis of 'Other specified ADHD'.

Table 1.1 DSM V criteria for inattentive and hyperactive impulsive presentations

Inattentive presentation	Hyperactive/Impulsive presentation
Fails to give close attention to details or makes careless mistakes	Fidgets with hands or feet or squirms in chair
Has difficulty sustaining attention	Has difficulty remaining seated
Does not appear to listen	Runs about or climbs excessively in children; extreme restlessness in adults
Struggles to follow through on instructions	Difficulty in engaging in activities quietly
Has difficulty with organisation	Acts as if driven by a motor; adults will often feel inside like they were driven by a motor
Avoids or dislikes tasks requiring a lot of thinking	Talks excessively
Loses things	Blurts out answers before questions have been completed
Is easily distracted	Difficulty waiting or taking turns
Is forgetful in daily activities	Interrupts or intrudes upon others

1.1.2 Persistence of ADHD into adulthood

ADHD is thought to affect around 5% of children (Polanczyk et al. 2007) and in both childhood and adulthood appears to disproportionately affect the male population (Willcutt 2012). In spite of popular assertions that the disorder is a westernised social construct, ADHD prevalence is equivalent across cultures (Faraone et al. 2003; Polanczyk et al. 2007), with variance in this likely explained by different diagnostic methodologies (Polanczyk et al. 2007). In particular, failure to apply the requirement of functional impairment in two settings can greatly alter diagnoses, which is highly problematic in studies using self-report diagnostic methods.

The persistence of ADHD into adulthood appears to show far greater variation than childhood (Simon et al. 2009). Follow-up studies, for example, appear to suggest a range of 4-66% cases persisting into adulthood. As in childhood studies this appears to reflect differences in diagnostic methodologies, with the increased reliance on self-report measures in adulthood likely explaining the greater variance in prevalence reported (Simon et al. 2009). This problem is compounded, however, by a tendency to treat ADHD symptoms as secondary to other comorbidities in adulthood (Ginsberg et al. 2014; Fayyad et al. 2007). As ADHD symptoms alter with maturation, they may be more subtle and less readily detected using previous DSM IV criteria (Kooij et al. 2010). For instance, whilst motor hyperactivity may wane in the disorder (Biederman et al. 2000), hyperactive symptoms can manifest in adults as feelings of inner or mental restlessness (Weyandt et al. 2003). Problematically, whilst adult ADHD most commonly takes the form of the predominantly inattentive subtype, those with combined subtype are significantly more likely to be referred to clinical services population (Willcutt 2012). Time will be required to determine whether changes in the DSM V aimed at assisting ADHD diagnosis in adulthood will reduce this variance.

1.1.3 Genetics of ADHD

Family and twin studies of childhood ADHD report a heritability of around 70-80% (Faraone et al. 2005). Heritability studies in adulthoods had initially suggested a lower heritability (~30-40%), although this too likely reflects an increased reliance on self-report measures (Franke et al. 2012). More recent evidence using psychiatric diagnoses (using the ICD-10, rather than DSM) has shown a heritability of around 88%

across the lifespan (Larsson et al. 2014). Most studies examining genetic contributions to ADHD have focussed on dopamine system encoding genes, of which the dopamine receptor DRD4 and DRD5, and dopamine transporter (DAT) encoding genes, are highly implicated (Gizer et al. 2009; Franke et al. 2012; Hawi et al. 2015). So far several studies have investigated the relationship between DRD4 and DAT polymorphisms and brain structural and function. For instance, studies have showed that DRD4 polymorphisms associated with ADHD are linked to thinning of the right orbitofrontal/inferior prefrontal and posterior parietal cortex (Shaw et al. 2007), dorsolateral prefrontal and cerebellar cortex (Monuteaux et al. 2008), and prefrontal cortex (Durston et al. 2005), whilst DAT1 polymorphisms associated with ADHD have been linked to the volume of the caudate nucleus (Durston et al. 2005). Functional imaging tasks have also shown highlighted links between activation of the striatum during response inhibition, DAT1 genotype and familial expression of ADHD (Durston et al. 2008; Bédard et al. 2010). Overall, both DAT1 and DRD4 polymorphisms have been linked to neuroanatomical and functional changes associated with ADHD (with the bulk of studies focussing on these genes (Durston 2010)).

Other genes that share prominent interactions with the dopamine system have also been implicated. For instance, nitric oxide synthase (NOS1) polymorphisms (Hoogman et al. 2011; Hawi et al. 2015) have been detected which may alter the inhibitory role of nitric oxide at the dopamine transporter (Kiss et al. 2004). Similarly, LPHN3 (a latrophilin family G protein coupled receptor gene) polymorporphisms are associated with ADHD (Franke et al. 2012; Hawi et al. 2015), and result in abnormal dopamine neuron development and ADHD like behaviours in animal models (Lange et al. 2012). Synaptosomal associated protein-25 (SNAP-25), serotonin system, and noradrenaline system encoding genes have also been strongly implicated in candidate gene studies (Hawi et al. 2015).

Such individual genetic contributions to ADHD do however appear to be of modest size, and genome wide association studies (GWAS) have had limited success in identifying candidate genes at stringent thresholds (Hawi et al. 2015). The genetic heterogeneity in ADHD has, as in most psychiatric disorders, limited inference as to any shared dysfunctional molecular pathways. More recent network analyses may help resolve these questions and point to how alterations to different genes of small effect can contribute to the same dysfunctional pathway. This involves using network analyses of genes previously associated with psychiatric disorders to model the functional domains in which they commonly interact. The functional molecular

pathways or 'modules' that are impacted in disorders can therefore be directly assessed, rather than focussing on the contribution of a single gene that may contribute to multiple such pathways. This has the benefit of examining how the range of genes of small effect that are associated with a disorder may individually and cumulatively contribute to a similar phenotype, whilst also accepting the heterogeneity of individual polymorphisms associated with psychiatric diagnoses. Such network analyses in ADHD have, for instance, implicated genes contributing to synaptic transmission, catecholamine metabolism, G-protein signalling pathways and cell migration in ADHD (Cristino et al. 2014). However, whilst the study of psychiatric genetics has moved towards these more complex approaches these have yet to be tested in terms of their effect on functional neuroanatomy. Future studies will be required to determine how such pathway models are linked to imaging data as a priori candidate genes have been (Durston 2010).

1.1.4   Stimulant medication in ADHD

Current first line treatment of ADHD consists of either methylphenidate or various formulations of amphetamine. Within the different formulations of amphetamine, in the UK, the dextrorotatory enantiomer D-amphetamine is typically used due to its increased potency in eliciting dopamine release and blocking its reuptake (Patrick & Markowitz 1997), as well as showing greater levels of symptom improvement when compared to L-amphetamine or racemic mixtures (Arnold et al. 1972; Gross 1976). Racemic and other mixed (typically 75% D-amphetamine, 25% L-amphetamine) are also used, however. More recently, the inactive prodrug lisdexamphetamine has also been used, which is converted to D-amphetamine in a manner that is rate limited by enzymatic cleavage of L-lysine over the course of approximately 12 hours (Blick & Keating 2007).

Methylphenidate acts primarily as a dopamine transport (DAT) reuptake inhibitor with some inhibitory actions at noradrenergic reuptake (NAT) sites (Wall et al. 1995). Amphetamine's primary actions appear to be competitive and non-competitive DAT uptake inhibition, and releasing vesicular dopamine into the cytosol whilst also promoting DAT mediated reverse transport of this dopamine into the synaptic cleft (Fleckenstein et al. 2007). Whilst both drugs also have some affinity for other dopaminergic, noradrenergic and serotonergic sites, their primary therapeutic

mechanism of action is considered to be increasing dopamine concentration in the synaptic cleft (Seeman & Madras 1998). Indeed, the dopamine increasing properties of both amphetamine and methylphenidate are orders of magnitude greater than their effects on noradrenaline and serotonin (Kuczenski & Segal 1997; Easton et al. 2007). At the low doses that are typically used to treat ADHD this enhances levels of tonic dopamine but reduces impulse-induced phasic dopamine release relative to tonic levels, ostensibly due to increased D2 receptor mediated inhibition of dopaminergic neurotransmission (Figure 1.1) (Dreyer et al. 2010; Seeman & Madras 1998). Accordingly, increased dopamine binding to D2/D3 receptors induced by methylphenidate has been observed to be predictive of symptom improvement (Volkow et al. 2012).

The half-life of methylphenidate is 2-3 hours, with peak plasma time achieved in around 2 hours. The duration of peak action is around 2-4 hours for instant release, 3-8 for sustained, and 8-12 for extended release methylphenidate (Kimko et al. 1999). The half-life of D-amphetamine is around 9-11 hours, with peak plasma levels occurring at 3 hours (United States Food and Drug Administration 2013).

Figure 1.1 Effects of stimulant medication on synaptic dopamine.
Reproduced from (Seeman & Madras 1998).

By blocking DAT reuptake of dopamine (1), Stimulant medication
increases synaptic tonic dopamine levels (C) relative to normal (A)
conditions. Presynaptic inhibitory D2 receptors (2) are preferentially
activated by this stimulant-induced increase in tonic dopamine levels,
reducing phasic (3) dopamine release in response to stimulation (D)
when compared to unmedicated conditions (B).

1.2   Neurobiology of ADHD

1.2.1   ADHD as a disorder of the dopamine system

Brain dopamine plays a central regulatory role in a range of functions that extend from the goal-directed motor functions for which it was initially ascribed, to the emotional, motivational and cognitive processes that drive them. Despite this large functional repertoire, dopaminergic cells make up only around 590,000 neurons in the brain (Chinta & Andersen 2005), approximately 90% of which are located within the dopaminergic midbrain, or SN/VTA. These neurons control motor, cognitive and motivational functions through extensive projections that terminate within the striatum, but also other subcortical regions such as the amygdala and hippocampus, and the cortex. These midbrain projection systems have typically been subdivided into mesolimbic projections terminating in the ventral striatum (as well as amygdala and hippocampus), nigrostriatal projections terminating in the dorsal striatum, and a mesocortical projection system that sends diffuse projections the cerebral cortex. Finally, a tubero-infundibular system projects from the tuberal hypothalamus to the pituitary gland (Figure 1.2).

Figure 1.2 Dopamine projection systems depicting mesolimbic, mesocortical, nigrostriatal and tubero-infundibular pathways.

Various lines of evidence have suggested the importance of dopaminergic dysfunction in ADHD. In particular, molecular imaging studies have consistently highlighted the importance of reduced D2/D3 receptor and dopamine transporter (DAT) binding potentials in the disorder (Volkow et al. 2009). Such studies have shown convergence with genetic evidence, where polymorphisms in DAT1, DRD4, and DRD5 have been fairly consistently detected in ADHD samples (Gizer et al. 2009). The most commonly identified locus of these molecular abnormalities has been within the striatum (Volkow et al. 2007; Volkow et al. 2009; Volkow et al. 2011; Volkow et al. 2012; Badgaiyan et al. 2015), and additionally the SN/VTA (Volkow et al. 2011; del Campo et al. 2013) and its connected limbic regions (Volkow et al. 2007). Importantly, such abnormalities in dopaminergic neurotransmission appear to be associated with both inattentive (Volkow et al. 2007; Volkow et al. 2009) and hyperactive/impulsive symptoms (Rosa Neto et al. 2002).

1.2.1.1 The nature of dopamine deficits in ADHD

The precise nature of dopaminergic abnormalities within ADHD have however been widely debated. Most broadly, ADHD has been considered to be a disorder characterised by low levels of brain dopamine (Volkow et al. 2005). However, others have suggested a more nuanced account.

For instance, the dynamic development theory DDT posits that low levels of tonic dopamine specifically explain key observations within ADHD, such as a steeper delay-of-reinforcement gradients (i.e. increased temporal discounting, described below), and slower extinction effects in reinforcement (Sagvolden et al. 2005). The dopamine transfer deficit (DTD) theory alternatively focusses on altered anticipatory firing to predictors of reward (Tripp & Wickens 2008). During normal learning, phasic dopamine firing is understood to shift from an unexpected reward to the cue signalling that reward. In ADHD, it is suggested that this transfer of phasic reward signalling fails to fully occur. As such the predictor of reward is signalled only partially, whilst the actual reward itself continues to elicit dopamine cell firing which would subside in normal learning. This theory also predicts critical neuropsychological components of ADHD such as increased temporal discounting. Other neurochemical models of dopamine dysfunction in ADHD have focused on the relative contributions of phasic and tonic dopamine (Cherkasova et al. 2014; Badgaiyan et al. 2015). Specifically, it has been suggested that that whilst tonic dopamine is reduced in the disorder, phasic dopamine is actually increased. This may also make sense of prior divergent findings that have

suggested both increased and decreased D2/D3 receptor binding potentials in ADHD (Cherkasova et al. 2014; Badgaiyan et al. 2015). It should be noted that these theories are not necessarily mutually exclusive. For instance, DTD and high-phasic/low-tonic theories could well dovetail. Future molecular work is required to resolve these neurochemical theories of dopamine abnormalities in ADHD (though see the discussion in Chapter 5 for further, albeit speculative, evidence). Other critical findings supporting the importance of dopamine systems in ADHD reflect functional and anatomical s within the core and extended structures within the dopaminergic system which are reviewed in the following sections.

1.2.1.2 The critical role of core and extended dopaminergic cortico-striato-thalamo-cortical networks to ADHD pathophysiology

In line with the weight of evidence linking dopaminergic molecular abnormalities to the striatum, morphometry studies have robustly linked childhood ADHD to striatal volumetric reductions and an extended cortico-striato-thalamo-cortical network (Castellanos et al. 2006; Almeida Montes et al. 2010; Seidman et al. 2011; Frodl & Skokauskas 2012; Nakao et al. 2011; Seidman et al. 2005; Valera et al. 2007; Batty et al. 2015; Ivanov et al. 2010; Proal et al. 2011; Xia et al. 2012; Stanley et al. 2008). These remarkably organised circuits process and regulate an axis of motivational – cognitive – motor functions through a set of parallel, looping circuits that also integrate and feed forward information between these functions. This functional axis is anatomically distributed over a ventromedial to dorsolateral gradient within each of the structures this loop comprises (Haber 2003) (Figure 1.3).

Figure 1.3 Gradients of cortisco-striatal connectivity. Reproduced from (Heimer 2003).

A gradient of ventromedial (red) – dorsolateral (blue) connectivity within the cortex and striatum represents parallel limbic, associative and motor networks. The red – blue gradient provides an illustration of how distinct functions are localised with the same structure. The red here represents the ventromedial components underpinning motivational functions, with yellow and green representation more dorsolateral regions with cognitive and associative functions. The blue segments represent the most dorsolateral subregions within these structures and are responsible for motor function. Overlapping projections within these regions allow integration of these processes. Reproduced from (Heimer 2003). This figuratively represents

Due to the breadth of functions associated with these loops, abnormalities within them have vast explanatory power for the numerous deficits associated with ADHD (Castellanos et al. 2006). For example, differences in orbitofrontal and ventral striatal regions are linked to reward dysfunction in ADHD (Scheres et al. 2007; Wilbertz et al. 2012; Rubia et al. 2009; Cubillo et al. 2012; Carmona et al. 2009; Hesslinger et al. 2002). Similarly, abnormalities in lateral frontal regions, as well as the dorsolateral striatum, have been linked to more traditionally 'cognitive' deficits in the disorder, such as attention and executive functioning (Cubillo et al. 2012; Depue, Burgess, Bidwell, et al. 2010; Depue, Burgess, Willcutt, Ruzic, et al. 2010; Depue, Burgess, Willcutt, Bidwell, et al. 2010).

Within the context of this cortico-striato-thalamo-cortical model, striatal abnormalities provide a key locus of dopaminergic dysfunction within this network which may play a primary role in the disorder, emerging prior to other neurobiological abnormalities (Stanley et al. 2008). In addition to the wealth of genetic studies linking ADHD to dopamine system encoding genes (Gizer et al. 2009; Franke et al. 2012), the prominence of childhood striatal abnormalities in a disorder that is otherwise marked by a large amount of neurobiological heterogeneity suggests this may well be the case. Interestingly, volumetric reductions within the striatum may represent a locus of neurobiological divergence between childhood ADHD and adulthood, where such abnormalities are less frequently detected (Nakao et al. 2011; Frodl & Skokauskas 2012). Chapter 3 addresses these issues in more detail, examining whether this reflects maturation and treatment related normalisation (Nakao et al. 2011) or if other, methodological factors, may account for this. Supporting this, the following section reviews morphological findings in ADHD, highlighting commonalities and areas of divergence between childhood and adult populations.

1.2.1.3 Morphological findings in childhood and adulthood ADHD implicate core dopaminergic/striatal and extended cortico-striato-thalamo-cortical abnormalities

Voxel-based morphometry (VBM) studies have offered a method of exploring structural brain abnormalities in a manner unconstrained by prior hypotheses. Meta-analyses of

VBM studies in childhood ADHD have confirmed the importance of striatal regions, in particular including reductions in the right putamen (extending to the globus pallidus) (Ellison-Wright et al. 2008; Frodl & Skokauskas 2012). ROI based meta-analyses have also implicated the caudate in childhood ADHD (Valera et al. 2007; Frodl & Skokauskas 2012). Though striatal abnormalities are rarely detected in whole brain adult ADHD analyses, ROI based studies have observed striatal abnormalities in ADHD (Seidman et al. 2011; Almeida Montes et al. 2010). Interestingly, one study that did detect whole-brain statistically corrected abnormalities in adult ADHD had followed up these patients from a childhood diagnosis (Proal et al. 2011). A recent study focusing on stimulus naïve adults suggested that caudate volumetric reductions are observed in adult ADHD, though these did not survive correction for multiple comparisons (Nikos Makris et al. 2015). The reduced prominence of striatal abnormalities in adult samples is consonant with independent studies and meta-analyses have suggested that both maturation and medication may normalize striatal volumes in ADHD (Nakao et al. 2011).

Other morphological abnormalities have also been observed in childhood, albeit not with the levels of replication to be implicated in meta-analytic studies. For instance, reduced hippocampus volume and amygdala surface area has been observed (Plessen et al. 2006), as well as thalamic morphological abnormalities (Ivanov et al. 2010). Specifically, reduced pulvinar volumes are observed in ADHD compared to controls and general thalamic and pulvinar volumes specifically appear to be increased by stimulant medication. Volumetric reductions of the lateral thalamic surface appears to be associated with hyperactivity symptoms, whilst increased volume of the medial thalamic surfaces appeared to associated with inattentive symptoms (Ivanov et al. 2010). The persistence of thalamic abnormalities into adulthood has been supported by longitudinal studies (Proal et al. 2011). Evidence for hippocampal volumes in adulthood has however been limited (Perlov et al. 2008) though some studies have detected changes at lenient statistical thresholds (Seidman et al. 2011). Similarly, findings implicating amygdala abnormalities in adulthood have been mixed (Perlov et al. 2008; Frodl et al. 2010), though given the limited amount of evidence implicating these regions in childhood, it is not possible to infer the likelihood of maturational effects.

Abnormal cerebellar volumes have also been consistently reported in childhood (Valera et al. 2007) and adult ADHD (Nikos Makris et al. 2015). Whilst the nature of cerebellar abnormalities has largely been ignored, a recent study implicated the cerebellar

subregions found to be abnormal in ADHD (lobule IX) to be regions interacting with ventral and dorsal attention networks (Stoodley 2014).

Within the cortex, abnormal volumes in prefrontal and premotor regions (Mostofsky et al. 2002), the supplementary motor area (SMA) and primary somatosensory areas (Duerden et al. 2012),the temporal lobe (Kobel et al. 2010), the anterior insula (Lopez-Larson et al. 2012), and the anterior cingulate cortex (ACC) (Semrud-Clikeman et al. 2006) have been found in children. Cortical thickness studies have also shown thinning effectively across the whole cortex, though this appears to be most pronounced in medial prefrontal regions (Shaw et al. 2006; Narr et al. 2009). In adulthood, individual studies generally reflect cortical findings in childhood, with abnormalities observed in right inferior frontal (Depue, Burgess, Bidwell, et al. 2010), dorsolateral prefrontal cortex, ACC (Seidman et al. 2006; Makris et al. 2007), inferior parietal lobe (Makris et al. 2007), orbitofrontal cortex (Hesslinger et al. 2002). Interestingly, ACC reductions observed in children have been suggested to be normalised by stimulant medication (Semrud-Clikeman et al. 2006). This appears to be at odds with findings from a meta-analysis of adult patients with ADHD, most of whom had been treated with stimulant medication, which found consistent volumetric reductions in the ACC (Frodl & Skokauskas 2012).

In summary, frontal and cerebellar reductions appear to be consistent across both childhood and adulthood, though other cortical, amygdala, hippocampal and thalamic alterations may differ. However, given the heterogeneity in findings even between studies in the same age group it is hard to draw conclusions about any developmental or treatment related effects. In contrast, striatal abnormalities are consistently detected in childhood but not in adulthood. Some evidence suggests that this may reflect medication and maturation effects, and Chapter 3 will assess these claims more closely.

1.2.1.4 Evidence for SN/VTA involvement in ADHD

Abnormal dopaminergic signalling is central to most neurobiological theories of ADHD (Luman et al. 2010). Whilst the SN/VTA is the core of the dopaminergic system, its direct role in ADHD pathophysiology is relatively unknown largely due to limitations in non-invasive imaging of the dopaminergic midbrain. Recent work has now directly

implicated the SN/VTA in ADHD. Still, there has been a paucity of studies examining the precise functional contribution of the SN/VTA and its subcomponents. For instance, increased echogenicity of the substantia nigra has been observed in children with ADHD using transcranial sonography (Romanos et al. 2010). However, inference as to the neurobiological differences underpinning these changes is limited. More recently, molecular imaging studies (Volkow et al. 2011; Buckholtz et al. 2010) have suggested that D2/D3 receptor binding densities in the SN/VTA may underpin essential components of ADHD.

Abnormal incentive motivation is increasingly recognised as a potentially central aetiological component in ADHD (Volkow et al. 2011; Silvetti et al. 2013). Recent findings indicate that dysfunctional SN/VTA reward pathways result in a motivational deficit in ADHD, and these may underpin inattentive symptoms in the disorder (Volkow et al. 2011). Similarly, D2/D3 receptor activity in the SN/VTA appears to encode a tendency towards impulsivity in the general population (Buckholtz et al. 2010). Whilst impulsivity is a multifaceted construct (Caswell et al. 2015), research in ADHD has specifically highlighted the relevance of waiting impulsivity, most typically in the form of increased temporal discounting (Thorell 2007; Scheres et al. 2008; Scheres et al. 2010). This tendency to prefer smaller, immediate rewards over larger temporally distant ones, appears to be a fundamental part of reward dysfunction in ADHD (Luman et al. 2005; Sonuga-Barke et al. 2008). Whilst preliminary evidence suggests that the SN/VTA has a role in both impulsivity and motivation, it is not clear how the subcomponents of the SN/VTA contribute to these different aspects of reward dysfunction.

1.2.1.5 Substantia nigra/ventral tegmental area heterogeneity

The SN/VTA is a highly heterogenous structure that is subdivisible at several different levels. Similar to the striatal structures which it regulates, a dorsomedial – ventrolateral functional gradient is observed in the SN/VTA. The dorsomedial component comprises the VTA, retrorubal cell groups and a dorsal element of the SN pars compacta (SNpc), and regulates emotional and motivational functions most prominently via mesolimbic projections to the ventral striatum, amygdala and hippocampus (Haber et al. 2000; Haber 2003; Haber & Knutson 2010). Conversely, the ventrolateral SN/VTA regulates a broad range of cognitive, associative motor functions via nigrostriatal projections to the

dorsal and lateral aspects of the striatum. Interestingly, these two components also show a range of differences in their pharmacological responses, with different reactivity to D- and L-amphetamine (Browder et al. 1981) and selective D3 (Ashby et al. 2000) and D1 receptor ligands (Goldstein & Litwin 1988), as well as serotonergic (Gervais & Rouillard 2000), noradrenergic (Mejías-Aponte et al. 2009) and nicotinic acetylcholinergic (Mereu et al. 1987; Klink et al. 2001) signalling.

Previous studies investigating the role of the SN/VTA in ADHD have not had sufficient anatomical resolution to dissociate the contributions of these mesolimbic and nigrostriatal components. The midbrain and striatal correlates of incentive motivation in particular remain unclear. Whilst initial accounts have suggested that the mesolimbic SN/VTA and the ventral striatum underpinned incentive motivation, recent evidence has suggested that motivational differences are related to the nigrostriatal SN/VTA (Rossi et al. 2013) and more dorsal aspects of the striatum (Volkow et al. 2002; Tomer et al. 2008). Chapter 4 optimises and applies subcortical imaging and parcellation techniques to address these questions.

1.2.2   Other network dysfunctions in ADHD

With the advent of functional connectivity analyses of resting state fMRI data, there has been an increasing focus on characterizing effects of ADHD on functionally-derived large scale brain networks. In particular, default-mode, fronto-parietal and dorsal and ventral attention networks have been suggested to play a key role in ADHD neurobiology (Castellanos & Proal 2012).

1.2.2.1 Fronto-parietal network

Abnormalities within a fronto-parietal 'control' network, which includes the lateral frontal, anterior cingulate (ACC), dorsolateral prefrontal cortex (DLPFC), anterior PFC (apFC), lateral cerebellum, anterior insula, caudate, and inferior parietal lobe (Figure 1.4) (Vincent et al. 2008), have been suggested to play an important role in ADHD (Castellanos & Proal 2012). Consonant with executive dysfunction in the disorder, this network appears to play a role in orchestrating goal-directed behaviours and adapting

to shifting environmental demands (Liston et al. 2006). In addition to regional hypoactivations during go/no go, response inhibition, attention, working memory and time discrimination tasks (Bush 2010; Vaidya & Stollstorff 2008; Schneider et al. 2006; Smith et al. 2008; Durston et al. 2007; Rubia 2011), abnormal functional connectivity within this network has also been detected in resting state studies (Cao et al. 2006; Yu-Feng et al. 2007; Wang et al. 2009; Cao et al. 2009).

1.2.2.2 Dorsal and ventral attention networks

The dorsal and ventral attention networks work in concert to regulate attention. The ventral attention network is involved in monitoring the environment for salient stimuli and may, in response to this, have a role in interrupting top-down attentional processing to induce an re-orienting response (Corbetta et al. 2008). This ventral attention network overlaps with functionally derived salience/fronto-opercular networks (Menon 2011; Dosenbach et al. 2008), and encompasses the temporoparietal junction, frontal operculum, anterior insula, and ventral frontal regions including the middle and inferior frontal gyri (Corbetta et al. 2008). By contrast, the dorsal attention network mediates top-down reorientation of attention and other goal-direction functions in response to competing demands. This network consists largely of superior parietal regions, including the intraparietal sulcus and superior parietal lobule, and dorsal frontal regions focused on the frontal eye field (Figure 1.4) (Corbetta et al. 2008). Abnormal activation patterns in insula, parietal and frontal regions associated with attention networks has been observed in ADHD during a variety of tasks (Dickstein et al. 2006). In addition to the apparent top-down control deficits in ADHD implicating the dorsal attention network specifically (Castellanos & Proal 2012), recent theoretical work has also proposed a specific role of ventral attention network hyperactivity in producing distractability in ADHD (Aboitiz et al. 2014).

1.2.2.3 Default-mode network

The default-mode network (DMN), and its interaction with other networks has been consistently implicated in ADHD. The default-mode network consists of medial prefontal cortex (mPFC), posterior cingulate cortex (PCC) (Figure 1.4), and the medial temporal lobe (MTL). Due to its association with reflection and self-referential processes, the DMN is highly active at rest, and reduced when engaging in most goal-

directed tasks (Buckner et al. 2008). As such, the DMN has an opposing, anticorrelated role in relation to control networks implicated in ADHD. Increased DMN activity during tasks has therefore been argued to reflect a disruption of goal directed processing that could account for momentary lapses in task performance (Sonuga-Barke & Castellanos 2007).

1.2.3 Does functionally derived network dysfunction reflect a primary deficit?

Whilst wide scale disruption to a variety of brain networks in ADHD is observed, it is unclear whether these represent a primary dysfunction, or if they are secondary to reduced dopaminergic function in ADHD. For instance, heightened DMN activity during response inhibition is only observed in patients when they are unmedicated and low motivational incentives are used. By enhancing dopaminergic signalling with either methylphenidate or increased motivational incentive with rewards, heightened DMN activity during tasks is ameliorated (Liddle et al. 2011). These findings suggest that DMN hyperactivity during tasks may actually reflect dysregulation of the DMN and control networks by hypodopaminergic signalling, rather than a discrete primary deficit. Similarly, hypothesised ventral attention network dysfunction is thought to reflect low tonic catecholaminergic signalling (Aboitiz et al. 2014). Overall it is noteworthy, that the functionally derived networks most consistently implicated in ADHD are prominently modulated by dopaminergic nuclei (Cole et al. 2013). As will be discussed below, when examining the effect of dopaminergic reward system contributions to neuropsychological dysfunction, a similar theme emerges.

7-Network Parcellation (N=1000)

Left Hemisphere

Right Hemisphere

Visual
Somatomotor
Dorsal Attention
Ventral Attention
Limbic
Frontoparietal
Default

Figure 1.4 Coarse (7-network) parcellation of the human cerebral cortex obtained through clustering of R-fMRI data of 1,000 subjects. Reproduced from (Castellanos & Proal 2012). Initially adapted from (Yeo et al. 2011).

Attention is not a unitary mechanism, but is rather a system supported by several distinct neurocognitive mechanisms. These can be conceptualised as four processes: alerting, orienting, executive control, and self-regulation (Petersen & Posner 2012).

The alerting system appears to be in large part underpinned by noradrenergic signalling from the locus coruleus and is responsible for production and maintenance of optimal vigilance during tasks. The orienting response reflects the direction of attention to a stimulus (Petersen & Posner 2012). This has been shown to reflect two distinct networks, the bottom-up ventral attention network and the top-down dorsal attention network (Corbetta et al. 2008) that have been detailed in previous sections. The executive control contributing toward maintains focus s attention has recently been suggested to reflect two distinct systems (Dosenbach et al. 2008). The first, cingulo-opercular control system acts as a stable background maintenance for task performance, whilst the frontoparietal system (detailed anatomically above) plays a role in initiation and switching of tasks (Dosenbach et al. 2008; Petersen & Posner 2012). Finally, more recent evidence has suggested the importance of a self-regulation system. This reflects the ability to control reflexive or dominant responses to less dominant ones, most typically assessed through use of the Stroop task (Petersen & Posner 2012). In reconciling clinical definitions of attention with neuropsychological criteria, the majority of early research conceptualised attentional deficits as reflecting abnormalities in executive function (subsuming, but not historically limited to the aforementioned networks contributing to executive control of attention).

1.3.2   Executive function in ADHD

As noted, impaired executive function has played a central role in previous definitions of neuropsychological dysfunction in ADHD (Willcutt et al. 2005). Whilst precise characterisation of a 'central executive' in the brain will likely always be problematic, executive function is largely taken to reflect a range of higher order processes that play a role in cognitive, behavioural and emotional regulation. Response inhibition, spatial working memory, vigilance and planning are frequently seen as the best validated measures of executive dysfunction in ADHD (Willcutt et al. 2005), with response inhibition and working memory deficits in particular have been the subject of a large amount of research.

1.3.2.1 Working memory

Working memory, the process by which information no longer in the immediate environment is kept 'on-line' for further processing (Baddeley 2003), has been a considerable focus in ADHD research. Working memory deficits appear to persist into adulthood and have been argued to represent a core deficit in ADHD (Alderson et al. 2013). Methylphenidate treatment improves working memory in both children (Barnett et al. 2001; Mehta et al. 2004) and adults (Ni et al. 2013) with ADHD. These working memory deficits appear to be underpinned by cortico-striato-thalamo-cortical (Mills et al. 2012) and fronto-parietal networks (Darki & Klingberg 2015). Accordingly, enhanced working memory by methylphenidate appears to be underpinned by cerebral blood flow changes within the prefrontal and parietal cortices (Mehta et al. 2000) and enhanced striatal dopaminergic signalling (Clatworthy et al. 2009). These effects of methylphenidate do not, however, appear to be specific to ADHD and have a similarly working memory enhancing effect in healthy controls (Mehta et al. 2000).

1.3.2.2 Response inhibition

The inability to suppress an inappropriate response has been argued to be another central component of executive dysfunction in ADHD (Wodka et al. 2007), and representative of abnormal impulsivity in the disorder. Response inhibition deficits indexed by the stop signal task are ameliorated by methylphenidate (Aron et al. 2003; DeVito et al. 2009) and atomoxetine (Chamberlain et al. 2007), suggesting that acute alteration of dopaminergic and noradrenergic signalling play a therapeutic role. Aberrant response inhibition in ADHD also appears to be underpinned by fronto-striatal abnormalities (Casey et al. 1997; Schulz et al. 2004; Cubillo et al. 2010).

1.3.3   Hot and cool executive dysfunction?

Although executive dysfunction has been linked to the real-life difficulties associated with ADHD (for instance, it appears executive dysfunction has been linked to academic outcomes in ADHD) (Biederman et al. 2004), such executive deficits are frequently absent in the disorder, and do not appear to be necessary or sufficient for its presence (Willcutt et al. 2005). Another prominent line of research in ADHD has focussed on aberrant reward-based decision-making. This has predominantly focussed on well-validated increases in temporal discounting of reward in ADHD (Scheres et al. 2006;

Scheres et al. 2008). This tendency to prefer smaller, more immediate rewards over larger, but temporally distant rewards appears to make distinct contributions from typical executive dysfunction in ADHD (Sonuga-Barke et al. 2003). In addition to other reward-based abnormalities such as risky decision making (Kerr & Zelazo 2004), this has been conceptualised as a form of 'hot' executive dysfunction contrasting to cognitive, or 'cool' executive deficits (Castellanos et al. 2006). This model attempts to encompass the heterogeneity of neuropsychological dysfunction in ADHD, and suggests that both forms of 'executive' dysfunction may reflect abnormalities within cortico-striato-thalamo-cortical loops that appear to play a significant role in the neurobiology of ADHD.

1.3.4   Reinforcement learning

A somewhat opposing view notes that whilst various higher order functions appear to be impacted in ADHD, a great deal of recent work has suggested that these may be underpinned by abnormalities in reinforcement learning (Luman et al. 2010). For instance, previous theories (Castellanos et al. 2006) have suggested that abnormal risk taking and temporal discounting in ADHD represent differences in higher order decision-making functions. However, the level of dysfunction of these processes is not necessarily higher order, and may rather reflect the acquisition and expression of learnt reward values. Contemporary approaches to modelling these reward and decision-making problems have focussed on isolating these factors to assess their individual contributions. For instance, rather than reflecting dysfunction in a unitary, higher-order process, the tendency to prefer smaller more immediate rewards can be described in terms of specific, tightly defined reward learning mechanisms (Williams & Dayan 2005). One prominent approach to these problems has been the application of temporal difference models of reinforcement learning (Sutton & Barto 1998) to behavioural and functional imaging data.

1.3.5   Temporal difference models of reward function

Temporal difference (TD) learning models are a computational approach to reinforcement learning, deriving in part from Monte-Carlo and dynamic programming

methods (Sutton & Barto 1998). Although this approach initially developed within AI research, this has been highly informative about the nature of reinforcement learning in humans and animals, and how accurate reward prediction is possible in the uncertain and changing environments which we inhabit. Moreover, as discussed further below, this has become a fertile ground for exploring reinforcement learning differences that are thought to be abnormal in ADHD. TD models are an approach to learning how to predict future rewards in a constantly updating environment. Specifically, this entails making predictions of a total expected reward value over any number of time steps. In other words, this prediction is intended to capture the total value of picking any given option over a (potentially indefinite) amount of time. At any given time step (for instance, a trial of an experimental task with a win/loss condition on each trial) this uses the error between the reward received and the prior prediction to update the expected reward value. This iterative error-driven learning process (detailed more formally in the equations and their explanations below) thus informs the dynamically perceived values and subsequent decisions of an agent within an environment, offering a computational description of reward related behaviours.

Indeed, such TD models of reinforcement learning have provided a powerful method for characterizing human reward-related behaviour, and have helped clarify mechanisms of reward dysfunction in other disorders of the brain dopamine system (Rutledge et al. 2009; Murray et al. 2008). These TD models are remarkably predictive about the behaviour of dopaminergic neurons in the substantia nigra/ventral tegmental area (SN/VTA) (Bayer & Glimcher 2005; Montague et al. 1996; O'Doherty et al. 2003; McClure et al. 2003; Waelti et al. 2001). Prediction error signals (described below) derived from such models appear to be an essential, quantifiable, measure of reinforcement learning in the brain – both tightly coupled to dopaminergic neuronal activity (Schultz et al. 1997; Hollerman & Schultz 1998), and necessary for learning from reward *in vivo* (Steinberg et al. 2013). In these models, it is possible to decompose discrete computational parameters that affect learning and decision making to assess their individual contributions to these processes. The following sections outline potential parameters of interest and how they may contribute to reward dysfunction in ADHD, with Chapter 5 later empirically addressing these questions.

1.3.5.1 Parameter contributions and derivation of prediction error

In TD models learning is formulated as a process that occurs to predict future reward (Sutton & Barto 1998). At the core of this learning process is the reward prediction error which, in its simplest form, signals the mismatch between an expected reward value V at a given time t, and the reward received r.

$$\delta(t) = r(t) - V(t)$$

In most basic reinforcement learning examples, this value may correspond to the reward value of selecting an option, for instance, the expected value of pulling a lever which is rigged to deliver a reward. In this case, the prediction error signals the difference between the expected value of a lever pull, and the reward received. In turn the prediction error shapes future expectations of reward value as follows:

$$V(t+1) = V(t) + \alpha \bullet \delta(t)$$

This iterative process continually updates the expectations of the agent in response to the state of the environment. Rewards greater than expected will result in a positive predictions error, and increase the predicted value of future rewards. Accordingly, rewards lower than predicted will elicit a negative prediction error, reducing the predicted value of future reward. In this model, the effect of the prediction error on V is modulated by the learning rate α, such that a relatively small α will result in slower updating of reward values in response to reward, and bias value predictions to previous experiences. In contrast, a high α will mean that predicted values will be largely informed by the most recent rewards received. Optimal learning strategies therefore balance the weighting given to previous and recent rewards according to the learning rate.

By forming predictions about the values of options in the environment, future decisions can be made on the basis of these value expectations. The assumption underpinning TD models of reinforcement learning, is that a decision making agent is driven to maximize future reward. However, simply consistently selecting options that are perceived to be of the highest value is not an optimal strategy to this end, and is also not descriptive of normal human reward behaviour. This highlights an essential aspect of reinforcement learning, namely that learning and decision making require flexibility, in large part due to the fact that they occur in a dynamic environment. Directing choice solely towards the option with the highest expected value limits exploration of other sources of reward. In an extreme example, given two options of with unknown reward probabilities, an agent that only selected the highest value option would persist

indefinitely in picking the first option that resulted in reward. To overcome this, more sophisticated selection strategies are required, that allow exploration of options that are not perceived to be the most rewarding. One such strategy, softmax selection, gives the probability of choosing a particular option c out of a set k at time t:

$$P(c,t) = \frac{exp(\beta \bullet Q(c,t))}{\sum_{k=1}^{3} exp(\beta \bullet Q(k,t))}$$

In this case, the value is moderated by an inverse-temperature parameter β that determines the extent to which choice is directed towards high value options. Differences in β thus introduce an element of 'randomness' when deciding whether to pick an option that is perceived to be high value, thus ensuring exploration of other potential sources of reward. In this sense, exploration is required to reduce uncertainty in value predictions.

1.3.6 Modelling mechanisms of reward dysfunction in ADHD

1.3.6.1 Learning rates in ADHD

Preliminary computational modeling work using simulated TD learning in ADHD has indicated several candidate mechanisms to explain impulsive reward dysfunction. Of particular interest, in simulated models altered learning rates have been implicated in ADHD (Williams & Dayan 2005), which have suggested that a reduced rate of updating values in response to reward may explain reward dysfunction observed in the disorder. Reduced learning rates are taken to reflect low dopamine levels in such models (Williams & Dayan 2005). Reduced learning rates in ADHD could therefore potentially tie neurobiological observations of hypodopaminergic abnormalities in mesolimbic reward pathways (Volkow et al. 2009; Volkow et al. 2011) with reward dysfunction that is observed in ADHD (Frank et al. 2007; Thoma et al. 2015; Scheres et al. 2007; Scheres et al. 2006). However, to date no direct evidence of altered learning rates in TD models of ADHD has been observed. Interestingly, impaired learning rates in other hypodopaminergic disorders such as Parkinson's disease are rescued by dopamine-enhancing drugs (Rutledge et al. 2009). Improved learning rates may therefore play a similar role in mediating the effects of stimulant medication in normalizing reward learning abnormalities in ADHD (Williams & Dayan 2005).

1.3.6.2 Exploratation/Inverse temperature parameters in ADHD

Rather than altered acquisition of reward values, another alternative explanation for reward dysfunction in ADHD is altered behaviour towards rewarding options. One recent study provided evidence for heightened inverse temperature parameters (β) in ADHD, reflecting a reduced tendency to exploit options known to be rewarding, instead exploring other options more frequently. Interestingly, this analysis also suggested that learning in ADHD was best characterized by a model assuming fixed learning rates that do not dynamically alter in response to environmental volatility and beliefs about values of objects (Hauser et al. 2014). Comparison with predictions from previous simulations is somewhat difficult however, due to a) the use of a reversal learning paradigm in which the value of options shifted over time, and b) the implementation of non TD models, specifically Rescorla-Wagner (Gläscher et al. 2009) and hierarchical Gaussian filter models (HGF) (Mathys et al. 2011; Iglesias et al. 2013). Rescorla-Wagner models are similar to TD models which have developed from them, but differ on several points. Most importantly, the reward values learnt in Rescorla-Wagner models are applied only to the next timestep (rather than as a predicted value of all future reward from a source). HGF models attempt to apply principles of probability theory into learning problems to overcome the poor performance of TD models where there are environmental states and action outcomes that are unknown to the agent (Mathys et al. 2011).

1.3.6.3 Novelty processing in ADHD

Valuation of novel stimuli may also play a role in abnormal reward function in ADHD, though to date this has been critically underexplored. Novelty has a highly adaptive role in learning and decision making, guiding an agent to explore unfamiliar options to identify new sources of potential reward (Wittmann et al. 2008). In doing this, stimulus novelty itself also elicits phasic dopaminergic activity in the mesolimbic reward system (Schultz 1998). This novelty-related activity can be modelled as a quantitative 'novelty bonus' that enhances the reward value of a novel option (Wittmann et al. 2008; Kakade & Dayan 2002). Whilst this may be essential for guiding normal exploratory behaviours, aberrantly high valuation of novelty is also associated with significant personal harm, including greater risk of substance abuse (Wills et al. 1994). Critically, variability in this novelty bonus may act as a quantitative index of poor, novelty-biased decision-making. For instance, heightened valuation of stimulus novelty is observed in patients with Parkinson's Disease who exhibit impulsive and compulsive behaviours in response to dopaminergic therapy (Djamshidian et al. 2011).

Heightened novelty seeking personality traits are also observed in ADHD (Downey et al. 1997; Lynn et al. 2005; Jacob et al. 2014), and ADHD (LaHoste et al. 1996; Rowe et al. 1998; Smalley et al. 1998; Faraone et al. 1999; Faraone et al. 2001; Barr et al. 2000; Eisenberg et al. 2000) and novelty seeking (Kluger et al. 2002; Munafò et al. 2008; Roussos et al. 2009; Ekelund et al. 1999; Tomitaka et al. 1999; Strobel et al. 1999; Okuyama et al. 2000; Ebstein et al. 1996) both appear to share genetic correlates in D4 receptor gene polymorphisms. However, to date no work has examined how increased novelty seeking impacts reward learning in the disorder.

1.3.6.4 Altered phasic prediction error and novelty signals in ADHD

By applying TD models to a reinforcement-learning task Chapter 5 also attempts to resolve several conflicting accounts of dopaminergic abnormalities in ADHD. ADHD is typically characterized as a hypodopaminergic disorder. However, several theoretical accounts suggest a more nuanced view. In disagreement with theories suggesting a completely blunted dopamine response (Volkow et al. 2005; Sagvolden et al. 2005), several findings have suggested that whilst tonic dopamine levels are reduced in the disorder, heightened phasic dopamine release is actually increased (Grace 2001; Seeman & Madras 2002; Badgaiyan et al. 2015). This is also in line with simulations suggesting that reward dysfunction in ADHD may be characterized by asymmetric positive and negative prediction error signals. Specifically, positive prediction error signals which are underpinned by phasic dopamine responses are expected to be heightened compared to negative prediction error signals (which may instead be mediated by inhibitory D2 receptors) (Cox et al. 2015). Clarification of these issues is central to developing accurate theoretical accounts of dopaminergic reward dysfunction in ADHD. As both prediction error and novelty signals are tightly coupled to phasic dopamine release, modelling these responses in blood oxygen level dependent (BOLD) (Ogawa et al. 1990) responses affords an indirect assessment of these hypotheses.

1.3.7 Motivation in ADHD

Another increasingly central component of dopaminergic reward dysfunction in ADHD is aberrant motivation. Incentive motivation, the process by which reward drives and

invigorates goal-directed behaviours, appears to be reduced in individuals with ADHD. Reductions in trait motivation in this disorder appear to be linked to lower D2/D3 receptor binding in the SN/VTA and ventral striatum (Volkow et al. 2011). In accordance with theories of ADHD positing reduced tonic dopamine, motivation to exert effort appears to be related to tonic dopamine levels (Niv et al. 2007). This lack of tonic motivational levels also appears to manifest as a heightened sensitivity to reward, with increasing motivational incentives improving performance on effortful tasks in ADHD (Fosco et al. 2015). Deficits in ostensibly higher order functions in ADHD may therefore be mediated at least in part by motivation. Indeed striatal dopamine appears to have a direct influence on cognitive flexibility (Aarts et al. 2010).

1.4 Acute and long term effects of methylphenidate on dopaminergic reward system

1.4.1 Acute effects on neuropsychology and neurobiology

As noted previously, stimulant medication appears to ameliorate executive functional deficits in ADHD (Barnett et al. 2001; Mehta et al. 2004; Ni et al. 2013; Aron et al. 2003; DeVito et al. 2009) and related network abnormalities in ADHD (Liddle et al. 2011). However, methylphenidate also appears to have similar effects on executive functions in controls (Mehta et al. 2000). This has led to speculation as to the lack of specificity of stimulant medication in treating ADHD, and even the validity of ADHD as a diagnosis. However, a different picture emerges when looking at reward function. For example, risky decision making is improved by methylphenidate in ADHD (DeVito et al. 2008a), but actually appears to be worsened in controls (Campbell-Meiklejohn et al. 2012). One possibility is that although methylphenidate may have similar actions on higher order functions that are not considered to rely primarily on dopaminergic function, it has different effects on reward and motivational processes directly linked to dopaminergic activity. Whilst stimulant medication may thus have a therapeutic effect by rebalancing abnormal dopaminergic activity in ADHD, these drugs may actually impair normal dopaminergic signaling. This is supported by findings methylphenidate has a greater therapeutic effect on reversal learning in more impulsive subjects

(Clatworthy et al. 2009). Similarly, other dopaminergic drugs appear to have distinct effects on reward learning in Parkinson's Disease (Rutledge et al. 2009) compared to healthy subjects (Pizzagalli et al. 2008). Chapters 4 and 5 address these potentially differential effects of stimulant medication on a) waiting impulsivity and b) reinforcement learning in ADHD and healthy controls.

1.4.2   Long term neurobiological effects of stimulant medication

Though long term benefits in broad outcome measures such as academic, social and occupational function   are clear (Shaw et al. 2012), the exact effects of long term stimulant treatment in humans in ADHD are relatively poorly understood. However, a variety of behavioural and neurobiological changes have been observed in animal models. For instance, increased plasticity (Dommett et al. 2008), dendritic spine formation (Kim et al. 2009) and heightened expression of growth factors (Roeding et al. 2014; Simchon-Tenenbaum et al. 2015; Amiri et al. 2013) in mesolimbic circuitry have been reported. In humans reduced DAT binding potentials after long term methyphenidate treatment have been observed, and largely interpreted as an effect of tolerance (Wang et al. 2013). Human imaging studies have also suggested that grey matter volumes may be normalised by stimulant medication to some degree (Nakao et al. 2011; Spencer et al. 2013). This thesis addresses the long term effects of stimulant medication on a) striatal volume, b) SN/VTA microstructure, and c) computation of stimulus novelty.

2 Methods

The following methods chapter gives an overview of recruitment, and overall study design. Specific details of tasks, data processing and analysis are nested within each experimental chapter.

2.1 Participants

Patients with ADHD were recruited from specialist ADHD clinics at Sussex Partnership NHS Foundation Trust (SPFT). All had a DSM-IV confirmed diagnosis of ADHD and had been managed on a stable regimen of methylphenidate (minimum 18mg) or dexamfetamine (mimimum 10mg) for at least 2 months prior to study enrolment. Patients were sent letters detailing the study or approached at clinic and offered study information sheets if they were interested in participating in research. Participant diagnoses were performed by psychiatrists within SPTF clinics, assisted by the self-report long form of the Connor's Adult ADHD Rating Scale (CAARS) (Conners et al. 1999) and had therefore been exposed to materials used for rating ADHD symptoms within the study before. Control participants were recruited via community and classified advertising websites, as well as the University of Brighton mailing lists. Individuals who responded were screened over the telephone to ensure that they fully met the study criteria.

Participants were excluded in the case of psychotic symptomatology, learning difficulties, anxiety or depressive disorders not currently in remission, any neurological disorder, active drug or alcohol abuse, significant physical disability, suspected diminished capacity to consent, significant impairment of vision, hearing, or language comprehension, or if they were pregnant or aged <18 or >65. Individuals with a prior history of severe head injury, or metallic objects in the body deemed unsafe for MRI scanning were also excluded from the study. Control participants were also excluded for having any known hypersensitivity to methylphenidate, glaucoma, history of seizures, tinnitus, family history of tinnitus, motor tics, family history of Tourette's syndrome, serious cardiovascular conditions, current or recent use of monoamine oxidase inhibitors or current use of coumarin anticoagulants, anticonvulsants or antipsychotics. Due to the high prevalence of substance abuse in ADHD populations, both ADHD and control groups were asked during screening whether they had current history of substance abuse to ensure that they were not enrolled in the study. Psychiatrists recommending patients to the study were also aware of this criteria to

assist in screening patients. Participants were reimbursed £22.50 per session. In addition, participants could earn up to an additional £5 per session based on their performance in the novelty task.

Participants gave written, informed consent following full explanation of the experimental procedures. Local and national ethical approvals were obtained from Brighton and Sussex Medical School Research Governance and Ethics Committee (14/014/HAR; 12/131/HAR) and the East of England (Hertfordshire) National Research Ethics Committee (reference: 12/EE/0256).

2.2   Study design

A repeated-measures randomized, placebo controlled study design was utilized in which all participants attended two experimental sessions separated by a minimum of 1 week. ADHD patients were asked to abstain from their regular ADHD medication for the test day and 2 days prior to testing. At the start of the first session participants were randomized to receive either stimulant medication or placebo. The alternate treatment was given on the second experimental session. ADHD participants were blindly administered either their normal morning medication dose or placebo. Control participants received either 20mg of methylphenidate or placebo. Control methylphenidate dose was based on the average daily dose in the ADHD group assuming the average 2.5 times daily dosing. All medication was concealed in an opaque, easily absorbed capsule to ensure both participant and researcher were blind to treatment. A consultant psychiatrist was aware of treatment allocation to ensure safety, though played no role in face-to-face participant testing.

2.3   Procedure

Participants arrived on their testing day and were given an opportunity to ask questions about the study before signing consent forms. Patients with ADHD were asked to bring their usual daily medication with them after two days of abstinence. Upon arrival this was taken from them for later dosing. On the first session, participants were then given the Connor's Adult ADHD Rating Scale (CAARS; Self Report, Long form), Becks Depression Inventory (BDI), and the State and Trait Anxiety Index (STAI) to fill out, before being blindly administered either drug or placebo masked in a gelatine

capsule. Immediately afterwards participants underwent two pre-task 'familiarisation' procedures for the 3-armed bandit (reinforcement learning and novelty; See Chapter 5 for details) task which was to be performed later in the MRI scanner. Participants were then administered the Tridimensional Personality Questionnaire (TPQ) and the National Adult Reading Test (NART).

One hour after dosing, participants were given a thorough explanation of the 3-armed bandit task, and assessed and prepared for the scanning environment. After the research and radiography teams were satisfied that the participant met all safety criteria, they were laid supine on the scanner bed with extra padding to reduce movement where necessary and given a demonstration of the button box used for task responses before scanning commenced. Each scanning session consisted of a standard functional EPI sequence during the 3-armed bandit task (spread over three individual runs) and a multi-echo functional EPI during rest, as well as a series of structural and diffusion imaging sequences that were collected over the course of the two sessions (Table 2.1). Scanning was timed so that participants performed the 3-armed bandit task 90 minutes after dosing to ensure peak brain concentration had been reached (Volkow et al. 1998). Following this, the participants underwent a series of behavioural tasks, including the 5-choice serial reaction time task (5-CSRTT). The 5-CSRTT data were analysed as part of this thesis and are discussed in more detail in Chapter 4. Data from the other behavioural tasks are not reported as part of this work.

During the second visit, participants underwent the same procedure and administered the capsule they had not taken on the previous session. An alternate set of stimuli was used for the 3-armed bandit task and prefamiliarisation sessions on the second session. They then completed the Multidimensional Personality Questionnaire (MPQ) before the scan. After scanning, participants completed scans and behavioural tasks as before. Participants were assessed for safety and debriefed. Additionally, patients with ADHD were interviewed to assess the length of their treatment prior to the study, as well as their medication and dosage history.

To combat fatigue with the length of the session participants were offered breaks between tasks as necessary. Retention rate was still relatively high, even within the ADHD group, with the final task being completed by 28 controls and 25 patients. It should also be noted that this attrition rate was not solely attributable to fatigue (e.g. several participants arrived late for and experimental sessions had to be cut short).

Table 2.1 Study protocol and timing

Dose time	Session 1	Dose time	Session 2
-00:20	Arrival	-00:20	Arrival
-00:20	Consent & safety check	-00:20	Safety check
-00:10	CAARS, BDI, STAI		
00:00	Dose	00:00	Dose
00:00	Stimuli familiarisation (passive)	00:00	Stimuli familiarisation (passive)
00:05	Stimuli familiarisation (active)	00:05	Stimuli familiarisation (active)
00:15	TPQ	00:15	MPQ
00:50	Task instruction	00:50	Task instruction
1:00	Enter scanner	1:00	Enter scanner
1:10	MT-MRI (and task practice)	1:10	MPRAGE (and task practice)
		1:18	Diffusion MRI
1:30	Task based functional EPI	1:30	Task based functional EPI
2:05	Resting state multi-echo EPI	2:05	Resting state multi-echo EPI
2:15	Exit scanner	2:15	Exit scanner
2:20	Exploration/Exploitation task	2:20	Exploration/Exploitation task
2:50	Model-based/Model-free task	2:50	Model-based/Model free-task
3:15	Impulsivity task	3:15	Impulsivity task
3:45	Debriefing	3:45	Debriefing

2.4 Materials

The long-form self report version of the CAARS was used to assess ADHD symptom severity (Conners et al. 1999). This consists of 8 clinical scales, and consists of 66 Likert items and is separable into 8 subscales: Inattentive/Memory problems, Hyperactivity/Restlessness, Impulsivity/Emotional Lability, Problems with Self-Concept, DSM IV Inattentive Symptoms, DSM IV Hyperactive-Impulsive Symptoms, Total DSM IV ADHD symptoms and the CAARS total ADHD Index. An inconsistency scale can additionally be derived to determine inconsistent reporting. However, this was not used in the present study due to each participant having a psychiatrist confirmed diagnosis of ADHD. The BDI is a 21-question self-report Likert scale assessing the severity of depression including both affective and physical components of the disorder (Beck et al. 1996). The STAI is a 40 question inventory of 40 self-report Likert items about anxiety affect that is divisible into two 20 item scales pertaining to trait anxiety 'How you feel generally' and state anxiety 'How you feel right now' (Spielberger 1983). The TPQ consists of 100 true-false questions measures originally measuring three factors: novelty seeking, harm avoidance and reward dependence each with four subscales (Cloninger et al. 1991). Of particular interest to this study, is the persistence subscale of reward dependence due to its questions probing motivation e.g. 'I usually push myself harder than most people do because I want to do as well as I possibly can.' The MPQ contains 276 true-false items across 3 broad factors (Positive Emotionality, Negative Emotionality and Contraint) and 11 primary trait dimensions (Tellegen & Waller 2008). Of particular interest is the trait dimension of Achievement (consisting of items such as 'I welcome difficult and demanding tasks') which has been used in previous studies to measure trait motivation in adult ADHD (Volkow et al. 2011).

2.5 Imaging

All imaging was performed on a 1.5T MRI scanner ((Siemens Magnetom Avanto, Siemens, Erlangen, Germany), with a maximum gradient strength of 44 mTm^{-1} and a 32-channel head coil for signal reception.

2.5.1 Diffusion MRI

For diffusion MR imaging a multi-slice twice refocused spin echo echo-planar imaging (EPI) acquisition was used, with 60 contiguous near axial slices acquired with 2.5mm^3 isotropic voxels. Acquisition had a TE of 86ms, and a TR of 7.7s. A maximum diffusion weighting of b=1500 smm^{-2} was applied. 60 diffusion-weighted brain volumes with diffusion gradients uniformly distributed in space were collected at each slice location, as well as 7 volumes without diffusion weighting applied. The number of diffusion directions (60) were collected in order to allow for the High Angular Resolution Diffusion Imaging (HARDI) approach adopted in Chapter 4 so as to be able to successfully resolve crossing fibre configurations (with a minimum of 45 recommended HARDI) (Tournier et al. 2013). Although a higher b value has also been recommended (Tournier et al. 2013), at 1.5T it was deemed the loss of SNR would not be worthwhile.

2.5.2 FLASH 3D

A multi-parameter protocol adapted from a 3D multi-echo fast low angle shot (FLASH) sequence was used to calculate MT saturation maps (Weiskopf & Helms 2008). Three co-localised 3D multi-echo flash sequences were acquired in the sagittal plane. Proton density weighted volumes were acquired with a TR of 24, a TE from 2.51 to 21.9ms (eight equidistant bipolar echoes collected), and flip angle (α) of 6°, with 1.25mm^3 resolution (FOV: 240x217.5mm^2, 144 partitions). T1 weighted volumes were acquired with a TR of 19, a TE ranging from 2.51 to 10.82ms (four equidistant bipolar echoes collected), and a flip angle of 20°, with 1.25mm^3 resolution (FOV: 240x217.5mm^2, 144 partitions). MT weighted volumes were acquired at a TR of 30, with a TE ranging from 2.51 to 10.82ms, a flip angle of 12°, with magnetisation transfer contrast on, and 1.25x1x1mm resolution. Calculation and optimisation of MT saturation maps and acquisition is discussed in Chapter 3.

2.5.3 MPRAGE

Standard T1 weighted volumes for VBM are acquired with a magnetization-prepared rapid gradient echo sequence (MPRAGE) (Mugler & Brookeman 1990) along the axial plane with an isotropic voxel resolution of 1mm^3 (FOV: 256x240mm^2, 192 partitions), with a TR of 27.3 ms, TE of 3.57ms and a flip angle of 7°.

2.5.4   Task-based fMRI

T2*-weighted echo planar images (EPIs) were acquired on a 1.5T Siemens Avanto MR scanner equipped with a 32 channel head-coil using a -30° tilted acquisition to reduce orbitofrontal dropout (Deichmann et al. 2003). Each volume provided whole brain coverage (34 interleaved ascending 3mm axial slices with 1mm inter-slice gap, echo-time 43msec: TR 2.52s, in-plane resolution 3mm).

2.5.5   Multi-echo resting state EPI

Resting-state functional images were collected with a multi-echo EPI sequence (Poser et al. 2006) with a FOV of 240x240mm and 31 axial slices. Slice thickness was 4.2mm, with an in plane resolution of 3.8mm^2. Acquisition occurs with a TR 2.57s, and flip angle of 90°. TEs are at 15, 34, and 54ms. Although these data were not analysed for this thesis, they were acquired within this overarching study so are here for completeness.

2.6　Demographics

Demographic and behavioural data for ADHD and control participants are summarized in Table 2.2.Groups were matched for age (ADHD: 33.7(±1.7) years, controls: 32.6(±1.7)) years, $F_{(1,58)}$=0.20, p=0.66), IQ (ADHD: 109.0±1.2, controls: 110.1±1.3, $F_{(1,58)}$=0.40, p=0.53), gender and handedness. The ADHD group scored significantly higher on all CAARS subscales. ADHD participants had significantly higher scores on the BDI (ADHD=13.7 (±0.9), controls = 5.6 (±1.2), $F_{(1,58)}$=17.01, p<0.001) and STAI trait anxiety (Trait: ADHD=53.5 (±2.0), controls=36.5 (±2.0), $F_{(1,58)}$= 36.51, p<0.001).

Table 2.2 Participant demographics

Measure	Mean scores (SE)		F	p
	ADHD	Controls		
N	30	30	---	---
Male	19	19	---	---
Female	11	11	---	---
Age	33.7 (1.74)	32.6 (1.2)	0.20	0.66
Handedness				
Right-dominant	28	29	---	---
Left-dominant	1	1	---	---
Ambidextrous	1	0	---	---
FSIQ[1]	109.0 (1.2)	110.1 (1.3)	0.40	0.53
CAARS ADHD Index	24.0 (1.0)	8.6 (0.9)	133.21	<.001
Attention/Memory problems	26.7 (1.0)	9.9 (1.0)	123.48	<.001
Hyperactivity/Motor restlessness	24.4 (1.2)	11.3 (1.0)	68.81	<.001
Impulsivity/Emotional lability	23.7 (1.3)	7.6 (0.8)	109.13	<.001
Problems with self-concept	11.3 (0.9)	5.6 (0.8)	22.50	<.001
DSM Total ADHD score	37.6 (1.6)	11.8 (1.3)	159.66	<.001
DSM Inattention	19.3 (0.8)	7.0 (0.8)	125.28	<.001
DSM Hyperactivity & Impulsivity	18.3 (1.0)	5.7 (0.7)	110.44	<.001

[1] As estimated by National Adult Reading Test (NART) scores

2.6.1 Medication

Twenty-eight ADHD participants were treated with methylphenidate and two with dexamphetamine. Within those taking methylphenidate, a variety of different regimens were observed (Figure 2.1). Several ADHD and control participants were also taking SSRI or SNRI antidepressant. Fischer's Exact Test (FET) detected no significant different between the groups (ADHD = 6, Controls = 1, p = .103). In order to calculate approximate equivalent doses between methylphenidate and dexamfetamine, dexamfetamine doses were doubled. This is supported by various studies performing comparative analysis of the two drugs (for a review, see (Arnold 2000)), as well as the maximum recommended dose according to NICE guidelines. The mean methylphenidate dose in mg for the ADHD group was 50 ± 21.0. Excluding participants currently taking dexamfetamine, daily methylphenidate dose in mg was 49.7 ± 21.7.

Immediate release methylphenidate dose for controls was matched to the daily doses observed in the ADHD group. The equivalent immediate release dose for the ADHD group was therefore calculated based on mean daily dose, to account for differences in drug formulation and release schedule. The NICE recommendation of an immediate-release methylphenidate dose schedule of 1-4 times (mean 2.5), therefore indicates a 20mg equivalent acute dose. As such, 20mg of immediate-release methylphenidate was administered to controls.

Figure 2.1 Distribution of medication regimens in the ADHD group

3 Detection of persistent striatal abnormalities in adult ADHD using MT saturation but not T1 weighted VBM

Attention Deficit Hyperactivity Disorder (ADHD) in childhood has been robustly linked to striatal volumetric abnormalities. By contrast, such differences have been less frequently detected in adult population voxel-based morphometry (VBM) studies. This has been suggested to reflect maturation- and treatment-related normalisation of striatal morphometry. The absence of striatal volumetric reductions in adult ADHD would also suggest that whilst abnormal striatal volumes are central to childhood ADHD, they do not necessarily explain the persistence of these symptoms in adulthood. However, several contradictory findings suggest that striatal morphological abnormalities may not remit over time. Instead, the lack of voxel-wise whole-brain corrected evidence implicating the striatum in adult ADHD may reflect the poor sensitivity of T1 weighted images to detecting subcortical changes. To address this, I performed VBM of both magnetisation transfer (MT) saturation maps optimised for subcortical contrast and T1 weighted images in 30 patients with ADHD and 30 age, IQ, gender and handedness matched controls. In ADHD, volumetric reductions within the left ventral striatum were observed using MT saturation VBM. Identically pre-processed VBM analyses of T1 weighted images in the same subjects were however insensitive to these differences. By contrast, both techniques report similar abnormalities in the right inferior parietal cortex. Finally, I show that differences in striatal iron content may explain the reduced sensitivity of T1-weighted images to detecting striatal volumetric differences in adult ADHD. These results suggest that prior VBM studies reporting an absence of differences in the striatum in adult ADHD reflects methodological insensitivity of T1 weighted VBM to these changes, and that striatal abnormalities in ADHD persist into adulthood.

3.1   Introduction

As discussed, the striatum has been a central focus of ADHD research. Morphometric studies have offered a non-invasive and easily replicable method for indexing striatal abnormalities in childhood ADHD. VBM results have confirmed the significance of these even in assumption free analyses without *a priori* regions of interest and using stringent criteria for whole brain statistical correction. These results have been less consistent in adulthood however, and whilst large scale meta-analyses have confirmed the importance of altered striatal morphology in childhood ADHD these reports have not supported the presence of these abnormalities in adulthood (Frodl & Skokauskas 2012). Such findings have suggested that this may be due to a normalisation of striatal volumes with age and long term treatment (Nakao et al. 2011). The absence of striatal differences in these symptomatic adult ADHD samples would also however suggest that ongoing abnormalities in striatal morphology are not required for the persistence of symptoms.

Other methodological explanations could however account for the absence of whole-brain corrected results implicating the striatum in adult ADHD. Indeed, less statistically stringent ROI based approaches have detected striatal changes in adult ADHD samples where whole-brain statistical correction were not met (Almeida Montes et al. 2010; Seidman et al. 2011). Importantly, large prospective VBM investigations have also suggested that striatal abnormalities are observed in adult ADHD when followed up from childhood (Proal et al. 2011). Interestingly, in this prospective dataset no effects of medication on these striatal differences were detected.

A currently unexplored reason for explaining these apparently contradictory findings may be poor methodological sensitivity. Not only have meta-analyses had smaller samples of adult studies to draw on, but T1 weighted volumes that are typically used in these VBM studies have poor subcortical contrast, and subsequently produce less accurate automated segmentations. Specifically, the complex white matter pathways entwined within subcortical structures mean that grey and white matter boundaries are less well defined (Helms et al. 2009). Moreover, the high levels of brain iron in these regions is well demonstrated to shorted T1 thus reducing image contrast (Helms et al. 2009). Problematically, subcortical segmentation accuracy using T1-weighted images may actually also worsen with age; striatal iron is well documented to accumulate over the lifespan (Martin et al. 1998). This would therefore be predicted to reduce

segmentation accuracy in older participants. Recent evidence has also suggested that ADHD (Cortese et al. 2012; Adisetiyo et al. 2014), and possibly its treatment (Adisetiyo et al. 2014), are also associated with altered brain iron levels. Previous investigations using T1 weighted images to examine the impact of ADHD status, medication and maturation on striatal volumes may therefore have been systematically biased by these factors. Improving methodological accuracy and sensitivity in VBM analyses is therefore essential to examine whether striatal volumetric differences associated with ADHD do indeed ameliorate with maturation and stimulant treatment, or if the absence of striatal findings in adulthood rather reflects other confounding factors.

MT saturation maps derived from a multi-echo fast angle low shot (FLASH) 3D multi-parameter protocols have exquisite subcortical contrast, providing superior automatic segmentation to T1 weighted images traditionally used in VBM (Helms et al. 2009). Due to the sensitivity to macromolecular proteins such as myelin, MT saturation maps allow more accurate delineation of the complex white patter pathways within the striatum and other subcortical regions. Importantly, MT saturation maps are also not affected by the T1 shortening effects of iron highly concentrated in the basal ganglia (Helms, Dathe, Kallenberg, et al. 2008). I therefore sought to leverage this improved anatomical accuracy to offer a more definitive examination of any structural changes associated with ADHD in adulthood. As well as attempting to reconcile some of the inconsistencies in the ADHD literature, I also sought to compare the sensitivity of MT saturation with T1 maps to structural differences in the same group of participants.

This work therefore employs VBM of MT saturation maps in 30 adults with ADHD and 30 age-, IQ- and gender-matched controls. To specifically assess any enhancements in sensitivity proffered by this approach, I compare these results to a typical VBM analysis of T1 weighted images in the same subjects.

3.2   Methods

3.2.1   MT background

3.2.1.1 The basis of MT contrast

Protons bound to macromolecules such as large proteins, myelin and cell membranes are not detectable by typical MR sequences, due to their restricted range of movement resulting in the MR signal decaying more rapidly (~tens of microseconds) than is measurable using typical echo times (~milliseconds). Such sequences are therefore restricted to measurement of 'free' protons in liquids that are highly mobile, and have longer signal decay times. However, as these free protons are in constant motion, they frequently come into contact with macromolecular proteins, where protons may exchange between the free and macromolecular pools. MT imaging exploits this interactive magnetisation exchange that occurs either by direct exchange of the hydrogen atom or spin-spin interactions to quantify macromolecular presence (Henkelman et al. 2001).

Proton T2 is reflected in the width of the resonance line in the MR spectrum. Mobile protons with a long T2 have a narrow resonance line around the L'armor frequency (the frequency at which proton magnetic moments precess in the magnetic field). By contrast, macromolecular protons with a short T2 have a broad resonance line (Figure 3.1). By using an RF pulse with a frequency that is distant from the central narrow resonance line ('off-resonance') that is characterised by long T2/mobile protons, it is possible to selectively excite macromolecular protons without affecting the liquid ones (Figure 3.2). With sufficient off-resonance power applied, macromolecular spins reach a state of saturation, where up and down spins are equalised and net magnetisation vector reaches zero. If this magnetisation is partially transferred to the liquid protons via magnetization exchange, they can become partially saturated, resulting in reduced signal intensity. This signal attenuation in regions where fluid and macromolecular protons are in contact forms the basis of MT contrast.

Figure 3.1 Magnetisation exchange between macromolecular and liquid protons. Reproduced from (Horsfield & Cercignani 2015).

A macromolecule with functional groups (R) with bonded hydrogen (H) atoms that are available to exchange with those in water. Hydrogen atoms within macromolecules are relatively immobile, thus exhibiting a short T2 not normally detectable on an MR image and a broad resonance line in the MR spectrum. Hydrogen atoms within liquids move freely, have a long T2 and a narrow line of resonance. Spin states of macromolecular and mobile protons are in exchange, so the magnetisation within the macromolecule has an effect on those in fluid.

Figure 3.2 Effects on magnetisation exchange on signal MR signal amplitude. Reproduced from (Horsfield & Cercignani 2015).

An off resonance frequency pulse will only directly excite bound molecular protons, and not those in fluid. However, if there is magnetisation is transferred to the fluid the signal amplitude is reduced (b), resulting in reduced signal in voxels where fluid is in contact with macromolecules.

3.2.1.2 MT saturation

This chapter employs measures of MT saturation with the specific goal of maximising subcortical contrast. Whilst other approaches have a greater ability to quantitatively index macromolecular proton properties, this is coupled with a higher level of model complexity and greater scan times needed for robust parameter estimation (Levesque & Pike 2009). Here I instead apply a simplified model of MT saturation developed by Helms et al which requires measurement of just three parameters (Helms, Dathe, Kallenberg, et al. 2008) using an adapted multi-parameter FLASH-3D protocol, and can be used to derive MT saturation maps with excellent subcortical contrast (Helms et al. 2009). Specifically, 3 volumes are acquired. The first 2, without MT saturation, are proton density- (S_{PD}) and T1-weighted (S_{T1}), respectively. If small flip angles (**α**) are used, and TRs are much shorter than the T_1 of tissue, the signal equation for a FLASH sequence can be approximated as

$$S = A\alpha \frac{TR/T_1}{\alpha^2/2 + TR/T_1}$$ [Eq 3.1]

By combining S_{PD} and S_{T1} and using Eq 3.1 it is possible to estimate *A* (the amplitude of the echo at TE) and T_1 (Helms, Dathe & Dechent 2008).

For the third volume, which is MT-weighted, Helms et al (Helms, Dathe & Dechent 2008) showed that the signal can be approximated by

$$S_{MT} = A\alpha \frac{TR/T_1}{\alpha^2/2 + \delta + TR/T_1},$$ [Eq 3.2]

Where δ is the MT saturation, which can be calculated with knowledge of A and T_1.

MT saturation derived from such protocols have been shown to be sensitive to myelin changes (Draganski et al. 2011), and offer superior contrast in subcortical regions to T1 weighted images (Helms et al. 2009). Due to the nature of these maps, they are also inherently corrected for B0 field inhomogeneities and T1 effects (Helms, Dathe, Kallenberg, et al. 2008). Importantly, for the purposes of the present study, this excludes bias resulting from the T1 shortening effects of iron.

3.2.2 MT Optimisation

To optimise the MT sequence used for the study, I sought to select the best combination of acquisition parameters within acceptable times to maximize the contrast-to-noise ratio (CNR) between the SN/VTA and the surrounding white matter. This was specifically performed on the SN/VTA to improve anatomical accuracy in manual tracing for the parcellation analyses in Chapter 4, but also assuming that the acquisition parameters derived would improve the contrast between all the subcortical structures and the neighbouring white matter.

3.2.2.1 Theory

Based on Eq 3.2, it is possible to estimate the MT saturation, δ as:

$$\delta = \left(\frac{A\alpha}{S_{MT}} - 1 \right) R_1 TR - \frac{\alpha^2}{2} \qquad \text{[Eq 3.3]}$$

Where R1: inverse of T_1. Contrast, C, on the MT saturation images, can therefore be defined as the difference between the MT saturation value in the substantia nigra (δ_{SN}) and in the white matter (δ_{WM}). As differing acquisition parameters also affect the signal-to-noise ratio (SNR) of the δ maps, and the CNR is affected by the SNR, the propagation of error equation (Bevington 1969) was used to estimate the variance of the signal in δ maps, relative to the variance of S_{MT} (MT signal):

$$var(\delta) = \frac{\partial \delta}{\partial S_{MT}} = \frac{A\alpha R_1 TR}{S_{MT}^2} \qquad \text{[Eq 3.4]}$$

With knowledge of the quantitative MT parameters of the anatomical areas of interest, it is possible to use Sled and Pike's model of MT (Sled & Pike 2000) signal to simulate S_{MT} in both, eq 3.1 and 3.2. This model expresses the expected signal in a MT-saturated acquisition as a function of both, intrinsic tissue parameters regulating relaxometry and MT exchange, and acquisition parameters such as the amount of MT saturation. The contrast-to-noise ratio (CNR) can then be estimated as:

$$CNR = \frac{\delta_{WM} - \delta_{SN}}{\frac{1}{2}\sqrt{var(\delta_{SN}) - var(\delta_{WM})}} \qquad \text{[Eq 3.5]}$$

3.2.2.2 Simulations

The quantitative MT parameters (R_1, T_{2f}, T_{2r}, k_f, F) in Sled and Pike's model were calculated from full qMT datasets obtained from 5 healthy subjects. First, the substantia nigra and cerebral peduncles were manually outlined on proton-density weighted images to avoid bias (Figure 3.3). S_{MT} was then calculated for the substantia nigra and cerebral peduncles (left and right pooled, averaged across subjects) as a function of MT saturation power and offset frequency. This expression was then incorporated into eqs 3.1 and 3.2, and thus eq 3.3. The maximum CNR value was then estimated by searching the parameter space using the following parameter ranges: TR: 20-30ms; α: 3° to 15°; MT pulse power (ω): 200 to 900 rad/s; MT pulse offset frequency (Δ): 1 to 5 kHz. This generated optimal acquisition values, i.e. the values of of TR, α, ω and Δ that maximises the CNR for the substantia nigra.

Figure 3.3 ROIs for qMT parameter estimates.

Estimates of qMT parameters were taken from ROIs (left and right substantia nigra, left and right cerebral peduncles) manually outlined on proton density scans (blue=left peduncle, red=right peduncle, green=left SN, orange=right SN)

3.2.2.3 Testing simulation predictions

To test whether the predictions from these simulations resulted in improved data from the MT sequence, I compared the optimal MT sequence against two sub-optimal sequences, all acquired from the same healthy participant (male, 24 years old). From this participant three MT-weighted 3D FLASH sequences (4 echoes, TEs ranging from 2.51 to 10.82 ms) were collected with 3 different combinations of TR, α, ω, and Δ

based on the results of the simulations. The optimal acquisition had a TR of 30ms, α of 12°, ω of 900 rad/s, Δ of 1kHz. The first suboptimal acquisition had a TR of 24ms, an α of 6°, ω of 900 rad/s, Δ of 1kHz, and the second suboptimal acquisition had a TR of 30ms, an α of 12°, ω of 300 rad/s, Δ of 1kHz. In addition to this one proton-density weighted multi-echo 3D FLASH (4 echoes, same TEs as above, TR=24, α=6°) and a T1-weighted 3D FLASH (4 echoes, same TEs as above, TR=19 ms, α=6°) set were acquired.

In order to ascertain if the optimal acquisition improved the CNR in this sample, A, R_1 and δ maps for each of the MT sequences were calculated as described above (Helms et al. 2009). From these maps, ROIs were delineated (as above). S_{MT} values were obtained from these ROIs for each of the 3 δ maps (Figure 3.4), with the relative contrast estimated for each as $C_r=(\delta_{WM}-\delta_{SN})/(\delta_{WM}+\delta_{SN})$.

Figure 3.4 δ maps with differing acquisition parameters.

(a) shows the optimal acquisition, (b) shows suboptimal acquisition 1 and (c) shows suboptimal acquisition 2

C_r was 0.126 for the optimal acquisition, 0.088 for suboptimal acquisition 1, and 0.160 for suboptimal acquisition 2. Visual examination of the images revealed that suboptimal acquisition 2 was too noisy to be considered for further analysis (Figure 3.4c), despite having the highest C_r, reiterating the importance of optimising the CNR, instead of the contrast. Of the two usable scans, the C_r was highest for the optimal acquisition. To ascertain the impact this analysis had on segmentation of the substantia nigra, the VBM8 segmentation tool was used. Results show far clearer segmentation of the substantia nigra on the optimal acquisition (Figure 3.5).

Figure 3.5 Segmentation of the substantia nigra after (a) Optimal acquisition (b) Suboptimal acquisition 1

3.2.3   VBM study methods

3.2.3.1 Participants

Data from all thirty patients with ADHD (mean 34 (±9.5) years; 19 male) and 30 controls (mean 33 (± 9.5) years; 19 male) were included in the analyses reported below. See Methods chapter (Chapter 2) for overall sample characteristics

3.2.3.2 Questionnaires

The CAARS (Conners et al. 1999) was used to index current ADHD symptom severity, and BDI (Beck et al. 1996) and STAI (Spielberger 1983) were used to assess depression and anxiety scores respectively.

3.2.3.3 Scanning

MT maps were calculated from a multi-parameter protocol adapted from a 3D FLASH sequence (Weiskopf & Helms 2008).   Three co-localised 3D multi-echo flash

sequences were acquired in the sagittal plane, each with 1.25mm^3 resolution (FOV: 240x217.5mm^2, 144 partitions). Proton density weighted volumes were acquired with TR=24ms, TE from 2.51 to 21.9ms (eight equidistant bipolar echoes collected), and flip angle (α) of 6°. T1 weighted volumes were acquired at TR=19ms, TE ranging from 2.51 to 10.82ms (four equidistant bipolar echoes collected), and a flip angle of 20°. MT weighted volumes were acquired at TR=30ms, with the same 4 TEs as the T1-weighted volumes, a flip angle of 12°, and with magnetisation transfer contrast on. These parameters were selected to maximise the contrast between the white matter and the substantia nigra as described in the previous section. Standard T1 weighted volumes for VBM are acquired with a magnetization-prepared rapid gradient echo sequence (MPRAGE) (Mugler & Brookeman 1990) along the axial plane with an isotropic voxel resolution of 1mm^3 (FOV: 256x240mm^2, 192 partitions), with TR=27.3ms, TE=3.57ms and a flip angle of 7°.

3.2.3.4 Computation of MT saturation maps

The multiple echoes were averaged for each acquisition volume, and the resulting volumes were co-registered (with FLIRT, part of FS) using the T1-weighted image as a reference. The MT saturation, δ, was calculated voxelwise according to Eq 3.3, after deriving A and T1 as described by Helms et al. (Helms, Dathe, Kallenberg, et al. 2008). The resulting maps show a contrast similar to T1-weighted scans and can be entered directly into a VBM pipeline.

3.2.3.5 VBM preprocessing and analysis

MT saturation and T1 weighted maps were processed with identical pipeline. First, they were segmented using the VBM8 toolbox in SPM8 (http://www.fil.ion.ucl.ac.uk/spm/) and then smoothed with a 5mm^3 Gaussian kernel. Group comparisons were performed according to the General Linear Model (GLM), controlling for age, total intracranial volumes (derived separately for each modality), and BDI and STAI trait scores. Treatment effects within the ADHD group were examined in SPM using regression analyses, with length of time on medication (in months) as the variable of interest and age, total intracranial volume, BDI and STAI trait scores as covariates. Analyses were thresholded at $p < 0.001$ uncorrected, with surviving

clusters thresholded at $p < 0.05$ corrected for False Discovery Rate (FDR) at cluster level.

3.2.3.6 Iron content assessment

Densely packed ferric ions in ferritin cause local changes in magnetic susceptibility, with surrounding water molecules experiencing a higher magnetic field and shortening relaxation times of molecules diffusing through them. T2* images, which measure 'observed' transverse relaxation time, incorporate relaxation associated with such field inhomogeneities, in addition to the contributions of 'true' tissue relaxation reflecting spin spin interactions (ie T2), in addition to contributions from local magnetic field inhomogeneity. R2* (1/T2*) therefore gives the rate of relaxation associated with local field inhomogeneities, and has been shown to correspond highly to grey matter iron concentrations in post-mortem investigations (Langkammer et al. 2010).

Post-hoc assessment of iron content was therefore indexed in the left ventral striatum using R2* (=1/T2*) maps and a mask derived from Martinez et al. (Martinez et al. 2003). R2* Maps were obtained from the PD-density images acquired during the 3D flash sequence. As 8 echoes are acquired for this scans, R2* could be estimated by linear fitting of the equation $\ln(S(t)) = \ln(S0) - tR2*$ to the 8 echo images. In the equation, S is the measured signal, S0 is the signal at the equilibrium, t is time at which the signal is sampled (corresponding to the 8 TEs) and R2* is the transverse relaxation rate to be estimated.

3.3   Results

3.3.1   MT saturation maps

Group average MT saturation map is shown alongside a corresponding T1 group average (Figure 3.6). The comparison clearly shows the augmented contrast in subcortical regions. The difference of averaged segmentations from each modality also shows clear enhancement in subcortical segmentation (Figure 3.6).

Figure 3.6 Comparison of group-averaged MT and T1 weighted volumes.

Top: Group averages of MT saturation compared to T1 show enhanced subcortical contrast. Bottom: Difference (MT-T1) in image intensity of segmented averaged maps showing enhanced contrast and segmentation in subcortical regions.

3.3.2   VBM results

MT saturation VBM revealed lower grey matter volumes in the left ventral striatum (*FDR p* < 0.05*)* and right inferior parietal lobe in ADHD compared to controls (*FDR p* < 0.05*)* (Figure 3.7; Figure 3.8; Table 3.1). By contrast, T1 weighted VBM reported the same abnormalities in the right inferior parietal lobe (albeit not reaching FDR cluster level significance), but did not reveal any volumetric alterations in striatal regions (Figure 3.8; Table 3.2). Neither modality detected statistically significant volumetric increases in the ADHD group compared to controls. Finally to test whether the length of time on medication indicated any normalisation or other changes in regional brain volumes within the ADHD group, I assessed negative and positive correlations between medication time and T1 and MT images. No statistically significant effects of medication were detected using T1 weighted or MT saturation VBM.

3.3.3   Iron alterations in the left ventral striatum

To examine whether abnormal iron content may contribute to the methodological insensitivity of T1 to the left hemispheric ventral striatal abnormalities reported, I used a ROI approach to assess $R2^*$ as an index for brain iron content. This revealed increased $R2^*$ in ADHD (14.20 ± 2.89) compared to controls (13.26 ± 1.56) in the left ventral striatum ($F(1, 54) = 5.60$, $p = 0.002$). Finally, I examined whether these iron differences in ADHD might be influenced by ageing or medication use. Left ventral striatal $R2^*$ correlated with age (*rho* = 0.37, $p = 0.045$), but not time on medication ($p > 0.05$).

Figure 3.7 Ventral striatal abnormalities in ADHD.

Left ventral striatal volumetric reductions in ADHD detected using MT saturation maps (*p unc.* < 0.001; *FDR* < 0.05) not detected in T1 weighted volumes.

Table 3.1 MT saturation VBM results: ADHD < Controls

Region	Peak Coordinates	Z	k (cluster)	p unc. (cluster)	p (FDR) (cluter)
Left ventral striatum	[-20 9 -14]	3.63	189	0.005	0.043*
	[-18 8 -8]	3.39			
Right inferior parietal	[59 -45 37]	4.46	294	0.001	0.014*
	[51 -42 -28]	4.24			

Figure 3.8. Inferior parietal volumetric abnormalities in ADHD.

Left inferior parietal volumetric reductions in ADHD detected using MT saturation maps (*p unc.* < 0.001; *FDR* < 0.05). The same reductions are detected in T1 images (*p < unc. 0.001*) but clusters (*p unc. = 0.027; p unc. = 0.078*) do not survive FDR correction.

Table 3.2 T1 VBM results: ADHD < Controls

Region	Peak Coordinates	Z	*k* *(cluster)*	*p unc.* *(cluster)*	*p (FDR)* *(cluter)*
Right inferior parietal	[51 -43 28]	4.31	111	0.027	0.377
Right inferior parietal	[56 -43 40]	3.87	67	0.078	0.543

3.4   Discussion

Using MT saturation VBM this work reports, contrary to previous findings, that ventral striatal volumetric reductions persist in adults with ADHD even in patients who have undergone long-term treatment with stimulant medication. Moreover, it shows that

identically analysed T1 weighted images of the same subjects are not sufficiently sensitive to detect these striatal abnormalities. Our data therefore strongly suggest that the absence of striatal volumetric differences in previous T1-weighted VBM studies reflect a low methodological sensitivity to subcortical changes, rather than volumetric normalisation associated with maturation or treatment. This appears to arise from poor segmentation accuracy owing to heightened iron content in the striatum. By contrast, both T1 weighted and MT saturation VBM produce similar results in non-subcortical regions such as the inferior parietal cortex.

The observed structural abnormalities in the ventral portion of the striatum indicate the importance of the mesolimbic reward system in ADHD. Inattentive (Volkow et al. 2007) and hyperactive symptoms (Rosa Neto et al. 2002) are linked to striatal dopaminergic signalling, and striatal reward dysfunction (Scheres et al. 2007) is increasingly seen as a central aetiological component of ADHD (Luman et al. 2010). Our findings suggest that these reward system abnormalities persist well into adulthood. This is in contrast to previous meta-analyses which have shifted focus to cortical regions in adulthood, such as the anterior (Frodl & Skokauskas 2012) and posterior cingulate (Nakao et al. 2011). The absence of striatal volumetric reductions in adulthood underpinning this has been suggested to reflect maturational or treatment effects (Nakao et al. 2011). However, this data suggests that this rather reflects difficulties with subcortical segmentation using T1 weighted volumes employed in these studies. Indeed, this work shows that MT saturation VBM has vastly improved sensitivity to striatal abnormalities in adult ADHD when compared to T1 weighted images of the same sample.

Whilst the present findings do not provide support for maturational or treatment related normalisation of the striatum, future longitudinal studies will be needed to directly assess this. Apparent effects of maturation and treatment on striatal volume are certainly credible. However, aging and stimulant treatment may induce various effects on neurobiology that are detectable using MRI aside from grey matter volume. For instance, our data support the association between age (Martin et al. 1998) and ADHD (Cortese et al. 2012; Adisetiyo et al. 2014) (but not medication) with brain iron levels. Future longitudinal work must therefore carefully isolate such factors to accurately study these effects. This is particularly problematic given that one alteration (e.g. brain iron) may interfere with the measurement of another (e.g. volumetric measurement using T1 weighted images) (Helms et al. 2009). Adopting appropriate MR metrics to disentangle these factors and study how they are affected by variables of interest is therefore essential. In particular, this report suggests that T1 weighted imaging of the

striatum is inherently biased by other modulators of the MR signal, and is likely to produce confounded results.

MT saturation maps derived from multi-parameter protocols show greatly enhanced subcortical segmentation, owing to their increased sensitivity to myelin and exclusion of T1-shortening effects of iron (Helms et al. 2009). A variety of measures to index proton density, macromolecular/myelin content and iron can also be derived from such protocols. Such approaches therefore not only enhance sensitivity and specificity of subcortical imaging in ADHD, but also offer a richer range of semi-quantitative indices. Given the inherent problems with T1 weighted imaging of subcortical structures, adoption of multi-parameter sequences into standard imaging protocols would be highly beneficial.

In addition to ventral striatal abnormalities, volumetric reductions within the right inferior parietal lobe are observed. Structural differences within this region has been observed in previous studies though none meeting particularly stringent statistical thresholds (Seidman et al. 2011; N. Makris et al. 2015). However, the direction and laterality of these changes have been inconsistent. For instance, one study has found increased volume in the left inferior parietal lobe (Seidman et al. 2011), whilst one found decreased volume in the left hemisphere and increased volume in the right hemisphere (N. Makris et al. 2015). It is important to note that any directional differences between these previous studies and the present one is not due to the modality used as we detect these changes in analyses of both MT and T1 images. Although the reason for these discrepancies is unclear, these findings all appear to support the importance of attention networks in ADHD. In particular, these reductions appear to be localised within the PFm of the supramarginal gyrus which functionally forms part of the middle inferior parietal lobule (Caspers et al. 2013). The middle inferior parietal lobule (which consists of the PFm and PF subregions) has previously been shown to be activated during nonspatial attention tasks, in particular in re-evaluating conflicting options (Vossel et al. 2006; Boorman et al. 2009; Mevorach et al. 2009; Caspers et al. 2011), as well as spatial attention and reorienting tasks (Rushworth et al. 2001; Corbetta et al. 2008). Interestingly, this region also forms part of the ventral attention network (Corbetta & Shulman 2002) that has been shown to have a role in orienting toward salient stimuli (Fox et al. 2006). Functional connectivity differences in this ventral attention network have also been observed in ADHD (McCarthy et al. 2013) and have been suggested to play a role in distractability in the disorder due to abnormal orienting of attention towards salient stimuli (Aboitiz et al. 2014). Future multimodal (i.e.

structural and resting state functional connectivity) work will be required to assess how these grey matter volumetric abnormalities contribute to dysfunctional ventral attention network connectivity and its neuropsychological consequences.

The present findings encourage interpretative caution in the absence of evidence in T1 weighted imaging studies. This work shows that, rather than reflecting age or treatment related normalisation, the absence of striatal differences in previous studies likely reflects the inadequacy of T1 weighted volumes in detecting them. By contrast, these striatal abnormalities in adult ADHD are readily detectable using MT saturation VBM. Adoption of such protocols offers enhanced subcortical segmentation, and increased statistical sensitivity to detect subcortical abnormalities. Leveraging these benefits is essential in clarifying the role of subcortical structures in ADHD, as both age and disorder related iron content changes may systematically bias analyses using typical T1 weighted images.

4 Microstructure of the mesolimbic and nigrostriatal SN/VTA in ADHD: Relationship to motivation, waiting impulsivity and medication

Theoretical appraisals of Attention Deficit/Hyperactivity Disorder (ADHD) have focussed on aberrant dopaminergic signalling. Whilst the substantia nigra/ventral tegmental area (SN/VTA) is the primary source of dopamine in the brain, little is known of its direct role in the disorder. Recent evidence has strongly implicated reward dysfunction in ADHD, with notable reductions in both incentive motivation and the ability to wait for later rewards, or 'waiting' impulsivity. Preliminary findings have suggested that abnormalities in the SN/VTA may account for these differences in motivational and impulsive profiles. Problematically however, the SN/VTA consists of functionally distinct subcomponents, and previous studies have been unable to localise dysfunction at this sub-structural level. I therefore employ advancements in diffusion MRI tractography to parcellate the SN/VTA, and assess how the microstructure of its mesolimbic and nigrostriatal subcomponents contribute to motivation and waiting impulsivity abnormalities in 30 adults with ADHD when compared to 30 age, IQ, gender and handedness matched controls. Additionally, as psychostimulant medication does not appear to improve waiting impulsivity in animal models of ADHD and actually increases waiting impulsivity in controls, I tested whether this dissociation is also observed in humans in a double-blind placebo controlled manner. This work suggests that increased waiting impulsivity in ADHD is related to FA and MT abnormalities in the mesolimbic SN/VTA. By contrast, no motivational deficits are observed, though this may reflect long-term therapeutic effects of stimulant medication on the nigrostriatal SN/VTA. These results suggest dissociable effects of midbrain dopaminergic subcomponents in ADHD, and a selective effect of long term medication on the nigrostriatal SN/VTA. However, as predicted by animal models, acute stimulant medication had no effect on waiting impulsivity in the ADHD group, and heightened it in controls.

4.1 Introduction

The substantia nigra/ventral tegmental area (SN/VTA) has a central role in dopaminergic modulation of cortico-striatal networks classically associated with ADHD. Even distinct networks prominently implicated in ADHD, such as the default-mode and frontoparietal networks (Konrad & Eickhoff 2010; Castellanos & Proal 2012), appear to show clear dopaminergic modulation by the SN/VTA and its striatal targets (Cole et al. 2013). In spite of this central regulatory role there has been a paucity of work examining the SN/VTA in ADHD, largely due to limitations in non-invasive midbrain imaging.

4.1.1 Abnormal motivation and impulsivity and their relation to SN/VTA subcomponents

Investigations into the neuropsychological mechanisms underpinning ADHD have increasingly come to focus on abnormalities in reward and motivational function that are underpinned by the SN/VTA. For instance, attention problems in the disorder may reflect abnormalities in incentive motivation (Volkow et al. 2011). Similarly, hyperactive/impulsive symptoms in the disorder may be related to a more specific form of 'waiting' impulsivity, most frequently characterised by increased temporal discounting of reward values (Thorell 2007; Scheres et al. 2008; Scheres et al. 2010).

Preliminary work has suggested that both motivational abnormalities in ADHD (Volkow et al. 2011) and trait impulsivity (Buckholtz et al. 2010) are linked to SN/VTA D2/D3 receptor binding. However, the SN/VTA is not a functionally homogenous structure, and previous findings have been unable to determine whether these abnormalities are specific to a particular SN/VTA subregion. This is essential, as these subcomponents are characterised not just by distinct functional roles and anatomical connectivity (Haber et al. 2000; Haber 2003; Haber & Knutson 2010), but also remarkably different pharmacological response profiles (Browder et al. 1981; Ashby et al. 2000; Gervais & Rouillard 2000; Mereu et al. 1987; Klink et al. 2001; Mejías-Aponte et al. 2009; Goldstein & Litwin 1988). This work therefore uses diffusion MRI tractography to parcellate the SN/VTA into these functional subcomponents.

4.1.2 Background to diffusion MRI tractography based parcellation

4.1.2.1 Diffusion MRI

Diffusion is the random translational motion of molecules resulting from their thermal energy. Hydrogen protons within water molecules that form the basis of most biological MR applications are subject to this process, obeying a Gaussian distribution within a free medium. The biologically informative nature of diffusion MRI rests on the sensitivity to detect and quantify such diffusion processes, and how they are moderated by their surroundings.

In biological tissues, diffusion MRI is sensitive to the hindrance of diffusion by tissue microstructure (Le Bihan 2003), and thus provides an indirect measure of the size, orientation, and shape of cellular structures in vivo. Diffusion MR exploits the natural sensitivity of MRI to motion, using a pair of gradient pulses. The first results in excitation of protons that varies according to their spatial location. A second pulse is then used to detect changes in displacement since the first. This approach to measuring diffusion enables the diffusion coefficient to be measured along a single direction at a time. Very early on it became clear that in the white matter of the brain the diffusion coefficient strongly depends on the direction of measurement. At the microstructural level, highly myelinated axons greatly hinder diffusion in directions perpendicular to the axon, but allow for largely unrestricted diffusion along these axonal pathways (Moseley et al. 1990). This property is termed diffusion anisotropy. In analogy with other anisotropic phenomena, diffusion can be described by a 3x3 tensor matrix (Basser et al. 1994), which enables the overall tissue directionality within a voxel to be characterized. The elements of the tensor are defined with respect to a specific frame of reference, and thus are different for each system of coordinates; however, it is possible to define a number of scalar quantities that are rotationally invariant. The most popular are the mean diffusivity (MD), which reflects the magnitude of diffusion, irrespectively of directionality, and the fractional anisotropy (FA; (Basser & Pierpaoli 1996)), which quantifies the directionality of the tensor in a voxel. As the diffusion tensor is symmetric and positive definite, it has 6 unique elements. It is therefore possible to estimate its components by collecting a minimum of 6 images, weighted along 6 non-collinear directions, and a non-diffusion weighted scan. Multivariate linear regression can then be performed based on the tensor model. This procedure also

allows the principal direction of diffusion in a voxel to be derived. In practice, due to the presence of noise, a much larger number of images are acquired.

4.1.2.2 Higher order models

While characterizing diffusion using a tensor allows anisotropy and principal direction of diffusion to be obtained, the model is unable to resolve complex intra-voxel structures such as crossing or branching fibers. More complex models, aiming at deriving directional information from the molecular displacement profile have been introduced. This work employs one of these models, persistent angular structure (PAS) MRI (Jansons & Alexander 2003), which samples the Fourier transform of the probability density function of the water molecular displacements.

4.1.2.3 Tractography

Based on the assumption that the principal direction of diffusion in a voxel coincides with the principal axonal direction, patterns of contiguous inter-voxel directionality have offered a method for constructing representations of white matter pathways within the brain (Basser & Pierpaoli 1996; Mori et al. 1999; Basser et al. 2000; Catani et al. 2002). This method of tractography has been shown to produce 'reconstructions' of white matter pathways that offer a reasonable representation of anatomy determined by more accurate but invasive *ex-vivo* methods such as post-mortem blunt dissections and axonal tracing studies (Lawes et al. 2008). There are two main types of tractography algorithms: deterministic and probabilistic. Deterministic tractography follows the principal direction of diffusion to reconstruct estimates of the path of fibre bundles. This algorithm produces a single trajectory, often described as a streamline. The probabilistic approach considers multiple pathways emanating from a single seed-point, and assigns a probability of connection to the seed-point to every voxel in the brain. This chapter focusses specifically on the application of such probabilistic tractography methods to parcellate grey matter into functional subregions according to their anatomical connectivity.

4.1.2.4 Diffusion tractography based parcellation

Tractography based parcellation of grey matter is motivated by the concept that the functional specialization of grey matter is in large part defined by its patterns of connectivity to other brain regions. Exploiting this has been a central component to understanding regional specification beyond the capacity of traditional structural

imaging techniques, as functional specialization does not necessarily obey the traditional anatomical boundaries of nuclei and laminal surfaces, and gyri and sulci. An example of particular interest is the functionally defined ventral striatum. Whilst this is largely taken to correspond to the nucleus accumbens, this also encompasses surrounding medial and ventral putamen and caudate regions (Haber 2003). Due to this lack of confinement to typical anatomical boundaries, the extent of ventral striatum is not delineable using traditional structural imaging alone. Instead, the ventral striatum can be defined by its different patterns of connectivity to, amongst other regions, more medial and ventral regions of frontal cortex than the dorsal component of the striatum, which preferentially connects to more dorsal and lateral frontal regions (Haber 2003). Tractography based parcellation can therefore use these different patterns of connectivity to define functionally distinct ventral and dorsal subregions within the striatum.

The first application of this approach focused on the nuclei of the thalamus (Behrens et al. 2003). These thalamic subregions, due to their connections to distinct cortical regions, control the relay of information necessary for a range of different function. The parcellation required the definition of a seed-region to be segmented (in this case the thalamus) and a set of target regions, known to be connected to the seed (in this case, separate cortical regions). By performing probabilistic tractography for each voxel corresponding to the thalamus in a diffusion dataset, produced probability of connection to each of the targets can be assigned to it. In this early example, this allowed estimation of the most densely connected cortical target region for each thalamic voxel using a winner-takes all strategy (Behrens et al. 2003). Similar techniques have been applied to the SN/VTA.

Figure 4.1 Parcellation of the thalamus according to cortical connectivity.

Seven cortical target ROIs, and a thalamic target region are defined. After this, 10,000 streamline iterations were produced for each thalamic seed voxel, with the probability of connectivity to each target determined as the number of streamlines connecting the seed to that target. Seed identity was then determined according to a winner-takes-all strategy (ie each seed region is defined by the target with the greatest connection probability.

Adapted from (Behrens et al. 2003)

4.1.2.5 Parcellation approaches to the SN/VTA

Although MT saturation maps offer vastly improved SN/VTA contrast, the subcomponents of the SN/VTA appear as a single continuous hypo-intense region with no discriminable boundaries. Two previous studies have however successfully exploited the differential connectivity patterns of these subcomponents to parcellate the SN/VTA into functional subdivisions (Menke et al. 2010; Chowdhury et al. 2013). One approach using a target ROI, winner-takes-all method as the above example, used the preferential connectivity of the mesolimbic/dorsomedial SN/VTA and the nigrostriatal/ventrolateral SN/VTA to the ventral and dorsal striatum respectively (Chowdhury et al. 2013). The second paper adopted an alternative approach, using k means clustering to parcellate the SN into the SNpc and SNpr respectively without prior target regions (Menke et al. 2010). As the focus of this chapter is the dopaminergic midbrain specifically, and since we can rely on strong prior anatomical hypotheses regarding these connections due to previous animal work (Haber 2003; Haber & Knutson 2010), this work employ an adaptation of the first approach.

4.1.3   Parcellation of the mesolimbic and nigrostriatal SN/VTA

This approach also allows assessment of prior hypotheses about the neural correlates of motivation and waiting impulsivity. Waiting impulsivity in particular is partially underpinned by dopaminergic processing within the nucleus accumbens (Economidou et al. 2012). It would therefore be expected that the mesolimbic, rather than the nigrostriatal, SN/VTA would be responsible for this dopaminergic modulation. However, no work to date has assessed this. The correlates of incentive motivation within the SN/VTA also remain unclear. As noted previously, whilst early accounts suggested that the mesolimbic SN/VTA and ventral striatum underpin incentive motivation, converging evidence suggests that the SNpc (Rossi et al. 2013) and dorsal striatum (Volkow et al. 2002; Tomer et al. 2008). may be responsible for motivational processing. This work therefore employs this mesolimbic/nigrostriatal distinction to assess how abnormalities in waiting impulsivity, as indexed by a recently developed human 4-choice serial reaction time (4CSRT) task (Voon et al. 2014; Voon et al. 2015) (based on the animal 5CSRT task (Robinson et al. 2009)) and trait motivation are

localised in the SN/VTA in ADHD. In doing so, this also offers three advancements to the techniques used in the prior study.

Firstly, I expanded the connectivity target regions to other important subcortical structures that are preferentially connected the mesolimbic SN/VTA – namely the amygdala and hippocampus (Haber & Knutson 2010). Secondly, due to the small size of the SN/VTA, a novel upsampling method which is detailed below was applied to the diffusion data to perform the analysis at a higher resolution. Finally, rather than using a tensor (ie DTI) model that computes only one principal direction (PD) of diffusion, PAS MRI was employed (Jansons & Alexander 2003), modelling diffusion in up to three PDs per voxel. In addition to resolving crossing fibre configurations, this allows more accurate modelling of potentially multidirectional projections from a single seed voxel.

4.1.4 Extending the concept of waiting impulsivity in adult ADHD: 'Premature responding' and acute effects of medication

As noted, most work examining waiting impulsivity in ADHD has focused on TD. By contrast, a rich literature has also developed in animal models examining 'premature responding' to reward cues using the 5CSRT (Dalley et al. 2011). The 5CSRT has recently been translated to humans (Voon et al. 2014), which also offers the possibility of confirming several pharmacological findings in animal models. Specifically, work with animal models of ADHD suggest that poorer performers do not benefit from stimulant treatment on the rodent 5CSRT (Paterson et al. 2011), whilst normal performers actually see increased waiting impulsivity (Navarra et al. 2008). As an additional component to this work, I therefore also sought to assess the differential role of stimulant medication on waiting impulsivity (measured by the 4CSRT) in ADHD and the healthy population.

4.2   Methods

4.2.1   Participants

The same cohort of thirty patients with ADHD (mean 34 (±9.5) years; 19 male) and 30 healthy control participants (mean 33 (± 9.5) years; 19 male) described previously were included in the study.

4.2.2   Questionnaires

The Conner's self-report Adult ADHD Rating Scale (CAARS)(Conners et al. 1999) was used to index current ADHD symptom severity, and Beck's Depression Inventory (BDI; (Beck et al. 1996)) and the State and Trait Anxiety Inventory (STAI;(Spielberger 1983)) were used to assess depression and anxiety scores respectively. The Tridimensional Personality Questionnaire (TPQ; (Cloninger et al. 1991)) and Multidimensional Personality Questionnaire (MPQ) were administered (Tellegen & Waller 2008), with their respective persistence and achievement (as in (Tomer et al. 2008; Volkow et al. 2011)) subscales used as measures of trait motivation.

4.2.3   Waiting Impulsivity Task

Waiting impulsivity was measured using a computerised 4C-SRT task for humans (Voon et al. 2014). Participants were seated in front of a touch screen monitor. When four boxes appeared on the screen, the subject pressed and held down the space bar on the keyboard with their dominant index finger, indicating the 'cue onset' time. After a specified period (cue-target interval), a green circle appeared briefly and randomly in one of the four boxes. Subjects were previously instructed to release the space bar upon this cue, and touch the on-screen box in which the target had appeared (Figure 4.2). Fast and accurate responses were rewarded, with faster accurate responses rewarded more highly than slower ones (Figure 4.2). The primary outcome measures for impulsivity were premature responses (ie presses before the reward cue) and premature releases and responses combined (ie releases of the space bar before the reward cue, including both premature responses and when no response was made). These measures thus indexed impulsive waiting for reward, defined operationally as the tendency to respond *before* the onset of a reward cue (Robbins 2002). This

therefore reflects a form of an inappropriate anticipatory response to expected but uncued reward.

Two baseline blocks without monetary feedback were used to individualize monetary feedback amounts for subsequent blocks on the basis of the mean fastest reaction time (RT) and SD of the individual. Four Test blocks with monetary feedback were optimized to increase premature responding and varied by duration and variability of the cue-target interval and the presence of distractors. The block order for the task was as follows: Baseline block 1; Test block 1; Baseline block 2; Test blocks 2–4. Twenty-five participants with ADHD, and 28 controls completed the task.

Figure 4.2 Outline of 4-CSRT task.

A) Representation of 4-CSRT task. Participants were instructed to hold their finger on the space bar until a green dot appeared, at which point why removed their finger to tap the location of the green dot. B) Participants were given reward feedback, with rewards contingent on accurate responses and the amount won or lost determined by response speed.

4.2.4   Procedure

ADHD and healthy controls underwent scanning and behavioural testing as part of the double-blind placebo-controlled study previously detailed. After scanning and behavioural tests previously reported, participants underwent the 4C-SRT approximately 3 hours after ingestion of drug or placebo. See Chapter 2 for further details on timing of procedures.

4.2.5   MRI

All scanning was performed on a 1.5T Siemens Avanto. The scanner's body coil is used for RF transmission, and a 32-channel head coil for signal reception. For diffusion MR imaging a multi-slice twice refocused spin echo echo-planar imaging (EPI) acquisition was used, with 60 contiguous near axial slices acquired with $2.5mm^3$ isotropic voxels. Acquisition had a TE of 86ms, and a TR of 7.7s. A maximum diffusion weighting of b=1500 smm^{-2} was applied. 60 diffusion-weighted brain volumes with diffusion gradients uniformly distributed in space were collected at each slice location, as well as 7 volumes without diffusion weighting applied.

MT maps were calculated from a multi-parameter protocol adapted from a 3D multi-echo fast low angle shot (FLASH) sequence, described in chapter xx.

4.2.6   ROI definition

SN/VTA seed regions were traced, blind to diagnosis, on MT saturation maps. Freesurfer's *recon_all* function was used to derive subject specific masks for target ROIs (Fischl et al. 2002). For the nigrostriatal target, the caudate and putamen were combined into a dorsal striatal ROI. For the mesolimbic target, I extended previous work (Chowdhury et al. 2013) which had defined the mesolimbic portion of the SN/VTA by its connectivity to the nucleus accumbens alone. Due to the additional, well-defined mesolimbic connectivity patterns with the amygdala and hippocampus (Haber 2003; Haber & Knutson 2010), these regions were also included in the mesolimbic target. Freesurfer segmentation quality was carefully inspected before use. Data from one

participant, for whom a reliable segmentation could not be gained, was excluded from tractography analyses.

4.2.7 Preprocessing

Diffusion weighted (DW) volumes were corrected for eddy currents distortions and involuntary motion by affine registration. First, a within b-value coregistration was performed, and average b=0, and b=1500 smm^{-2} images were created and skull-stripped. The average DW image was coregistered to the mean b=0 image to obtain the transformation matching them. Each DW volume was realigned to the mean DW image and the transformation matching each DW volume with the b=0 image was obtained by combining the partial transformations from either previous steps. B matrices were then rotated according this combined transformation (Leemans & Jones 2009). The diffusion tensor was then estimated in every voxel and FA maps were exported using Camino (Cook et al. 2006). A PAS model of diffusion (Jansons & Alexander 2003) was then fitted at every voxel to obtain the fibre orientation distribution (FOD). The local maxima of this function corresponding to the principal directions of diffusion (PDs) were then extracted for each voxel, with a maximum of three PDs extracted per voxel.

Due to the small size of the SN/VTA connectivity-based parcellation was performed at the higher spatial resolution of the MT data, rather than the native diffusion space. Due to the nature of diffusion data, this operation requires a more complex pipeline than a simple coregistration. First, FA maps for each subject were warped to MT saturation maps using an initial affine transformation (T_{aff}) and a diffeomorphic non-linear transformation (T_{diff}) (using a greedy symmetric normalisation SyN model; (Avants et al. 2011)). To simplify rotation of the PDs in the transformation of diffusion data I applied only the linear (T_{aff}) transform to the diffusion data, and used the inverse non-linear (T_{diff}) transform to warp ROIs into this intermediate 'affine' space (Figure 4.3). As PDs from the PAS function are represented by vectors, a dyadic tensor was calculated from each set of PDs to preserve directional information during transformation as in (Cercignani et al. 2012). Diffusion data were therefore transformed according to T_{aff} with dyadic tensors rotated accordingly, before deriving new PDs from the tensors. Finally, probabilistic index of connectivity (PiCo) maps were then calculated for probabilistic tractography.

Figure 4.3 Co-registration pipeline for tractography analysis

FA images were registered to MT saturation maps with A) an initial affine transformation followed by B) a diffeomorphic nonlinear registration. Diffusion information were C) registered to intermediate 'affine' space (using transformation A) to simplify rotation of PDs. For this transformation, PDs were transformed into dyadic tensors to preserve rotational information, before being converted back to PDs. D) ROIs were transformed from MT space using the inverse diffeomorphic transform (from B).

4.2.8 Diffusion MRI tractography

Probabilistic tractography was performed using Euler integration and linear interpolation, and 5000 iterations for each PD in each seed voxel. Streamlines terminated when they reached either the dorsal striatum or limbic targets, or if they exceeded a curvature threshold of >80°. Each voxel connectivity value was then used to binarise the connection probability maps for each seed with a winner-takes-all strategy across each of the PDs. For group average map visualisation, results were transformed into a common space and thresholded at 50% of their maximum overlap.

4.2.9 Extraction of mean ROI microstructural indices

Micostructural indices were extracted from MT saturation and FA maps using subject-specific binarised masks of the nigrostriatal and mesolimbic SN/VTA produced during the tractography analyses.

4.2.10 Statistics

Statistical analyses were performed in SPSS 22. Repeated measures mixed model ANOVAs used to assess group differences in FA and MT separately, with Hemisphere and Subcomponent as within subject factors. Correlations were calculated Pearson's *r* partial correlation. Data were assessed for normality and normalised where possible, with medication duration log-transformed. In cases where transformations did not yield a normal distribution (TPQ 'Persistence' and MPQ 'Achievement' subscales), Spearman's *rho* partial correlations were used instead. One extreme outlier (> 4 SD from mean) in the 4CSRT RT data was removed. All comparisons were controlled for age, and BDI and trait anxiety scores, with additional control for total intracranial volume for brain imaging data.

4.3   Results

4.3.1   Behavioural findings

4.3.1.1 Premature responding

A significant drug*group interaction was observed for premature releases and responses ($F_{(1,48)}$ = 4.13, p = 0.048). Post hoc tests revealed that on placebo, the ADHD group were more prone to premature releasing and responding (17.4 ± 11.2) than the control group (12.1 ± 8.9) at trendwise significance (p = 0.063). Interestingly, drug administration showed a trend towards increased premature releases and responses in the control (20.3 ± 27.7; $F_{(1,27)}$ = 3.09, p = 0.090), but not the ADHD group (17.4 ± 11.7; $F_{(1,27)}$ = <0.01, p = 0.990). A similar interaction was also observed for premature releases/responses alone ($F_{(1,48)}$ = 4.12, p = 0.048), with the ADHD group showing similar performance on drug (9.9 ± 7.1)   and placebo (8.4 ± 6.6), and increased premature responding/releasing in the control group on drug (9.4 ± 19.8) compared to placebo (6.5 ± 5.2). However, post-hoc testing did not reveal any trends towards significance between the ADHD and control groups on premature releasing alone. No differences in reaction time were observed (Group x Drug: $F_{(1,47)}$ = <0.01, p = 0.957; Drug: $F_{(1,47)}$ = 0.31, p = 0.578; Group: $F_{(1,47)}$ = <0.01, p = 0.957 (Table 4.1).

Table 4.1 Behavioural responses on 4CSRT task

Measure	Mean scores (SD)	
	ADHD	Controls
Drug		
Prem. responses	9.9 (7.1)	9.4 (19.8)
Prem. releases & responses	17.4 (11.7)	20.3 (27.7)
Reaction time (ms)	605.0 (263.3)	609.1 (126.9)
Placebo		
Prem. responses	8.4 (6.6)	6.5 (5.2)
Prem. releases & responses	17.4 (11.2)	12.1 (8.9)
Reaction time (ms)	578.7 (135.4)	593.0 (105.5)

4.3.1.2 Motivation

In contrast with previous results in medication-naïve subjects with ADHD (Volkow et al. 2011), there appear to be no differences in motivation compared to controls in either the TPQ (ADHD: 5.3 ± 2.3; Control: 4.7 ± 2.0; $F_{(1,54)}$ = 0.77, p = 0.383) or MPQ subscales (ADHD: 11.8 ± 5.1; Control: 11.4 ± 4.5; $F_{(1,54)}$ = 2.45, p = 0.123).

4.3.2   Parcellation

The parcellation produced results comparable with animal tracer studies (Haber et al. 2000) and previously published parcellations of the substantia nigra (Chowdhury et al. 2013). This reveals a nigrostriatal cluster (Left: 533.7±161.95mm^3 Right: 548.7±135.40161.95mm^3) comprising the ventrolateral portion of the SN/VTA, and a mesolimbic cluster (Left: 103.2±68.58mm^3 Right: 90.0±62.20mm^3) in a more dorsomedial region (Figure 4.4).

Figure 4.4 Parcellation of the SN/VTA into mesolimbic (light blue) and nigrostriatal (dark blue) components.

Table 4.2. Fractional anisotropy and MT saturation values in the SN/VTA

Measure	Mean scores (SD)		F	p
	ADHD	Controls		
FA				
L. Nigrostriatal	0.411 (0.030)	0.415 (0.029)	1.00	0.323
L. Mesolimbic	0.339 (0.048)	0.366 (0.047)	4.98	0.030*
R. Nigrostriatal	0.413 (0.031)	0.423 (0.027)	2.90	0.094
R. Mesolimbic	0.338 (0.065)	0.340 (0.042)	0.02	0.897
MT				
L. Nigrostriatal	4.563 (0.210)	4.561 (0.564)	0.41	0.526
L. Mesolimbic	3.810 (0.564)	4.110 (0.431)	3.84	0.055
R. Nigrostriatal	4.591 (0.222)	4.602 (0.212)	1.35	0.251
R. Mesolimbic	3.857 (0.823)	3.713 (0.575)	0.45	0.503

4.3.2.1 Substantia nigra/ventral tegmental area microstructural measures

Differences were observed in FA of SN/VTA subregions, with a significant group x subregion x hemisphere interaction ($F_{(1,54)}$ = 4.39, *p* = 0.041), with post hoc comparisons revealed significant differences in the left dorsomedial component (*p* = 0.030), and trend to significance in the right ventrolateral component (*p* = 0.094; Table 4.1). Group differences in MT saturation in these regions were also observed (group x subregion x hemisphere; $F_{(1,54)}$ = 4.20, *p* = 0.046).

4.3.2.2 Relationship between behavioural measures and SN/VTA microstructure

Increased waiting impulsivity in ADHD was associated with reduced FA (Responses: *r* = -0.59, *p* = 0.006; Responses and Releases: *r* = -0.55, *p* = 0.012) and MT saturation level (Responses: *r* = -0.48, *p* = 0.032; Responses and Releases: *r* = -0.49, *p* = 0.028) in the right mesolimbic SN/VTA. By contrast, both greater trait motivation in patients (MPQ: *rho* = -0.50, *p* = 0.014; TPQ: *rho* = -0.39, *p* = 0.066) were selectively related to FA within the right nigrostriatal SN/VTA. Interestingly, the length of time (*r* = -0.47, *p* = 0.020) for which patients had been medicated was also related to FA in the right nigrostriatal SN/VTA, suggesting long term effects of medication on the SN/VTA subregions underpinning incentive motivation.

4.4   Discussion

Failure to inhibit premature responses during waiting is a central component to theoretical conceptualisations of impulsivity in ADHD. Similarly, motivational abnormalities have become an increasingly salient marker of dopamine system dysfunction in the disorder. This work shows an anatomical dissociation of these two abnormalities at the level of the dopaminergic midbrain: Whilst disruptions to the mesolimbic SN/VTA appear to contribute to waiting impulsivity in ADHD, trait motivation appears to be linked to the nigrostriatal component. However, in contrast to previous findings in medication naïve patients (Volkow et al. 2011), trait motivation is not reduced in those have been treated with stimulant medication. Instead, this data suggests that long term stimulant treatment of ADHD is associated with microstructural changes consonant with increased motivation in the disorder.

In order to accurately separate the mesolimbic and nigrostriatal components of the SN/VTA this work used their connectivity patterns, as defined by DWI tractography. While this had been achieved before (Chowdhury et al. 2013), here I introduced a number of methodological improvements. First, instead of DTI, a PAS model of diffusion was used, allowing for up to 3 PDs per voxel. In addition to resolving crossed fibre configurations during tractography, this also better models potentially multidirectional projections from seed regions enhancing intra-voxel parcellation accuracy. Next, tractography was performed in the higher resolution space of the MT images, thus obtaining finer parcellation of the SN/VTA and reducing the variance associated with winner-takes all approaches to seed voxel classification. Finally, this work incorporates further classifier regions that are known to connect to the mesolimbic SN/VTA to improve parcellation accuracy.

We report that heightened waiting impulsivity in ADHD is linked to a disruption of anisotropic tissue organization in the mesolimbic SN/VTA. Consonant with blunted mesolimbic dopaminergic systems in ADHD (Volkow et al. 2007; Volkow et al. 2011; Silvetti et al. 2013), this pattern of reduced FA (Vaillancourt et al. 2009) and MT measures (Eckert et al. 2004) has been linked to dopaminergic midbrain degeneration in Parkinson disease.

Whilst numerous mechanisms including reward valuation and cognitive control have been shown to contribute to temporal discounting (Peters & Büchel 2011), our data suggest that waiting abnormalities in ADHD appear to be at least in part underpinned by disruption to the midbrain reward system. Further specification of the mechanisms underpinning this is required, however. Abnormal valuation of temporally distant rewards has frequently been suggested to underpin waiting deficits in ADHD (Luman et al. 2005; Sonuga-Barke et al. 2008). However, as the mesolimbic SN/VTA also has a prominent role in aversion (Lammel et al. 2012), and our results may also reflect an abnormal aversive valuation of waiting. Future work will be required to discern to what extent these two mesolimbic processes contribute to waiting impulsivity.

Our findings that methylphenidate did not ameliorate waiting impulsivity in ADHD mirror findings in animal models (Paterson et al. 2011) and suggest that a review of pharmacological therapies used to treat impulsivity may be required. This lack of efficacy may well reflect the promiscuity of methylphenidate at both dopamine and noradrenaline transporters, as these catecholamines have opposing waiting impulsivity-enhancing and -reducing effects respectively in the nucleus accumbens

core and shell (Economidou et al. 2012). Contrastingly, by selectively targeting blockade of the noradrenergic transporter atomoxetine has shown far more promise in treating waiting impulsivity in animals models (Navarra et al. 2008; Paterson et al. 2011; Economidou et al. 2012; Parker et al. 2014). Whilst translation of these effects to humans is necessary before definitive recommendations can be made, this may have far-reaching clinical implications for how different subtypes of ADHD should be pharmacologically targeted.

These findings also have implications for use of methylphenidate as a cognitively-enhancing agent in the healthy population (Sahakian & Morein-Zamir 2015). In line with previous observations in humans (Voon et al. 2015) and rodents (Navarra et al. 2008; Loos et al. 2010) these data show that healthy, non-impulsive subjects show increases in waiting impulsivity when given methylphenidate. These findings add to a growing body of evidence that whilst methylphenidate confers some similar cognitive gains in healthy individuals and controls (Agay et al. 2010), there is a clear divergence of effects in other functions. Interestingly, this divergence seems to be most profound in behaviours and functions typically associated with 'core' dopaminergic processes, such as reinforcement learning (See Chapter 5) and impulsivity. Given these striking differences in acute effects, it is worthy of concern that the long term safety and tolerability of methylphenidate use that is observed in ADHD may not be transferable to the general population.

In line with findings that have shifted research into incentive motivation to the SNpc (Rossi et al. 2013) and more dorsal aspects of the striatum (Volkow et al. 2002; Tomer et al. 2008), this work shows that motivation appears to be linked to the nigrostriatal SN/VTA. Our findings combined with these previous results suggest a role of the nigrostriatal SN/VTA and its afferent dorsal striatal regions as opposed to mesolimbic SN/VTA and the ventral striatum. However, unlike stimulant naïve participants (Volkow et al. 2011), patients who have been medicated long term do not appear to present with reduced motivation. Our data suggest that this may reflect therapeutic effects of long term medication on the nigrostriatal SN/VTA that are consonant with heightened motivation.

Methylphenidate acutely enhances motivation in ADHD (Chelonis et al. 2011), and normalizes activity in motivational networks (Rubia et al. 2009). Methylphenidate enhancement of D2/D3 receptor signaling in motivational regions such as the ventral striatum also predict improvements in attention after long term treatment with

methylphenidate (Volkow et al. 2012). Similar to reports of structural grey matter changes in response to treatment in ADHD (Frodl & Skokauskas 2012), our findings are suggestive of long term microstructural alterations in the nigrostriatal SN/VTA.

One possible explanation for the relationship between longer periods of medication and motivation with lower diffusion anisotropy in the nigrostriatal SN/VTA may be explained by downstream effects on cell morphology and organization that enhance intraregional communication. Methylphenidate-driven upregulation of BDNF and GDNF (Roeding et al. 2014; Simchon-Tenenbaum et al. 2015) can induce such neurotrophic and protective changes in the SN/VTA (Lin et al. 1993; Tomac et al. 1995; Hyman et al. 1991) and GDNF in particular has been shown to increase axonal sprouting and cell survival but not striatal innervation by midbrain neurons (Rosenblad et al. 2000). Accordingly, reduced FA that is observed in long term treatment could reflect local, multidirectional neurite growth. Such an explanation would therefore posit that methylphenidate upregulates various growth factors that increase multidirectional neurite growth in the nigrostriatal SN/VTA which consequently improves motivation.

Although such an explanation remains speculative, GDNF and BDNF plasma levels are abnormal in ADHD (Shim et al. 2015; Corominas-Roso et al. 2013; Shim et al. 2008) and are altered by stimulant medication (Amiri et al. 2013). Further molecular studies will be required to elucidate the therapeutic role of these molecules in long term stimulant treatment, if any. Similarly, future work using models of diffusion that can assess neurite dispersion and density accurately in grey matter may offer direct measures of the multidirectional neurite growth posited here to explain reduced FA (Zhang et al. 2012). Although the mechanisms of these changes is highly speculative, it is noteworthy that the directionality within these regions is supported by another study. Specifically, patients with depression who are associated with reduced motivation, show *heightened* FA in the SN/VTA (Blood et al. 2010). This is consonant with our findings that indicate that increased motivation is somewhat counter-intuitively linked to *reduced* FA.

Further research examining the acute and longitudinal effects of medication is also necessary. This work specifically studied trait motivation, adopting measures used in previous medication naïve studies (Volkow et al. 2011). Although using standardized metrics has the appeal of replicability and comparison between studies, such measures are not appropriate for measuring acute effects of medication. Future work modelling different components of motivation (Berridge 2012) will be essential to better

specify these changes. Additionally, future work will have to assess the apparent specificity of these long term microstructural changes to the nigrostriatal but not mesolimbic SN/VTA. Due to the high level of heterogeneity in pharmacological responses in these regions (Browder et al. 1981; Ashby et al. 2000; Goldstein & Litwin 1988; Gervais & Rouillard 2000; Mejías-Aponte et al. 2009; Mereu et al. 1987; Klink et al. 2001), numerous mechanisms could account for this. Further animal work will be required to disentangle how stimulant medication exerts these selective long-term effects.

5 Disorder-specific effects of psychostimulants on reward and novelty computation in ADHD

A comprehensive theoretical model of ADHD needs to account for impaired reward-related behavior and its amelioration by stimulant medication. Computational models of reinforcement-learning have helped dissect discrete components of reward-related function. Novel options, even when unrelated to choice outcome, bias decision-making as if possessing intrinsic reward value to guide decisions toward uncertain options. Individuals with ADHD show heightened novelty-seeking personality traits, yet how this influences reinforcement-learning or is improved by medication, is currently uncertain. Here I use a reinforcement-learning task during fMRI to model effects of novelty on reward-related behavior in 30 adults with ADHD and 30 healthy participants. Both groups were tested twice (on and off stimulant medication) to examine therapeutic effects. ADHD patients showed impaired task performance as resulting from a greater tendency to pick novel options, itself associated with heightened novelty processing within the substantia nigra/ventral tegmental area (SN/VTA). These deficits were rescued by stimulant medication in a disorder-specific manner. Specifically, in ADHD medication reduced selection of non-rewarding novel items and normalized reinforcement-learning deficits. This improved performance was also associated with reduced neural responses to novelty within SN/VTA. In contrast, stimulant medication amplified SN/VTA responses to novelty and impaired reinforcement-learning in controls. In addition, aberrant novelty valuation was normalized during long-term stimulant treatment: patients taking medication for longer exhibited significantly lower novelty bonus and decreased SN/VTA reactivity to novelty. Together these findings provide a neurocomputational account of how aberrant novelty processing biases reward-related choice and acts as a disorder-specific target for the pharmacological management of ADHD symptoms.

5.1   Introduction

Impaired reward learning in ADHD (Frank et al. 2007; Thoma et al. 2015) has been theorized to play a central role in both the symptomatic expression and aetiology of the disorder (Luman et al. 2010). Temporal difference (TD) learning models may play an important role in clarifying the nature of these abnormalities. TD models are a computational approach to reinforcement learning, addressing how sources of reward are accurately determined by an agent in a constantly updating environment. This occurs through an iterative error-driven learning, that is described more fully in Chapter 1.

Over the past decade these TD learning models have allowed computation of 'hidden' learning signals and quantification of learning from reward *in vivo* and have also provided a powerful method for characterizing human reward-related behavior (Steinberg et al. 2013). Through calculation of trial-by-trial prediction error signals TD models have demonstrated a tight coupling between reward-related learning signals and dopaminergic neuronal activity (Schultz et al. 1997; Hollerman & Schultz 1998) within the substantia nigra/ventral tegmental area (SN/VTA) and ventral striatum (Bayer & Glimcher 2005; Montague et al. 1996; O'Doherty et al. 2003; McClure et al. 2003; Waelti et al. 2001). This approach has helped clarify mechanisms of impaired reward-related processing in other disorders characterized by dopaminergic dysfunction including Schizophrenia and Parkinson's disease (Rutledge et al. 2009; Murray et al. 2008). More broadly, TD models also present a theoretical framework for characterizing the behavioral impact of other salient influences, such as stimulus novelty, on reward-related decision-making processes and their instantiation within the brain (Wittmann et al. 2008). Importantly however, there is as yet no precise account of how reinforcement-learning to reward is altered in ADHD, nor how this is ameliorated by stimulant medication (Frank et al. 2007; Thoma et al. 2015; Luman et al. 2010).

As outlined in Chapter 1, reduced learning rates in TD models (i.e. slower updating of reward values with experience) are associated with reduced dopamine levels (Rutledge et al. 2009), and may therefore mediate the association between impulsive reward seeking and hypodopaminergia in ADHD (Williams & Dayan 2005). Such an account may also help explain the efficacy of stimulant medication in improving reward-learning in ADHD (Frank et al. 2007; Thoma et al. 2015), since dopaminergic medications enhance reward-related learning rates in Parkinson's disease (Rutledge et al. 2009).

Another pressing issue highlighted in Chapter 1 that has yet to be explored in ADHD is the role of aberrant novelty signaling in the disorder. Stimulus novelty is a potent trigger for the activation of dopaminergic neurons within SN/VTA (Schultz 1998). This mechanism can bias preference towards novel options and drive exploratory behavior (Wittmann et al. 2008; Kakade & Dayan 2002). Novelty preference is highly adaptive, enabling the identification of new sources of potential reward and reducing the uncertainty evoked by unfamiliar stimuli. However, novelty preference also entails risk. Aberrantly high novelty valuation is linked to significant personal harm, including development of substance abuse (Wills et al. 1994). It is noteworthy that heightened novelty seeking is robustly observed in ADHD (Downey et al. 1997; Lynn et al. 2005; Jacob et al. 2014), and ADHD populations appear to be at higher risk of clinical problems associated with these traits, such as substance use disorders (Harpin 2005). Furthermore, novelty-seeking personality traits (Kluger et al. 2002; Munafò et al. 2008; Roussos et al. 2009; Ekelund et al. 1999; Tomitaka et al. 1999; Strobel et al. 1999; Okuyama et al. 2000; Ebstein et al. 1996) and ADHD (LaHoste et al. 1996; Rowe et al. 1998; Smalley et al. 1998; Faraone et al. 1999; Faraone et al. 2001; Barr et al. 2000; Eisenberg et al. 2000) share genetic correlates in dopamine receptor (particularly DRD4) polymorphisms. These genetic differences may play an important role in the development of inattentive phenotypes (Lasky-Su et al. 2008; Gizer & Waldman 2012), as they appears to influence attention processing even in infancy (Auerbach et al. 2001). However, to date no work has specifically examined how increased novelty-seeking impacts reward learning in ADHD.

TD models may again be able to help address this. Computational accounts of reward learning propose that novelty encourages exploratory behavior through a fictive 'bonus' signal that enhances the reward value of novel stimuli (Kakade & Dayan 2002). Supporting this, both novelty bonus and reward prediction error signals are associated with phasic dopaminergic activity in mesolimbic reward pathways (Steinfels et al. 1983; Ljungberg et al. 1992; Horvitz et al. 1997; Schiemann et al. 2012; Kakade & Dayan 2002; Wittmann et al. 2008; Bunzeck & Düzel 2006; Zald et al. 2008). Correspondingly, increased novelty bonus signals are also observed in patients with impulse control disorders associated with Parkinson's disease (Djamshidian et al. 2011). It appears possible that similar changes underpin the impairments in impulse control that are characteristic of ADHD, yet this is currently unknown. Furthermore, it remains unclear why stimulant medications improve hyperactive/impulsive symptoms in ADHD, given

the expectation that they may heighten novelty associated 'bonus' signals and potentially exacerbate these symptoms.

To address these questions, I tested thirty ADHD patients and thirty matched controls on a reinforcement-learning task shown to be sensitive to effects of stimulus novelty on reward-related behavior. Each participant completed the task during fMRI on two separate occasions, once after taking stimulant medication and the other after placebo administration, in a randomized double-blinded study.

5.2   Methods

5.2.1   Participants

The same cohort of 30 adults with ADHD and 30 matched controls were used as in previous chapters.

5.2.2   Study design

As described previously, a randomized, repeated-measures, double-blind, placebo-controlled study design was used in which all participants attended two experimental sessions separated by a minimum of 1 week. See Chapter 2 for further details on dosing and timings.

5.2.3   Reinforcement learning task with novelty manipulation

After drug administration, participants were immediately familiarized with 32 grey-scale landscape images (Bunzeck & Düzel 2006) over a fifteen minute session. This timing was important to ensure equivalent encoding (familiarization) across drug and placebo conditions. The computerized familiarization session consisted of two components: (i) A passive viewing component, where they were exposed to each of the 32 pictures 4 times in a random sequence, and (ii) an active familiarization paradigm where they were asked whether each picture had a building in it, with each picture again presented four times.

Ninety minutes after drug dosing, participants completed an MRI session (75 minutes duration), including three runs of the reinforcement-learning task (three-armed bandit task) encompassing a novelty manipulation (Wittmann et al. 2008; Djamshidian et al. 2011) (Figure 5.1). Task performance was timed to coincide with peak dopamine transporter occupancy of the drug (Volkow et al. 1998). Each run lasted thirteen minutes and contained eighty consecutive trials, each consisting of three options represented by grey-scale landscape images (Wittmann et al. 2008).

Each trial the participant was presented with three options, each of which had a fixed random probability (mean: 33%) of winning a £1 reward. Participants were instructed to choose options that maximized their total reward wins, and they were informed that reimbursement would be proportional to overall task performance. As participants did not have any prior knowledge of the value (ie probability of winning) of each option, to maximize reward they were forced to learn the value of options by selecting them over several trials. Between each trial, options were randomly spatially rearranged to ensure that participants were responding to the option (ie the image) rather than the position.

On 25% of trials, an existing option was randomly replaced by a new one. Half of the newly introduced images were novel (previously unseen during the familiarization component of the task detailed above) and half were familiar (previously seen during the initial familiarization phase) (Figure 5.1) (Panel iii). Critically, while each picture differed in its reward value, the 32 image sets of novel and familiar stimuli were balanced to have the same reward probability distributions (mean 33%). This allowed measurement of participants' subjective valuation of novel and familiar stimuli that are otherwise identical in expected value.

Alternate versions of the task (with non-overlapping stimulus sets) were used for each testing session (randomized across participants) to maintain the novelty manipulation. No significant differences in reward or behavioural performance were observed between the two alternative versions of the task (all $p > 0.05$). In each trial, participants were given 3.5s to select an option on each trial, after which their choice was highlighted with a grey border (3s) before feedback (1.5s) in the form of a '£1' or '£0' sign as superimposed on the chosen stimulus (Figure 5.1). If participants failed to respond in time, 'No response' was displayed on the screen for 4.5s. A fixation cross was displayed between each trial for 1-3.5s.

Figure 5.1 Novelty processing task.

A set of 64 pictures (A or B top left) was randomly allocated for each session. i) Participants were familiarized to half of the pictures by passive viewing then answering whether the picture contained a building. ii) During fMRI participants performed a three-armed bandit task, choosing between three options on each trial. Each option was represented as an image and had a fixed probability of reward. Each trial consists of stimulus presentation, choice feedback, and reward feedback. This is followed by a jittered inter-trial period in which a fixation cross is presented. After each trial, option locations are randomly shuffled. (iii) On 25% of trials at a fixed period an option is randomly replaced by a new one from either the familiar or novel subset.

5.2.4 Computational modeling of choice behavior

We characterized each participant's trial-to-trial choices using a temporal-difference learning model with four free parameters as it Wittmann et al. (Wittmann et al. 2008): α learning rate, β inverse temperature or choice randomness, and Q_f and Q_n, the initial values of familiar and novel stimuli respectively. Initial values of each picture were set to Q_f if the picture had been pre-exposed during the familiarization phase, and to Q_n if not. Values for the chosen option (Q) were updated according to the delta (δ) rule:

$$Q(c, t+1) = Q(c,t) + \alpha \bullet \delta(t)$$

Where δ denotes the reward (r) prediction error:

$$\delta(t) = r(t) - Q(c,t)$$

The probability of choosing an option was modeled according to a softmax selection strategy, where the probability of choosing an option c (out of the 3 options k) on trial t is:

$$P(c,t) = \frac{exp(\beta \bullet Q(c,t))}{\sum_{k=1}^{3} exp(\beta \bullet Q(k,t))}$$

Model parameters were optimized on a per-subject, per-session basis to minimize the negative log-likelihood of the observed sequence of choices. Model fit did not differ between ADHD and control groups. Novelty bonus was calculated as Q_n-Q_f, with a positive value reflecting a preference for novel over familiar options.

Model-based regressors were generated for analysis of the neuroimaging data by entering each participant's actual sequence of rewards and choices within the learning model to produce per-subject, per-trial estimates of the values Q(c,t) and error signals δ(t).

To study effects of pharmacological manipulation and ADHD diagnosis on novelty processing specifically, following Wittman et al.(Wittmann et al. 2008), I repeated these simulations using a second model where the initial value of novel and familiar stimuli were set to be equal i.e. Q_n=Q_f. This generated a second sequence of values

$Q_{base}(c,t)$ and prediction errors $\delta_{base}(t)$, representing baseline values *without* the additional effect of novelty. By comparing these two models, I calculated the additive value $Q_{add}(c,t) = (Q(c,t) - Q_{base}(c,t))$ and prediction error $\delta_{add}(t) = \delta(c,t) - \delta_{base}(t)$ associated with stimulus-novelty. Primary behavioral outcome measures included the four free model parameters, i.e. α learning rates, β inverse-temperature, initial stimulus valuations Q_n and Q_f. To study novelty specifically, I examined novelty bonus (Q_n-Q_f), tendency to pick novel options on their first presentation, and the number of consecutive trials in which the novel object was selected.

5.2.5   Magnetic Resonance Imaging (MRI)

T2*-weighted echo planar images (EPIs) were acquired on a 1.5T Siemens Avanto MR scanner equipped with a 32 channel head-coil using a -30° tilted acquisition to reduce orbitofrontal dropout (Deichmann et al. 2003). Each volume provided whole brain coverage (34 interleaved ascending 3mm axial slices with 1mm inter-slice gap, echo-time 43msec: TR 2.52s, in-plane resolution 3mm). Multi-parameter mapping using three co-localized 3D multi-echo flash sequences (See Chapters 2 and 3 for further details) was additionally acquired to provide high-resolution magnetization transfer (MT) saturation images with high contrast for sub-cortical regions of interest (Helms et al. 2009). MT images were segmented then normalized in SPM8 (http://www.fil.ion.ucl.ac.uk/spm/) to aid group level anatomical localization. Diffusion weighted MRI and multi-echo resting state EPI datasets were also acquired, though are not reported here.

EPIs were analyzed in an event-related manner in SPM8: Pre-processing consisted of spatial realignment, segmentation and normalization of the mean EPI image to a standard EPI template then spatial smoothing with an 8mm FWHM Gaussian kernel. Subject-specific realignment parameters were modeled as covariates of no interest to correct for motion artifacts. Stimulus and outcome onsets were modeled as separate delta functions and convolved with a canonical hemodynamic response function and its temporal derivative. Computationally determined prediction errors ($\delta_{base}(t)$ and $\delta_{add}(t)$) and Q-values ($Q_{base}(c,t)$ and $Q_{add}(c,t)$), were used as additional regressors that parametrically modulated outcome and cue onsets respectively. Linear contrasts of regression coefficients were computed at the individual subject level then taken to group level mixed measures ANOVA (repeated factor: (drug, placebo), between-

subject factor: group (ADHD, control)) to assess critical group x condition interactions for $\delta_{base}(t)$ and the novelty signal ($Q_{add}(c,t)$ and $\delta_{add}(t)$).

5.2.6   A priori regions-of-interest

Bilateral ventral striatum and the substantia nigra/ventral tegmental area (SN/VTA) were each defined as *a priori* regions-of-interest (ROI), based on published findings of Wittmann et al. using this task.(Wittmann et al. 2008) The ventral striatum region was defined using the mask of Martinez et al. (Martinez et al. 2003) and included the nucleus accumbens, ventral caudate rostral to the anterior commissure (AC), and the ventral putamen rostral to the AC. The SN/VTA was manually traced from the mean normalized template of all participants' MT saturation maps (Düzel et al. 2008). Results are reported for clusters surviving stringent Family-Wise-Error (FWE) $p<0.05$ correction for the whole brain or appropriate ROI.

5.2.7   Questionnaires

The Conner's self-report Adult ADHD Rating Scale (CAARS) (Conners et al. 1999) was used to index current ADHD symptom severity and the Tridimensional Personality Questionnaire (TPQ) (Cloninger et al. 1991) to measure trait novelty-seeking. Beck's Depression Inventory (BDI) (Beck et al. 1996) and the State and Trait Anxiety Inventory (STAI) (Spielberger 1983) were used to assess depression and anxiety scores respectively. The Multidimensional Personality Questionnaire (MPQ) was also administered (Tellegen & Waller 2008) for use in a separate study. Behavioral analyses were performed in SPSS using mixed-measures ANOVAs followed by post-hoc t-tests. Spearman's *rho* was used to assess relationships between behavioral measures.

5.3   Results

5.3.1   Novelty seeking personality traits

Consistent with larger population studies (Downey et al. 1997; Lynn et al. 2005; Jacob et al. 2014), ADHD participants scored significantly higher on novelty-seeking and

harm-avoidance factors of the TPQ (Novelty-seeking: ADHD=22.9±4.8, controls=17.6±5.6, $F_{(1,57)}$=15.29, $p<0.001$, Harm-avoidance: ADHD=17.1±7.5, controls=11.9±7.5, $F_{(1,57)}$=15.29, $p=0.01$), but not reward-dependence (ADHD=13.0 ±4.0, controls=12.3±3.8, $F_{(1,57)}$=0.55, $p=0.46$) or persistence (ADHD=5.3 ±2.3, controls=4.6±2.0, $F_{(1,56)}$=1.38, $p=0.245$).

5.3.2   Behavioral Responses

Stimulant medication had strikingly different effects on the performance of participants with ADHD, compared to controls. Specifically, stimulant medication enhanced the performance of ADHD participants (amount won on task, mean±SE: stimulant: £90.5±1.85; placebo £86.3±1.76), yet impaired the performance of controls (stimulant: £87.6±1.52; placebo: £91.8±1.80; Drug x Group: $F_{(1,58)}$=6.95, $p=0.011$; Group: $F_{(1,58)}$=0.59, $p=0.445$; Drug: $F_{(1,58)}<0.01$, $p=0.988$)). This effect remained significant after controlling for differences in mood (BDI) or trait anxiety (STAI) ($p=0.019$). Post-hoc comparisons revealed that unmedicated patients showed impaired performance compared to controls on placebo ($F_{(1,58)}$=5.17, $p=0.027$).

To investigate these behavioural differences in more detail, this work first tested for effects on individual parameters of the behavioural model. Similar to effects observed in task performance, stimulant medication had dissociable effects on learning rates in the ADHD and control groups (Drug x Group: $F_{(1,58)}$=4.17, $p=0.046$) with no main effect for drug ($F_{(1,58)}$=0.03, $p=0.873$) or group ($F_{(1,58)}$=1.27, $p=0.264$) independently. Stimulant medication increased basal learning rates in ADHD (mean±SE, stimulant: 0.48±0.06; placebo: 0.39±0.04), but had the opposite effect in controls (stimulant: 0.46±0.06; placebo: 0.54 ± 0.05). Post-hoc comparisons revealed that unmedicated ADHD was associated with lower learning rates than controls ($F_{(1,58)}$=4.93, $p=0.030$). Although this interaction only met trendwise significance ($p = 0.110$) after correction for BDI and STAI scores, neither BDI or STAI scores predicted baseline learning rates (BDI: $r = 0.21$, $p = 0.262$; STAI: $r = -0.11$, $p = 0.560$). Choice-randomness (β) did not significantly differ (Drug: $F_{(1,58)}$=0.28, $p=0.598$; Group: $F_{(1,58)}$=0.12, $p=0.730$; Drug x Group: $F_{(1,58)}$=0.06, $p=0.803$; ADHD: stimulant: 7.18±1.54; placebo: 7.58±2.06; Controls: stimulant: 7.58±1.27; placebo: 8.69±2.29).

Table 5.1 Behavioural Data and Model parameter estimates in ADHD and controls

Measure	ADHD		Controls	
	Drug	Placebo	Drug	Placebo
Amount won (£)	90.5 (1.85)	86.3 (1.76)	87.6 (1.80)	91.8 (1.80)
Novel options picked on first presentation (%)	16.8 (1.40)	17.2 (1.46)	12.3 (0.96)	12.3 (1.08)
Familiar options picked on first presentation (%)	14.8 (1.32)	16.5 (1.20)	15.0 (1.30)	13.0 (14.0)
Persistence in picking optimal novel options	4.5 (0.27)	3.9 (0.19)	4.12 (0.13)	4.24 (0.11)
Persistence in picking non-optimal novel options	3.2 (0.28)	3.8 (0.31)	3.77 (0.29)	3.64 (0.25)
Persistence in picking non-optimal familiar options	4.6 (0.35)	4.7 (0.15)	4.5 (0.21)	4.8 (0.19)
Persistence in picking non-optimal familiar options	3.6 (0.19)	3.6 (0.21)	3.6 (0.24)	3.4 (0.27)
Qn	0.62 (0.06)	0.57 (0.07)	0.53 (0.05)	0.46 (0.05)
Qf	0.56 (0.06)	0.52 (0.06)	0.49 (0.05)	0.45 (0.06)
α	0.48 (0.06)	0.39 (0.04)	0.46 (0.06)	0.54 (0.05)
β	7.18 (1.54)	7.58 (2.06)	7.58 (1.27)	8.69 (2.29)

Amount won: Cumulative amount won over the course of the task; *Novel/familiar options picked on first presentation (%):* The percentage of novel/familiar options that are selected on their first presentation within the paradigm; *Persistence in picking optimal/non-optimal novel/familiar options:* The number of times a familiar/novel option was consecutively selected after it was first introduced and selected. Optimal/non-optimal refers to whether the option being selected was the most valuable of the options present at that point. *Qf & Qn:* The initial values of familiar and novel stimuli respectively; *α:* the learning rate; *β:* the inverse temperature parameter.

Across groups, participants showed a preference for novel compared to familiar stimuli: novelty bonus = £0.039±0.01; $F_{(1,58)}$=10.84, p<0.005). ADHD participants expressed a novelty bonus more than double that observed in controls (£0.054±0.018 versus £0.024±0.015). ADHD participants were also significantly more likely than controls (Group x Familiarity: $F_{(1,58)}$=8.83, p=0.030) to choose novel than familiar options on their first presentation (% novel items selected on first presentation: ADHD: 16.8±1.23; Control: 12.3±0.09, $F_{(1,58)}$=8.83, p=0.004), % familiar items selected on first presentation: ADHD: 15.3±1.03; Control: 14.0±1.05; $F_{(1,58)}$=0.72, p=0.399), indicating a heightened salience of intrinsically 'novel' stimuli in the ADHD group rather than an increased propensity to choose all newly introduced stimuli. Whilst only a trend remained (Group x Familiarity; p = 0.078) for the interaction after controlling for depression and anxiety, again, neither score was associated with the tendency to pick novel (BDI: r = -0.14, p = 0.471; STAI: r = 0.05, p = 0.801) or familiar stimuli (BDI: r = -0.24, p = 0.210; STAI: r = -0.12, p = 0.523).

5.3.3 Relating novelty responses to drug-induced enhancement of task performance

We further investigated the relationship between novelty and task performance, by testing whether differences in ADHD participants' responses to novel vs familiar stimuli underpinned inter-individual differences in drug-related enhancement of performance on the task ([money (£) won on stimulant - money won on placebo]/ money won on placebo). As anticipated, better performance on medication was associated with a lower (i.e. more accurate) initial valuation of both novel (Qn) and familiar (Qf) stimuli (both *rho* = -0.53, p = 0.009; Table 5.1). However, *persistence* in selecting novel and familiar stimuli after their initial introduction differentially predicted performance on the task. Specifically, poorer un-medicated performance was associated with a greater persistence in selecting novel stimuli after their initial introduction (*rho* = -0.41, p = 0.025) and a trend towards lower persistence in selecting familiar options (*rho* = 0.36, p = 0.055). This baseline preference for novel options additionally predicted greater performance enhancement on stimulant medication (*rho* = 0.46, p = 0.011).

As the additive novelty bonus decays as a product of the learning rate, the increased learning rates observed in medicated patients resulted in a steeper decay of novelty valuation. Consequently on medication, valuation biases of novel stimuli were reduced

over fewer trials, potentially allowing more accurate discrimination of high and low value novel options. To test this, I examined the number of consecutive trials in which participants chose novel options when they were optimal (i.e. when the novel option had the greatest value out of the available choices) or non-optimal (i.e. when the novel option was not of greatest value).

Overall, participants showed a greater tendency to persist with optimal options rather than non-optimal ones ($F_{(1,58)}$=10.04, p=0.002). Medication ($F_{(1,58)}$<.01, p=0.970) or group status ($F_{(1,58)}$=0.32, p=0.572) did not have any general effects on choice persistence. However, medication did differentially effect how long participants selected optimal and non-optimal choices in each group (Drug x Optimality x Group: $F_{(1,58)}$=4.80, p=0.032; Figure 5.2B). In patients with ADHD, medication selectively *enhanced* persistence towards optimal novel options (Drug: 4.5±0.27; trials Placebo: 3.9±0.19 trials), and *reduced* persistence for non-optimal options (Drug: 3.2±0.28 trials; Placebo: 3.8±0.31 trials) (Drug x Optimality: $F_{(1,28)}$=7.60, p=0.010). This pattern of effects was not observed in the control group (Optimal trials: Drug: 4.1±0.13 trials; Placebo: 4.2±0.11 trials; Non-optimal trials: Drug: 3.8±0.29 trials; Placebo: 3.6±0.25 trials; Drug x Optimality $F_{(1,28)}$=0.25, p=0.624). Furthermore, this shift towards more optimal choices was not observed for familiar stimuli ($F_{(1, 58)}$=0.10, p=0.756), indicating that stimulant medication selectively enhanced ADHD participants' performance by inducing a steeper decay in the additive value of novelty. This subsequently optimized decisions directed at both familiar and non-familiar stimuli. Again, only a trend remained for the (Group x Drug x Optimality; p = 0.082) interaction after controlling for depression and anxiety, though neither score was associated with the tendency to pick optimal (BDI: r = 0.10, p = 0.592; STAI: r = 0.07, p = 0.592) or non-optimal options for longer (BDI: r = 0.15, p = 0.437; STAI: r = -0.21, p = 0.261).

Figure 5.2 Novelty bonus decay and novelty-directed choice optimality

(a) The effect of learning rate on decay of the novelty signal within different conditions. As a novel stimuli is familiarised over a series of trials it decays according to the learning rate (α). Enhanced learning rates in the ADHD condition results in a steeper decline of the additional value attributed towards a novel stimulus. Despite starting marginally higher, the effect of this increased decay means that this novelty bias is actually lower in the drug condition by the second presentation (Drug: 0.029; Placebo: 0.031). (b) Pattern of effects of stimulant medication on optimal vs non optimal choices. In ADHD, medication significantly reduced the length of time spent choosing a newly introduced novel option that was low valued, whilst enhancing time spent picking novel options if it was high valued.

5.3.4 Effects of treatment duration on responses to novelty

Despite having a mean novelty bonus more than double that of controls, ADHD patients showed marked inter-individual differences that overshadowed the statistical significance of group effects ($F_{(1,58)}$=1.59, p=0.213). Previous studies show long-term alterations in striatal dopamine availability following sustained methylphenidate use (Volkov et al., 2012). The present study therefore investigated whether, in the ADHD group, individual differences in novelty bonus related to duration of stimulant medication treatment. Strikingly, this analysis demonstrated a significant negative correlation between treatment duration and baseline novelty bonus (*rho*=-0.44, *p*=0.018; after additionally controlling for BDI and STAI *rho* = -0.43, *p* = 0.036), i.e. patients treated the longest showed the lowest novel bonuses.

5.3.5 Striatal and SN/VTA reward and novelty signals

Consistent with earlier reports (McClure et al. 2003; O'Doherty et al. 2003; Pessiglione et al. 2006), computationally determined reward prediction error (δ_{base}) showed a tight correlation (whole brain FWE p<0.001), with bilateral ventral striatum and orbitofrontal cortex activity, and in several other frontal and parietal regions across groups (Figure 5.3; Table 5.2). In addition, this data also revealed a significant Group x Drug interaction for δ_{base} within the left ventral striatum (SVC: p = 0.021; after correction for BDI and STAI, SVC: p = 0.027), where the ADHD group exhibited a significant reduction in neural signals encoding reward prediction error while on stimulant medication compared to placebo. The opposite pattern was observed in controls (Figure 5.4a).

Figure 5.3 Main effect of δ_{base} with prominent activations in the ventral striatum. Thresholded at $p_{FWE} < 0.05$

Table 5.2: Main effect of reward prediction error (δ_{base})

Side	Region	Peak Coordinates	Z	K (cluster)	FWE p
L	Ventral striatum	[-12 8 -12]	>8	539	<0.001
R	Ventral striatum	[14 12 -10]	>8	733	<0.001
L	SN/VTA	[-8 -24 -14]	3.29	2	(0.02)
R	SN/VTA	[8 -14 -12]	3.56	13	(0.007)
L	Inferior frontal, orbitalis	[-30 22 6]	6.71	186	<0.001
R	Inferior frontal, orbitalis	[35 25 -10]	7.30	570	<0.001
L/R	PCC	[0 -28 38]	>8	1333	<0.001
L	Inferior parietal	[-54 44 48]	>8	1845	<0.001
R	Inferior parietal	[52 -56 32]	6.46	473	<0.001
L/R	Medial prefrontal	[4 40 16]	7.37	1249	<0.001
L	Middle temporal	[-58 -42 0]	7.29	832	<0.001
R	Middle temporal	[62 -38 -2]	6.63	274	<0.001
L	Superior frontal	[12 46 46]	6.75	219	<0.001
R	Superior frontal	[-14 36 48]	6.94	552	<0.001
L	Insula	[-38 0 6]	5.55	34	<0.001
R	Insula	[40 2 4]	6.62	90	<0.001
R	Cerebellum	[36 -70 -38]	6.48	83	<0.001
L	Precuneus	[-4 -68 34]	6.25	83	<0.001
L	Pars Orbitalis/triangularis	[-48 38 0]	6.12	211	<0.001
L	Pars triangularis	[-52 12 14]	6.00	83	<0.001
L/R	Thalamus	[8 -2 14]	5.87	219	<0.001
L	Middle frontal	[-40 12 44]	5.83	72	<0.001
R	Pars triangularis	[54 24 16]	5.30	33	<0.001

Across conditions, a corresponding correlation with novelty prediction error was not observed at the stringent thresholds employed here. However, complementing the findings for reward prediction error, a significant group x drug interaction in the SN/VTA was observed (whole-brain cluster *FWE p* = 0.027; After correction for BDI and STAI: *FWE p* = 0.036) indicating a significant reduction of novelty-related prediction error in ADHD participants on stimulant medication compared to placebo, and a converse pattern observed in controls (Figure 5.4b). Corresponding to the reduction in behavioural novelty bonus observed in patients who had been on medication longer, activity within this cluster correlated negatively with time on medication (SVC: *FWE p*=0.003).

Finally, I sought to investigate whether drug-related reductions in baseline ventral striatal prediction error signaling or SN/VTA novelty processing best explained the drug-induced enhancement of performance in ADHD. Consonant with the behavioural findings, drug-induced reductions in SN/VTA novelty-related prediction error (*rho* = -0.45, *p* = 0.037) but not ventral striatal reward prediction error signaling (*rho* = 0.04, *p* = 0.873) was related to improved reward learning. Of note these findings, survived correction for age, total brain volume and anxious and depressive symptomatology.

Figure 5.4 Group x Drug interactions for δ_{base} and novelty signaling.

(a) Group x Drug interaction of δ_{base} in the ventral striatum. Thresholded at $p_{unc} < 0.005$ for display purposes. (b) Group x Drug interaction of δ_{base} in the substantia nigra/ventral tegmental area. Thresholded at $p_{unc} < 0.001$.

5.4   Discussion

These results provide evidence of impaired reward learning in ADHD and demonstrate attenuation of this deficit by stimulant medication. Furthermore, they identify specific neuro-computational mechanisms underpinning these abnormalities. Specifically, ADHD participants were characterized by both greater reinforcing value of novelty ('novelty bonus') that was linked to heightened phasic signaling in the SN/VTA, and a reduction in the rate of value-updating in response to reward (lower learning rate). This heightened valuation of novelty, coupled with a slower decay in its rewarding properties, served to bias ADHD patients to repeatedly select novel options at the cost of choosing familiar, potentially more rewarding ones. Interestingly, stimulant medication selectively remediated these abnormalities in ADHD, yet demonstrated a strikingly different effect profile in controls where it simultaneously heightened striatal RPE and SN/VTA novelty signals, reduced reward-learning rates and impaired overall performance. Preliminary cross-sectional evidence also suggests that long-term stimulant treatment is associated with a reduction in the rewarding value of novelty. Together, these results highlight a central role for aberrant novelty valuation in reward-related decision-making abnormalities observed in ADHD.

Previous modeling with simulated data has predicted that hypo-dopaminergic abnormalities will reduce learning rates and in turn account for key components of impulsive reward dysfunction in ADHD (Williams & Dayan 2005). By showing that ADHD patients exhibit reduced reward-related learning rates off medication, this work provides the first empirical evidence to support this. In addition, our data show a perturbation in the *acquisition* of reward-related behaviors in ADHD, supporting models that predict slower learning following positive reinforcement (Luman et al. 2010). This reduction in reward-learning rate may also underlie observations of reduced adaptability to changing reward schedules (Kollins et al. 1997) and increased temporal discounting (Williams & Dayan 2005) and help explain why reward-related learning deficits appear more pronounced when rewards are probabilistic or intermittent rather than continuous (Aase & Sagvolden 2006). Critically, our results also indicate that stimulant medication normalizes both learning rates and reinforcement-learning.

At first glance, the increased novelty and RPE signals we observed in ADHD may appear at odds with the hypo-dopaminergic profile believed to be central to this

disorder. However, this divergence is predicted by a number of accounts of ADHD which suggest that despite a reduction in tonic dopamine, phasic dopamine release is likely increased (Grace 2001; Seeman & Madras 2002; Cherkasova et al. 2014; Badgaiyan et al. 2015). Although it is not possible to directly address within the present fMRI study, these data show heightened error and novelty signals that are believed to be tightly linked to phasic dopamine. One possible mechanism underpinning this heightened phasic novelty profile is lower mesolimbic D2/D3 receptor density in ADHD (Volkow et al. 2009; Volkow et al. 2011). Functionally, a reduction in D2/D3 receptors would lead to disinhibited phasic dopamine release (Volkow et al. 2009; Volkow et al. 2011), potentially explaining the increased sensitivity to stimulus novelty we observe. Evidence to support this comes from molecular imaging studies of trait novelty-seeking in the healthy population, where lower D2/D3 (auto)receptor binding in SN/VTA is linked to higher novelty-seeking traits (Zald et al. 2008). The reduction of SN/VTA novelty signaling observed here after stimulant medication may equally reflect increased inhibition of these signals by D2/D3 activity, as methylphenidate exerts at least some of its therapeutic effects via increased dopamine binding to D2 receptors (Volkow et al. 2012). Indeed, stimulant-induced enhancement of tonic dopamine is predicted to preferentially activate D2/D3 receptors that inhibit phasic dopamine (Dreyer et al. 2010). Enhanced D2-mediated inhibition is consistent with the observation in ADHD of a more rapid decay in phasic response to novelty in response to stimulant medication despite no difference in the initial novelty signal (novelty valuation).

In contrast to the therapeutic effects observed in ADHD, methylphenidate impaired decision-making and learning rates and enhanced phasic RPE and novelty signaling in controls, to the extent they resembled un-medicated patients. These results are made more surprising by the fact that previous work has shown that in other, broader cognitive domains, methylphenidate has similar effects in both ADHD patients and controls (Agay et al. 2010). Thus, while stimulant medication appears to have equal impact on higher order cognitive functions in ADHD and controls (Agay et al. 2010), it appears to engender strikingly different effects on processes related to reinforcement-learning to reward. Reinforcement-learning abnormalities may therefore reflect a precise and disorder-specific therapeutic target for stimulant medication in ADHD. The fundamental origin of these differential effects remains unclear, though likely reflect baseline properties of the mesolimbic reward system. Indeed, while enhanced tonic dopamine and D2 activity may have a corrective role in ADHD and other hypo-

dopaminergic disorders such as Parkinson's Disease (Rutledge et al. 2009), increased D2 activity induced by methylphenidate in healthy controls (Volkow et al. 2001) may explain their poorer performance on drug. Correspondingly, selective D2 agonists appear to impair reward-learning in healthy subjects (Pizzagalli et al. 2008).

One possible explanation for the present findings is the difference in previous medication status. For instance, as ADHD participants were not taking there medication it is possible that their poorer un-medicated performance reflected a state of withdrawal rather than 'un-medicated' performance *per se*. To combat differences in medication status patients were asked to refrain from medication for 2 days prior to the session to ensure washout of the medication in line with prior research (Posner et al. 2011), and at least 4 times the half-life of available psychostimulant medications. However, the possibility of withdrawal effects on performance on the ADHD group cannot be fully ruled out and sufficiently long abstinence periods to ensure the absence of withdrawal effects may be considered to be ethically problematic. Future work with medication naïve patients may help to address this, however it is not possible to ensure that such individuals have appropriate therapeutic responses the study have an appropriately therapeutic response to a given medication or dose. As such, studies using medicated and medication-naïve individuals are both important to accurately assess baseline characteristics of ADHD and therapeutic effects of medication.

A further, preliminary finding from this study was an association between long-term stimulant treatment and a relative attenuation of both novelty valuation and SN/VTA responsiveness to novelty. The molecular mechanisms underpinning this potentially sustained improvement in novelty valuation are unclear. However, the current findings may link observations that markers of ventral striatal D2/D3 reactivity predict long term symptomatic improvements in attention (Volkow et al. 2012), and prior associations between SN/VTA D2/D3 receptor density and novelty-seeking behavior (Zald et al. 2008). Reductions in dopamine transporter (DAT) density after long term methylphenidate treatment are largely interpreted as effects of tolerance (Wang et al. 2013), yet a set of other neurobiological changes ascribed to methylphenidate use may also underpin potential long-term therapeutic benefits. These include increased neuroplasticity (Dommett et al. 2008), dendritic spine formation (Kim et al. 2009) and heightened expression of growth factors (Roeding et al. 2014; Simchon-Tenenbaum et al. 2015; Amiri et al. 2013) within limbic circuitry supporting novelty processing which

additionally contribute to long term therapeutic effects, independent of current stimulant medication status.

Further work is required to consolidate the broader clinical implications of the heightened novelty valuation observed here. For example, in addition to apparent roles in inattention and poor decision-making, heightened novelty valuation could well contribute to the high prevalence of substance use disorders observed in ADHD. Conversely, the apparent reduction in novelty valuation observed here with prolonged treatment, could underlie the reported reduction in substance abuse risks associated with long-term medication use (Wilens et al. 2003; Mannuzza et al. 2008). Longitudinal data is clearly required to investigate this hypothesis. To conclude, these findings suggest that novelty valuation has an important role in defining the ADHD phenotype and likely treatment response. Indeed, effects of methylphenidate on novelty processing revealed a remarkably disorder-specific effect not observed for other broader neuropsychological domains (Agay et al. 2010). Thus while some of the beneficial effects conferred by stimulant medication appear compensatory rather than corrective, actions on reinforcement-learning, and novelty processing in particular, appear to represent specific pathological targets.

6 General Discussion

This work employs recent methodological advancements to address several issues in the ADHD literature, focussing on the role of structures central to dopaminergic signalling. Various authors have questioned the importance of the brain dopamine system in ADHD. For instance, the putative absence of striatal volumetric abnormalities in adulthood has suggested that this region is not central to the persistence of symptoms (Nakao et al. 2011; Frodl & Skokauskas 2012). Chapter 3 shows that persistent striatal abnormalities are readily detectable in VBM analyses of adult ADHD when using MT saturation maps optimised for subcortical contrast. Furthermore, this chapter shows that previous T1-weighted VBM studies may have been insufficiently sensitive to detect these changes in adults. Chapter 4 provides evidence that altered microstructure of the primary dopaminergic nucleus in the brain, the SN/VTA, contributes to distinct forms of reward dysfunction considered to be central to ADHD. Specifically, incentive motivation and waiting impulsivity in ADHD appear to be linked to the microstructure of nigrostriatal and mesolimbic SN/VTA subcomponents respectively. Finally, Chapter 5 reveals that abnormal reward learning and decision making in ADHD is in part driven by aberrant novelty processing within the SN/VTA. Not only are these deficits rescued by dopaminergic medication in ADHD, but these therapeutic effects appear to be specific to ADHD individuals. Collectively, this work shows that application of appropriate methodological advancements reveals a clear picture of persistent abnormalities of the brain dopamine system in adult ADHD that are selectively targeted by short and long term stimulant medication use. The following chapter discusses the anatomical, functional, methodological and clinical implications of these findings.

6.1.1   Anatomical contributions of the dopamine system in ADHD

Previous findings have suggested that ongoing volumetric abnormalities within the striatum are not necessary for the persistence of ADHD into adulthood. However, it appears that this view may have been heavily influenced by the methodological approach these earlier studies adopted. The present work shows that striatal abnormalities are readily detected in an adult ADHD sample when using imaging contrasts specifically adapted to the challenges of subcortical imaging. By contrast, these striatal differences are not detected in exactly the same subjects when using T1-weighted volumes similar to those used in previous studies. These findings show that it

is necessary to be critically aware that structural imaging data does not offer a pure representation of brain morphology. Instead, T1 volumetry appears to be influenced by a range of other factors that are related to clinical and demographic variables of interest but do not actually represent changes in volume. This work shows that these confounding effects on analyses are not trivial – by using contrasts that exclude such confounds, a picture of persistent, rather than remittent, striatal abnormalities emerges.

By employing MT saturation maps in conjunction with diffusion tractography analysis, this work also highlights a role for the SN/VTA in ADHD. Moreover, whilst previous studies had shown that impulsivity (Buckholtz et al. 2010) and motivation (Volkow et al. 2011) were related to the dopaminergic midbrain, this work was able to functional localise these abnormalities to distinct subcomponents within the SN/VTA. Various models have posited the importance of describing how different functional abnormalities arise from distinct dopaminergic subregions (Castellanos et al. 2006). However, this work presents the first dissociation of neuropsychological differences in ADHD at the level of the SN/VTA.

6.1.2   Long term effects of stimulant medication on dopamine system anatomy

The methodological advancements employed by this thesis also offers an updated perspective on the long term structural effects of stimulant medication in ADHD. Contrary to previous findings this work does not detect any long term effects of medication on striatal volume, and points to the problematic nature of such inferences in previous studies. It is worth noting that the largest follow-up study of children with ADHD in adulthood also did not detect effects of medication on striatal volumes (Proal et al. 2011). Despite the potential confounds in previous reports, work in animal models does support the idea of long-term striatal alterations in response to medication (Kim et al. 2009). Well-controlled future MRI studies in humans using appropriate scanning protocols may be able to detect striatal volumetric changes.

In contrast to these striatal findings, the present study does find evidence for long-term changes in microstructural measures of the nigrostriatal, but not mesolimbic SN/VTA. Whilst longitudinal evidence is needed to confirm these findings, it appears that such changes may underpin long-term improvements in trait motivation in the disorder. Future studies are also required to examine precisely what underpins these changes in

microstructure. As previously noted, one possible explanation is stimulant-induced upregulation of growth factors (Roeding et al. 2014; Simchon-Tenenbaum et al. 2015) inducing multidirectional neurite development in this region (Rosenblad et al. 2000; Lin et al. 1993; Tomac et al. 1995; Hyman et al. 1991), however such an explanation remains purely speculative. Future work using models of diffusion that can assess neurite dispersion and density accurately in grey matter may provide some confirmation of this (Zhang et al. 2012). Additionally, future work will have to assess the apparent specificity of these long term microstructural changes to the nigrostriatal but not mesolimbic SN/VTA. Due to the high level of heterogeneity in pharmacological responses in these regions (Browder et al. 1981; Ashby et al. 2000; Goldstein & Litwin 1988; Gervais & Rouillard 2000; Mejías-Aponte et al. 2009; Mereu et al. 1987; Klink et al. 2001), numerous mechanisms could account for this. Further animal work will be required to disentangle how stimulant medication exerts these selective long-term effects.

6.2   Dopaminergic medication has disorder-specific effects in ADHD

First-line treatments of ADHD consist of dopamine-enhancing medications. The efficacy of these therapies has led to a theoretical focus on dopamine system abnormalities in ADHD. However, since then, the pathogenic and therapeutic importance of the dopamine system in ADHD has been called into question. This has been reinforced by studies suggesting that ADHD does not appear to be associated with dopamine abnormalities above and beyond poor attentional performance alone (del Campo et al. 2013), and that dopaminergic medication appears to enhance cognitive performance equally in the healthy population (Agay et al. 2010; Clatworthy et al. 2009). Paired with the observed heterogeneity of higher-order cognitive abnormalities in ADHD, such findings have led to some speculation as to its validity as a diagnostic construct. However, this thesis suggests that the neuropsychological non-specificity of ADHD appears to occur only in higher order cognitive functions. When examining specific functions that are tightly linked to dopaminergic function, a high degree of effects specifically associated with ADHD are observed.

6.2.1   Disorder specificity of medication in impulsivity and reinforcement learning

In both waiting impulsivity and reinforcement learning tasks employed here, stimulant medication appears to have effects that differ dramatically according to diagnosis. In the reinforcement learning task, stimulant medication has therapeutic effects of reward learning, novelty-directed behaviours, learning rates and novelty and error signals in ADHD, whilst the opposite effects are observed in controls. Although in waiting impulsivity, stimulant medication does not appear to confer therapeutic benefits in ADHD, it actually heightens waiting impulsivity in the healthy population.

These findings contrast starkly with observations that stimulant medication has comparable effects on higher-order cognitive functions in the healthy population (Agay et al. 2010; Clatworthy et al. 2009). This appears to show that the divergent effects of methylphenidate in ADHD and controls only occur in certain domains, and that these differential effects are most pronounced in impulsivity and learning and decision making (Dalley et al. 2007; Perry et al. 2008; Clatworthy et al. 2009; DeVito et al. 2008b; Campbell-Meiklejohn et al. 2012). Whilst it has been suggested that dopaminergic abnormalities are not central to ADHD (del Campo et al. 2013), these findings strongly suggest otherwise, as functions such as reward learning that are tightly tied to dopaminergic signalling show the greatest disorder-specificity in medication response. Whilst abnormalities in executive function may not therefore appear to have any level of specificity to ADHD, differences in dopaminergic function do appear to capture unique aspects of the ADHD phenotype and its responsiveness to therapy.

High levels of divergence in reward processing are also evident in the absence of pharmacological probes. For instance, whilst impulsivity in ADHD is associated with reduced activity in the ventral striatum during anticipation of reward, in healthy controls higher impulsivity is actually associated with greater ventral striatal anticipatory activity (Plichta & Scheres 2014). These findings collectively suggest the importance of dopaminergic abnormalities in defining ADHD pathogenesis, and highlight that different mechanisms appear to underlie impulsivity in ADHD and the general population.

These findings collectively indicate that ADHD diagnosis appears to have a profound impact on reward system function and its responsiveness to medication. The inverse nature of these effects in both groups appears to indicate that these individuals do not lie along a spectrum of heterogeneously poor performance, but appear to show distinct reward profiles according to diagnosis that are differentially modulated by dopaminergic interventions. By applying computational modelling methods, this work

also shows that it is possible to go beyond coarse descriptions of reward abnormalities and identify specific parameters contributing to them. Critically, it appears that these parameters share the same pattern of disorder-specific effects as reward learning performance. In particular, learning rates, prediction error signalling, and novelty processing all appear to show disorder-specific effects of psychostimulants. The following section attempts to integrate these findings with current models of dopamine dysfunction in ADHD.

6.3   Understanding the relationship between dopamine systems and abnormal reward function

Due to the development of more specific markers of reward dysfunction that are highlighted here, it has become increasingly possible to integrate observed reward abnormalities in ADHD with theories of abnormal mesolimbic dopamine function. As previously discussed, various theories of ADHD pathophysiology differ in their appraisal of altered dopaminergic function in ADHD. Whilst a general hypodopaminergic deficit has been postulated (Volkow et al. 2005; Sagvolden et al. 2005), other accounts have suggested that reduced tonic but heightened phasic dopamine is observed (Grace 2001; Seeman & Madras 2002; Badgaiyan et al. 2015). By modelling error and novelty signals that reflect phasic dopamine release (Schultz & Dickinson 2000), the present data is able to contribute to this debate. Specifically, the increased error and novelty signals that are observed in ADHD supports models that predict a hyper-phasic signalling profile. Moreover, this data suggests that heightened phasic dopamine signals are reduced by stimulant medication, likely via enhanced D2-mediated inhibition of phasic dopamine as previously discussed (Dreyer et al. 2010; Seeman & Madras 1998).   Recent PET studies also appear to support this low-tonic, high-phasic dopamine theory of ADHD (Badgaiyan et al. 2015). Interesting, such a model of dopamine pathophysiology would also predict other neuropsychological components of ADHD. For instance, as incentive motivation is linked to tonic dopamine levels (Niv et al. 2007), reduced motivation in ADHD would actually be predicted by a model suggesting low tonic dopamine in the disorder.

Linking other abnormalities in ADHD to such a model is more challenging however. For instance, this work reveals low learning rates in ADHD. Learning rates are frequently taken to represent dopamine levels (Williams & Dayan 2005), though a more precise

neurobiological interpretation is lacking. It is tempting to ascribe a linear relationship between tonic dopamine levels and learning rates, though such an analysis does not appear to hold. Whilst enhancing synaptic dopamine levels by administration of methylphenidate appears to increase learning rates in ADHD, precisely the opposite relationship is found in controls. This appears to suggest a more complex relationship of learning rates to tonic dopamine levels. One possibility is an inverted-U shaped relationship between tonic dopamine and learning rates. In this instance, enhancement of tonic dopamine levels in ADHD and other hypodopaminergic disorders would increase learning rates, whilst increasing already optimal tonic dopamine above this threshold would reduce them. Such a model would however struggle to explain how high learning rates could be described in terms of tonic dopamine levels alone. Another, perhaps more plausible model may describe variation in learning rates in relation to a balance between phasic and tonic dopamine levels. However, such possibilities remain purely speculative, as no work to date has attempted to clarify the precise relationship between brain dopamine and learning rates.

Another area in need of clarification is the relationship of waiting impulsivity to dopaminergic and/or noradrenergic abnormalities in ADHD. This work shows that abnormal waiting impulsivity is related to abnormal microstructure of the mesolimbic SN/VTA. This is consonant with findings that the nucleus accumbens, one of the key regulatory targets of the mesolimbic SN/VTA, also has a central role in waiting impulsivity (Economidou et al. 2012). However, as previously noted, methylphenidate appears to exert its effects through opponent processes mediated by dopaminergic and noradrenergic signalling in the nucleus accumbens core and shell respectively (Economidou et al. 2012). In ADHD, the dopaminergic effects of methylphenidate on waiting impulsivity appear to be altered or less pronounced, somewhat counter-intuitively inhibiting the impulsivity enhancing effects of this drug that is observed in controls (Voon et al. 2015). Future work must therefore carefully examine the interactions between dopaminergic and noradrenergic signalling in the core and shell of the accumbens, and assess how this is modulated by the mesolimbic SN/VTA.

6.4   Future methodological considerations

This work highlights the importance of employing advancements in MR and neuropsychological methodologies in refining pathological and therapeutic

mechanisms in ADHD. The following sections will review these approaches and how they may be further applied within ADHD, but also more broadly to other problems.

6.4.1 Improving structural investigations and analyses

Firstly, this work shows that the employment of alternate structural imaging methods has an appreciable impact on results. In the case presented here, recognising the limitations of T1 imaging of subcortical structures and adjusting protocols accordingly has the capacity to resolve previous inconsistencies in the literature regarding striatal morphometry in adult ADHD. Similarly, this work highlights the utility of MT saturation maps in imaging the SN/VTA which is not visible in typical T1 weighted volumes. This heightened contrast not just in ADHD, but also other disorders with hypothesised subcortical components. Importantly, this also highlights the necessity of adopting such methodologies in any maturational studies (Martin et al. 1998), where iron content associated with age may bias volumetric investigations. This is also essential when investigating disorders of the dopamine system, due to the relationship between brain iron and dopamine (Youdim et al. 1983; Bianco et al. 2008). Apparent volumetric differences, or their absence, that are associated with age or dopaminergic disorders could therefore be biased by iron differences linked to these conditions. These findings highlight the potential of these pitfalls, with implications for morphometric analyses of the brain in various conditions.

Secondly, this work shows that using diffusion MRI tractography to parcellate structures of interest can greatly enhance specificity of structural investigations. Using these techniques it is possible to functionally localise abnormalities to different substructures. In this case, impulsivity and motivational abnormalities have both been previously ascribed to the SN/VTA, and using parcellation methods it is possible to localise these differences to the mesolimbic and nigrostriatal SN/VTA respectively. In addition to refining description of functional-anatomical relationships in ADHD, these findings also have possible implications for therapy, as long-term stimulant treatment only appears to affect one of these components, and only those functions ascribed to it. Employing microstructural measures may also provide a more sensitive measure of long-term changes, as these data reveal long-term effects of medication on SN/VTA subcomponent microstructure but not volume.

This work also uses a novel up-sampling technique that allows for higher-resolution parcellation analyses of smaller structures without altering acquisition. This intends to

improve parcellation results in the boundaries between subregions within small structures, particularly in winner-takes-all strategies. A slightly higher probability of connection to one target than another in a single voxel will result in the same binary identity being assigned as a much larger difference between these two targets. In small structures where a single such boundary voxel makes a relatively large contribution this is particularly problematic. The current up-sampling approach allows for a potentially smoother parcellation within these small structures, allowing for the gradient region between subregions to be parcellated at a finer scale. It must be noted however, that this upsampling is only in effect smoothing the data to reduce variance and is not offering novel information at this higher resolution. Parcellating small structures with more than two subregions, where a single gradient cannot be assumed, may therefore be problematic. For instance, the periaqeductal grey (PAG) contains several subdivisions along both rostral-caudal and superior-inferior dimensions (Coulombe et al. 2016), and interpolation may interfere with identifying these accurately.

6.4.2 Improving modelling of reward and medication

Finally, this thesis also shows the importance of computationally refining neuropsychological constructs. Reward abnormalities in ADHD have been frequently observed, but by applying computational models this work demonstrates that it is possible to isolate specific pathological mechanisms, and show how these are altered by medication. Going forward, this will be essential to further clarify the nature of abnormalities in ADHD. This will, for instance be essential in highlighting the nature of motivational abnormalities in ADHD beyond the coarse concept treated here.

In contrast to the work studying reinforcement learning in this thesis, the measures of incentive motivation are relatively course. This work employs indices of trait motivation that afford ease of comparison to previous studies in ADHD (Volkow et al. 2011). However, by using trait measures it is not possible to measure acute responses to medication. Moreover, motivation is not a unitary function and future work is necessary to refine how differences in intrinsic and extrinsic motivation contribute to ADHD. Whilst the majority of motivation research has focussed on extrinsic motivation that is, put simply, the extent to which behaviour and effort is motivated by reward, no work has examined how intrinsic motivation (ie motivation to engage in behaviours that are not

externally rewarded) is altered in ADHD. Future work may be able to model these intrinsic factors in reinforcement learning paradigms (Barto 2013). Similarly, the motivation to perform an action for reward is also modulated by a variety of factors, such as satiety, boredom, appetitive states. Modelling the contribution of these factors is in its relative infancy (Berridge 2012), but critical for further clarifying reward and motivational processes in ADHD. This is highly relevant, as motivated behaviours are not uniformly impacted in ADHD. For instance, inattention and response inhibition deficits are completely normalised when more game-like representations of typical neuropsychological tests are used (Bioulac et al. 2014; Shaw et al. 2005). Computational modelling may help to quantify these altered motivational states, assess how they are neurobiologically instantiated, and start to investigate how they might be best maintained during tasks that individuals with ADHD find challenging.

6.4.3   Study limitations

A more general methodological concern in the present work is the high depression and anxiety scores. However, ADHD is strongly associated with depressive and anxious symptoms. The prevalence of depression specifically is at around 19% in adults with ADHD, compared to approximately 8% in individuals without (Kessler et al. 2006). Even in the absence of clinically significant scores, many ADHD participants exhibited higher levels of depressive symptoms than controls. It is unlikely these effects account for the results reported however. The majority of results reported survive correction for BDI and STAI scores, and outcome measures that were reduced to trendwise significance after correction were not associated with either depression or anxiety levels.

One final issue that could influence the interpretation of the current studies is the difference in medication exposure between the two groups of participants. ADHD patients had all been taking regular doses of stimulant medication to ensure clinical efficacy, but control participants had never taken these drugs. This set up was also required to allow for cross-sectional investigation of the neurobiological correlates of long-term medication. This could however have affected acute responses to these medications. To minimize this risk, patients were medication abstinent for two days before each experimental session. Interpretation of the acute effects of medication in these groups must however take this into consideration. It does however appear

unlikely differences in medication exposure could account for these results. In particular, the strikingly different patterns of effect that are observed in reinforcement learning and novelty signalling appear unlikely to be the result of any effects of tolerance. Although it appears initially more plausible that the lack of effects of medication on waiting impulsivity in ADHD compared to controls could reflect tolerance, this also appears unlikely as animal models without drug pre-exposure show similar results (Paterson et al. 2011).

6.5   Clinical implications

Clinically these findings provide a mixed picture of the efficacy of dopaminergic medication in ADHD. Stimulant drugs appear to normalise reward learning and novelty processing, highlighting their importance in treating abnormalities directly related to dopaminergic systems in ADHD. In addition to these acute effects however, this work suggest that stimulant drugs may have long-term therapeutic effects on reward and motivational abnormalities. If such observations are replicated, future clinical work will be necessary to examine whether such normalisations persist following prolonged periods of abstinence. Evidence has suggested that childhood treatment of ADHD is associated with reduced propensity to substance abuse (Mannuzza et al. 2003) and higher likelihood of adult employment even after controlling for current treatment status (Halmøy et al. 2009). These findings highlight the critical importance of early treatment in long-term outcome. The long-term changes in novelty processing and motivational systems that are observed may underpin such changes in childhood. However, the current studies also suggest that such long-term changes may also be observable in treatment of adults ADHD. Whilst it is clear that early intervention is paramount for long term outcome, these findings may also suggest a more optimistic outlook in the remittance of ADHD symptoms and improved outcome even in adulthood. Future work monitoring long-term treatment effects in patients diagnosed in adulthood will be necessary to add to this clinical picture, and open up the possibilities of examining the requirement of lifelong medication regimes in patients who show stable long-term responses.

Although this work highlights the efficacy of dopaminergic medications in reward abnormalities, their lack of efficacy in treating waiting impulsivity deficits highlights the importance of reviewing current therapies based on symptom profiles. Indeed, current

evidence suggests that atomoxetine may have greater success in treating impulsive symptoms. Future studies must closely examine the effects of dopamine and noradrenaline acting drugs in treating combined, predominantly hyperactive and predominantly inattentive subtypes of ADHD. Whilst the presence of ADHD subtypes has long been diagnostically recognised, this is currently not a primary consideration when opting for dopaminergic therapy. If future work confirms the efficacy of atomoxetine in treating waiting impulsivity, altering this approach will be necessary, as the present study suggests that stimulant medication may lack any therapeutic effect in treating primarily hyperactive and impulsive subtypes.

Developing such approaches may also be important for future drug development. Chapter 4 suggests that ADHD pathophysiology occurs within both mesolimbic and nigrostriatal SN/VTA, however data from this chapter also indicates that the nigrostriatal rather than mesolimbic SN/VTA appears to be therapeutically targeted by current psychostimulant medications. For instance, waiting impulsivity which appears to be underpinned by the mesolimbic SN/VTA, does not seem to be behaviourally affected by acute medicate in ADHD. Moreover, Chapter 4 presents preliminary evidence that long term exposure appears to be related to the microstructure of the nigrostriatal but not mesolimbic SN/VTA. Due to the extensive differences in pharmacological profile in this region, it is difficult to speculate precisely why current psychostimulants affect only the nigrostriatal but not mesolimbic SN/VTA therapeutically. Though future work will be required to determine if this is indeed the case, this model would predict that drugs with selective therapeutic effects on the mesolimbic SN/VTA may be important for preferentially treating impulsivity in ADHD. In instances of combined type ADHD future drugs targeting both subsystems may be required, as current treatments appear to have selective therapeutic effects on the nigrostriatal SN/VTA.

Owing to the ostensibly similar cognitive benefits of methylphenidate in the healthy population (Agay et al. 2010), a growing interest has developed in the use of methylphenidate as a cognitive-enhancing substance (Sahakian & Morein-Zamir 2015). Whilst the beneficial effects of methylphenidate may be shared by the general population in some domains, this work highlights highly detrimental effects of the drug in reward learning and impulsivity. The use of methylphenidate as a cognitive-enhancer should therefore be treated with some degree of caution. Due to these stark differences of effect in ADHD and controls that are observed here, the long-term safety

and tolerability profile of these drugs that is observed in ADHD may not be transferrable to the general population.

6.6 Future studies

In addition to the suggested future directions described above, several potential studies that follow near directly from questions raised by this work should be highlighted. Firstly, much of the discussion of the results from Chapter 5 has suggested that novelty processing in ADHD is linked to enhanced phasic novelty signalling, and that increased D2 mediated inhibition of these phasic signals may explain the reduction of novelty signalling we observe in response to medication (See Chapter 5 discussion and above within this chapter). Future dual tracer PET studies will be important to test this directly. In particular, assessing the binding potentials of D1 and D2 receptors with radiolabelled ligands will help assess the hypothesis that reduced novelty signalling reflects a relative increase in activity of the inhibitory D2 receptors to D1. Whether this can be applied specifically to novelty processing is a challenge however, as the paradigm utilised here requires a temporal resolution greater than that offered by PET imaging. A block design task using novel and familiar images on and off medication may allow the assessment of D1/D2 binding during novelty processing, though it would be difficult envisage how such a task would work within a reinforcement learning framework. Alternatively D1/D2 binding ratios could be related to behavioural changes detected in data collected prior/post scanning.

Another pressing future study is a longitudinal examination of ADHD neurobiology using MT saturation VBM. Although we find no evidence of long term structural therapeutic changes in the striatum using MT saturation VBM, we also cannot rule out the possibility in this cross-sectional study. Whilst this work uses subcortically optimised structural imaging to detect differences in adults in ADHD that have been argued to remit, this does not rule out the possibility of some effects of treatment and maturation. Similarly, the long term effects of medication in both Chapters 4 and 5 we do observe must be validated with longitudinal designs. Though such studies are challenging, they are essential to accurately infer therapeutic and maturational effects in ADHD.

6.7 Conclusions

Overall, these findings highlight the ongoing relevance of the anatomy and function of mesolimbic and nigrostriatal systems in ADHD. These networks appear to underpin key neuropsychological abnormalities in the disorder that are targeted by dopaminergic medications in a disorder-specific manner. Moreover, this thesis presents preliminary, cross-sectional evidence for therapeutic structural and functions alterations in response to these medications. However, it is also clear that ADHD is also associated with a range of abnormalities in higher order functions and the networks underpinning them. A developing idea is that these higher order deficits are underpinned by differences in core dopaminergic functions. Not only are higher-order networks modulated by dopaminergic nuclei (Cole et al. 2013), but the functions they subserve can be therapeutically targeted by both dopaminergic medication and naturalistically altering the rewarding and motivationally salient properties of tasks (Liddle et al. 2011). It appears likely then, that mesolimbic and nigrostriatal differences in reward and motivation may explain such higher order deficits. This work takes steps to refining the current understanding of structural and functional abnormalities in motivational and reward networks that may underpin this. Future work will be required to further refine abnormal dopaminergic function in ADHD, and determine how it relates to the higher order deficits that have long been used to define the disorder.

7 References

Aarts, E. et al., 2010. Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 35(9), pp.1943–51. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3055632&tool=pmcentrez&rendertype=abstract [Accessed February 24, 2016].

Aase, H. & Sagvolden, T., 2006. Infrequent, but not frequent, reinforcers produce more variable responding and deficient sustained attention in young children with attention-deficit/hyperactivity disorder (ADHD). *Journal of child psychology and psychiatry, and allied disciplines*, 47(5), pp.457–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16671929 [Accessed April 29, 2015].

Aboitiz, F. et al., 2014. Irrelevant stimulus processing in ADHD: catecholamine dynamics and attentional networks. *Frontiers in psychology*, 5, p.183. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3972460&tool=pmcentrez&rendertype=abstract [Accessed January 18, 2016].

Adisetiyo, V. et al., 2014. Multimodal MR imaging of brain iron in attention deficit hyperactivity disorder: a noninvasive biomarker that responds to psychostimulant treatment? *Radiology*, 272(2), pp.524–32. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4263268&tool=pmcentrez&rendertype=abstract [Accessed January 13, 2016].

Agay, N. et al., 2010. Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. *Psychopharmacology*, 210(4), pp.511–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20424828 [Accessed June 9, 2015].

Alderson, R.M. et al., 2013. Attention-deficit/hyperactivity disorder (ADHD) and working memory in adults: a meta-analytic review. *Neuropsychology*, 27(3), pp.287–302. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23688211 [Accessed February 21, 2016].

Almeida Montes, L.G. et al., 2010. Clinical correlations of grey matter reductions in the

caudate nucleus of adults with attention deficit hyperactivity disorder. *Journal of psychiatry & neuroscience : JPN*, 35(4), pp.238–46. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2895154&tool=pmcentrez&rendertype=abstract [Accessed November 11, 2015].

American Psychiatric Association, 2013. *Diagnostic and statistical manual of mental disorders*, Washington, D.C.: American Psychiatric Association.

Amiri, A. et al., 2013. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD). *Progress in neuro-psychopharmacology & biological psychiatry*, 47, pp.20–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23933054 [Accessed October 16, 2015].

Arnold, L.E. et al., 1972. Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms. *Archives of general psychiatry*, 27(6), pp.816–22. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4564954 [Accessed March 21, 2016].

Arnold, L.E., 2000. Methyiphenidate vs. amphetamine: Comparative review. *Journal of Attention Disorders*, 3(4), pp.200–211. Available at: http://jad.sagepub.com/content/3/4/200.refs [Accessed April 15, 2015].

Aron, A.R. et al., 2003. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. *Biological psychiatry*, 54(12), pp.1465–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14675812 [Accessed January 23, 2016].

Ashby, C.R. et al., 2000. Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. *The Journal of pharmacology and experimental therapeutics*, 294(3), pp.1166–74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10945873 [Accessed October 14, 2015].

Auerbach, J.G. et al., 2001. DRD4 related to infant attention and information processing: a developmental link to ADHD? *Psychiatric genetics*, 11(1), pp.31–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11409697 [Accessed May 28, 2015].

Avants, B.B. et al., 2011. A reproducible evaluation of ANTs similarity metric

performance in brain image registration. *NeuroImage*, 54(3), pp.2033–44. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3065962&tool=pmce ntrez&rendertype=abstract [Accessed August 4, 2015].

Baddeley, A., 2003. Working memory: looking back and looking forward. *Nature reviews. Neuroscience*, 4(10), pp.829–39. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14523382 [Accessed July 11, 2014].

Badgaiyan, R.D. et al., 2015. Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder J. A. Beeler, ed. *PLOS ONE*, 10(9), p.e0137326. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4589406&tool=pmce ntrez&rendertype=abstract [Accessed October 1, 2015].

Barnett, R. et al., 2001. Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. *Psychological medicine*, 31(6), pp.1107–15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11513378 [Accessed February 21, 2016].

Barr, C.L. et al., 2000. Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. *American journal of medical genetics*, 96(3), pp.262–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10898896 [Accessed May 28, 2015].

Barto, A.G., 2013. Intrinsically Motivated Learning in Natural and Artificial Systems. In G. Baldassarre & M. Mirolli, eds. Berlin, Heidelberg: Springer Berlin Heidelberg, pp. 17–47. Available at: http://dx.doi.org/10.1007/978-3-642-32375-1_2.

Basser, P.J. et al., 2000. In vivo fiber tractography using DT-MRI data. *Magnetic resonance in medicine*, 44(4), pp.625–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11025519 [Accessed July 2, 2015].

Basser, P.J., Mattiello, J. & LeBihan, D., 1994. Estimation of the effective self-diffusion tensor from the NMR spin echo. *Journal of magnetic resonance. Series B*, 103(3), pp.247–54. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8019776 [Accessed December 18, 2015].

Basser, P.J. & Pierpaoli, C., 1996. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. *Journal of magnetic resonance.*

Series B, 111(3), pp.209–19. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8661285 [Accessed January 8, 2016].

Batty, M.J. et al., 2015. Morphological abnormalities in prefrontal surface area and thalamic volume in attention deficit/hyperactivity disorder. *Psychiatry research*, 233(2), pp.225–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26190555 [Accessed December 10, 2015].

Bayer, H.M. & Glimcher, P.W., 2005. Midbrain dopamine neurons encode a quantitative reward prediction error signal. *Neuron*, 47(1), pp.129–41. Available at: http://www.sciencedirect.com/science/article/pii/S0896627305004678 [Accessed April 10, 2015].

Beck, A., Steer, R. & Brown, G., 1996. *Manual for the Beck Depression Inventory-II*, San Antonio, TX: Psychological Corporation.

Bédard, A.-C. et al., 2010. Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. *NeuroImage*, 53(3), pp.935–942. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20026227 [Accessed January 23, 2017].

Behrens, T.E.J. et al., 2003. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. *Nature neuroscience*, 6(7), pp.750–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12808459 [Accessed November 28, 2014].

Berridge, K.C., 2012. From prediction error to incentive salience: mesolimbic computation of reward motivation. *The European journal of neuroscience*, 35(7), pp.1124–43. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3325516&tool=pmcentrez&rendertype=abstract [Accessed March 26, 2015].

Bevington, P.R., 1969. *Data reduction and error analysis for the physical sciences*, Ney York: McGraw-Hill.

Bianco, L.E. et al., 2008. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. *Journal of neurochemistry*, 106(1), pp.205–15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18363828 [Accessed March 13, 2016].

Biederman, J. et al., 2004. Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. *Journal*

of consulting and clinical psychology, 72(5), pp.757–66. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15482034 [Accessed December 11, 2015].

Biederman, J., Mick, E. & Faraone, S. V, 2000. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. *The American journal of psychiatry*, 157(5), pp.816–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10784477 [Accessed January 30, 2016].

Le Bihan, D., 2003. Looking into the functional architecture of the brain with diffusion MRI. *Nature reviews. Neuroscience*, 4(6), pp.469–80. Available at: http://dx.doi.org/10.1038/nrn1119 [Accessed February 11, 2016].

Bioulac, S. et al., 2014. Video game performances are preserved in ADHD children compared with controls. *Journal of attention disorders*, 18(6), pp.542–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22628143 [Accessed February 3, 2016].

Blick, S.K.A. & Keating, G.M., 2007. Lisdexamfetamine. *Paediatric drugs*, 9(2), pp.129–35; discussion 136–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17407369 [Accessed March 21, 2016].

Blood, A.J. et al., 2010. Microstructural abnormalities in subcortical reward circuitry of subjects with major depressive disorder. *PloS one*, 5(11), p.e13945. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2993928&tool=pmce ntrez&rendertype=abstract [Accessed November 12, 2015].

Boorman, E.D. et al., 2009. How Green Is the Grass on the Other Side? Frontopolar Cortex and the Evidence in Favor of Alternative Courses of Action. *Neuron*, 62(5), pp.733–743. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19524531 [Accessed February 12, 2017].

Browder, S., German, D.C. & Shore, P.A., 1981. Midbrain dopamine neurons: differential responses to amphetamine isomers. *Brain research*, 207(2), pp.333–42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7470912 [Accessed October 12, 2015].

Buckholtz, J.W. et al., 2010. Dopaminergic network differences in human impulsivity. *Science (New York, N.Y.)*, 329(5991), p.532. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3161413&tool=pmce ntrez&rendertype=abstract [Accessed August 12, 2015].

Buckner, R.L., Andrews-Hanna, J.R. & Schacter, D.L., 2008. The brain's default network: anatomy, function, and relevance to disease. *Annals of the New York Academy of Sciences*, 1124, pp.1–38. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18400922 [Accessed July 10, 2014].

Bunzeck, N. & Düzel, E., 2006. Absolute coding of stimulus novelty in the human substantia nigra/VTA. *Neuron*, 51(3), pp.369–79. Available at: http://www.sciencedirect.com/science/article/pii/S0896627306004752 [Accessed May 17, 2015].

Bush, G., 2010. Attention-deficit/hyperactivity disorder and attention networks. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 35(1), pp.278–300. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3055423&tool=pmcentrez&rendertype=abstract [Accessed February 15, 2016].

Campbell-Meiklejohn, D. et al., 2012. In for a penny, in for a pound: methylphenidate reduces the inhibitory effect of high stakes on persistent risky choice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 32(38), pp.13032–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22993421 [Accessed June 9, 2015].

del Campo, N. et al., 2013. A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. *Brain*, 136(11), pp.3252–3270. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4125626&tool=pmcentrez&rendertype=abstract [Accessed January 9, 2016].

Cao, Q. et al., 2006. Abnormal neural activity in children with attention deficit hyperactivity disorder: a resting-state functional magnetic resonance imaging study. *Neuroreport*, 17(10), pp.1033–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16791098 [Accessed February 23, 2016].

Cao, X. et al., 2009. Abnormal resting-state functional connectivity patterns of the putamen in medication-naïve children with attention deficit hyperactivity disorder. *Brain research*, 1303, pp.195–206. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19699190 [Accessed February 4, 2016].

Carmona, S. et al., 2009. Ventro-striatal reductions underpin symptoms of hyperactivity and impulsivity in attention-deficit/hyperactivity disorder. *Biological*

psychiatry, 66(10), pp.972–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19576573 [Accessed November 18, 2015].

Casey, B.J. et al., 1997. Implication of right frontostriatal circuitry in response inhibition and attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 36(3), pp.374–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9055518 [Accessed November 5, 2015].

Caspers, S. et al., 2011. Moral concepts set decision strategies to abstract values. *PloS one*, 6(4), p.e18451. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21483767 [Accessed February 12, 2017].

Caspers, S. et al., 2013. Organization of the human inferior parietal lobule based on receptor architectonics. *Cerebral cortex (New York, N.Y. : 1991)*, 23(3), pp.615–28. Available at: http://cercor.oxfordjournals.org/content/early/2012/02/28/cercor.bhs048.full [Accessed November 14, 2015].

Castellanos, F.X. et al., 2006. Characterizing cognition in ADHD: beyond executive dysfunction. *Trends in cognitive sciences*, 10(3), pp.117–23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16460990 [Accessed July 18, 2014].

Castellanos, F.X. & Proal, E., 2012. Large-scale brain systems in ADHD: beyond the prefrontal-striatal model. *Trends in cognitive sciences*, 16(1), pp.17–26. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3272832&tool=pmcentrez&rendertype=abstract [Accessed November 13, 2014].

Caswell, A.J. et al., 2015. Further evidence of the heterogeneous nature of impulsivity. *Personality and individual differences*, 76, pp.68–74. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4316178&tool=pmcentrez&rendertype=abstract [Accessed November 16, 2015].

Catani, M. et al., 2002. Virtual in vivo interactive dissection of white matter fasciculi in the human brain. *NeuroImage*, 17(1), pp.77–94. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12482069 [Accessed February 18, 2016].

Cercignani, M. et al., 2012. Group-averaged anatomical connectivity mapping for improved human white matter pathway visualisation. *NMR in Biomedicine*, 25(11), pp.1224–1233. Available at: http://doi.wiley.com/10.1002/nbm.2793 [Accessed

November 2, 2015].

Chamberlain, S.R. et al., 2007. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. *Biological psychiatry*, 62(9), pp.977–84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17644072 [Accessed February 21, 2016].

Chang, Z. et al., 2014. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. *JAMA psychiatry*, 71(3), pp.319–25. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3949159&tool=pmcentrez&rendertype=abstract [Accessed November 27, 2015].

Chelonis, J.J. et al., 2011. Effect of methylphenidate on motivation in children with attention-deficit/hyperactivity disorder. *Experimental and clinical psychopharmacology*, 19(2), pp.145–53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21463072 [Accessed December 2, 2015].

Cherkasova, M. V et al., 2014. Amphetamine-induced dopamine release and neurocognitive function in treatment-naive adults with ADHD. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 39(6), pp.1498–507. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3988554&tool=pmcentrez&rendertype=abstract [Accessed September 30, 2015].

Chinta, S.J. & Andersen, J.K., 2005. Dopaminergic neurons. *The international journal of biochemistry & cell biology*, 37(5), pp.942–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15743669 [Accessed November 25, 2015].

Chowdhury, R. et al., 2013. Parcellation of the human substantia nigra based on anatomical connectivity to the striatum. *NeuroImage*, 81, pp.191–198. Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3734352&tool=pmcentrez&rendertype=abstract [Accessed October 1, 2015].

Clatworthy, P.L. et al., 2009. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 29(15), pp.4690–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19369539 [Accessed February 8, 2016].

Cloninger, C.R., Przybeck, T.R. & Svrakic, D.M., 1991. The Tridimensional Personality Questionnaire: U.S. normative data. *Psychological reports*, 69(3 Pt 1), pp.1047–57. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1784653 [Accessed April 25, 2015].

Cole, D.M. et al., 2013. Dopamine-dependent architecture of cortico-subcortical network connectivity. *Cerebral cortex (New York, N.Y. : 1991)*, 23(7), pp.1509–16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22645252 [Accessed October 6, 2015].

Conners, K.C., Erhardt, D. & Sparrow, E., 1999. *Conner's Adult ADHD Rating Scales: CAARS*, Toronto: MHS.

Cook, P. a et al., 2006. Camino: Open-Source Diffusion-MRI Reconstruction and Processing. *14th Scientific Meeting of the International Society for Magnetic Resonance in Medicine*, 14, p.2759.

Corbetta, M., Patel, G. & Shulman, G.L., 2008. The reorienting system of the human brain: from environment to theory of mind. *Neuron*, 58(3), pp.306–24. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2441869&tool=pmcentrez&rendertype=abstract [Accessed August 7, 2015].

Corbetta, M. & Shulman, G.L., 2002. Control of goal-directed and stimulus-driven attention in the brain. *Nature reviews. Neuroscience*, 3(3), pp.201–15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11994752 [Accessed July 10, 2014].

Corominas-Roso, M. et al., 2013. Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)*, pp.1–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23363778 [Accessed October 16, 2015].

Cortese, S. et al., 2012. Brain iron levels in attention-deficit/hyperactivity disorder: a pilot MRI study. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry*, 13(3), pp.223–31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21585274 [Accessed November 30, 2015].

Coulombe, M.-A. et al., 2016. Intrinsic functional connectivity of periaqueductal gray

subregions in humans. *Human brain mapping*, 37(4), pp.1514–30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26821847 [Accessed March 13, 2016].

Cox, S.M.L. et al., 2015. Striatal D1 and D2 signaling differentially predict learning from positive and negative outcomes. *NeuroImage*, 109, pp.95–101. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25562824 [Accessed May 8, 2015].

Cristino, A.S. et al., 2014. Neurodevelopmental and neuropsychiatric disorders represent an interconnected molecular system. *Molecular psychiatry*, 19(3), pp.294–301. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23439483 [Accessed February 5, 2016].

Cubillo, A. et al., 2012. A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. *Cortex; a journal devoted to the study of the nervous system and behavior*, 48(2), pp.194–215. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21575934 [Accessed January 2, 2015].

Cubillo, A. et al., 2010. Reduced activation and inter-regional functional connectivity of fronto-striatal networks in adults with childhood Attention-Deficit Hyperactivity Disorder (ADHD) and persisting symptoms during tasks of motor inhibition and cognitive switching. *Journal of psychiatric research*, 44(10), pp.629–39. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20060129 [Accessed February 21, 2016].

Dalley, J.W. et al., 2007. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. *Science (New York, N.Y.)*, 315(5816), pp.1267–70. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1892797&tool=pmcentrez&rendertype=abstract [Accessed June 9, 2015].

Dalley, J.W., Everitt, B.J. & Robbins, T.W., 2011. Impulsivity, Compulsivity, and Top-Down Cognitive Control. *Neuron*, 69(4), pp.680–694. Available at: http://www.sciencedirect.com/science/article/pii/S0896627311000687 [Accessed April 16, 2015].

Darki, F. & Klingberg, T., 2015. The role of fronto-parietal and fronto-striatal networks in the development of working memory: a longitudinal study. *Cerebral cortex (New York, N.Y. : 1991)*, 25(6), pp.1587–95. Available at:

http://www.ncbi.nlm.nih.gov/pubmed/24414278 [Accessed January 29, 2016].

Deichmann, R. et al., 2003. Optimized EPI for fMRI studies of the orbitofrontal cortex. *NeuroImage*, 19(2 Pt 1), pp.430–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12814592 [Accessed September 2, 2015].

Depue, B.E., Burgess, G.C., Bidwell, L.C., et al., 2010. Behavioral performance predicts grey matter reductions in the right inferior frontal gyrus in young adults with combined type ADHD. *Psychiatry research*, 182(3), pp.231–7. Available at: http://www.sciencedirect.com/science/article/pii/S0925492710000375 [Accessed November 11, 2015].

Depue, B.E., Burgess, G.C., Willcutt, E.G., Ruzic, L., et al., 2010. Inhibitory control of memory retrieval and motor processing associated with the right lateral prefrontal cortex: evidence from deficits in individuals with ADHD. *Neuropsychologia*, 48(13), pp.3909–17. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2979319&tool=pmcentrez&rendertype=abstract [Accessed December 10, 2015].

Depue, B.E., Burgess, G.C., Willcutt, E.G., Bidwell, L.C., et al., 2010. Symptom-correlated brain regions in young adults with combined-type ADHD: their organization, variability, and relation to behavioral performance. *Psychiatry research*, 182(2), pp.96–102. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2878757&tool=pmcentrez&rendertype=abstract [Accessed December 10, 2015].

DeVito, E.E. et al., 2009. Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD). *Psychopharmacology*, 202(1-3), pp.531–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2704617&tool=pmcentrez&rendertype=abstract [Accessed February 21, 2016].

DeVito, E.E. et al., 2008a. The effects of methylphenidate on decision making in attention-deficit/hyperactivity disorder. *Biological psychiatry*, 64(7), pp.636–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2577132&tool=pmcentrez&rendertype=abstract [Accessed February 25, 2016].

DeVito, E.E. et al., 2008b. The effects of methylphenidate on decision making in attention-deficit/hyperactivity disorder. *Biological psychiatry*, 64(7), pp.636–9.

Available at:
http://www.sciencedirect.com/science/article/pii/S0006322308004708
[Accessed May 12, 2015].

Dickstein, S.G. et al., 2006. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. *Journal of child psychology and psychiatry, and allied disciplines*, 47(10), pp.1051–62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17073984 [Accessed April 24, 2015].

Djamshidian, A. et al., 2011. Novelty seeking behaviour in Parkinson's disease. *Neuropsychologia*, 49(9), pp.2483–8. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3137690&tool=pmce ntrez&rendertype=abstract [Accessed May 27, 2015].

Dommett, E.J. et al., 2008. Methylphenidate amplifies long-term plasticity in the hippocampus via noradrenergic mechanisms. *Learning & memory (Cold Spring Harbor, N.Y.)*, 15(8), pp.580–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18685149 [Accessed September 10, 2015].

Dosenbach, N.U.F. et al., 2008. A dual-networks architecture of top-down control. *Trends in cognitive sciences*, 12(3), pp.99–105. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3632449&tool=pmce ntrez&rendertype=abstract [Accessed February 24, 2016].

Downey, K.K. et al., 1997. Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. *The Journal of nervous and mental disease*, 185(1), pp.32–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9040531 [Accessed May 28, 2015].

Draganski, B. et al., 2011. Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ). *NeuroImage*, 55(4), pp.1423–34. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3093621&tool=pmce ntrez&rendertype=abstract [Accessed January 16, 2016].

Dreyer, J.K. et al., 2010. Influence of phasic and tonic dopamine release on receptor activation. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 30(42), pp.14273–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20962248 [Accessed September 19,

2015].

Duerden, E.G., Tannock, R. & Dockstader, C., 2012. Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. *Brain research*, 1445, pp.82–91. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22325095 [Accessed March 4, 2016].

Durston, S. et al., 2005. Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. *Molecular Psychiatry*, 10(7), pp.678–685. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15724142 [Accessed January 23, 2017].

Durston, S. et al., 2008. Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. *Journal of the American Academy of Child and Adolescent Psychiatry*, 47(1), pp.61–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18174826 [Accessed May 12, 2015].

Durston, S., 2010. Imaging genetics in ADHD. *NeuroImage*, 53(3), pp.832–838. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20206707 [Accessed January 24, 2017].

Durston, S. et al., 2007. Neural and behavioral correlates of expectancy violations in attention-deficit hyperactivity disorder. *Journal of child psychology and psychiatry, and allied disciplines*, 48(9), pp.881–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17714373 [Accessed January 22, 2016].

Düzel, S. et al., 2008. A close relationship between verbal memory and SN/VTA integrity in young and older adults. *Neuropsychologia*, 46(13), pp.3042–52. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18601938 [Accessed September 2, 2015].

Easton, N. et al., 2007. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. *Neuropharmacology*, 52(2), pp.405–14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17020775 [Accessed March 21, 2016].

Ebstein, R.P. et al., 1996. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. *Nature genetics*,

12(1), pp.78–80. Available at: http://dx.doi.org/10.1038/ng0196-78 [Accessed January 18, 2015].

Eckert, T. et al., 2004. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. *NeuroImage*, 21(1), pp.229–35. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14741660 [Accessed November 12, 2015].

Economidou, D. et al., 2012. Norepinephrine and dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleus accumbens. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 37(9), pp.2057–66. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3398724&tool=pmcentrez&rendertype=abstract [Accessed August 28, 2015].

Eisenberg, J. et al., 2000. A haplotype relative risk study of the dopamine D4 receptor (DRD4) exon III repeat polymorphism and attention deficit hyperactivity disorder (ADHD). *American journal of medical genetics*, 96(3), pp.258–61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10898895 [Accessed May 28, 2015].

Ekelund, J. et al., 1999. Association between novelty seeking and the type 4 dopamine receptor gene in a large Finnish cohort sample. *The American journal of psychiatry*, 156(9), pp.1453–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10484963 [Accessed May 28, 2015].

Ellison-Wright, I., Ellison-Wright, Z. & Bullmore, E., 2008. Structural brain change in Attention Deficit Hyperactivity Disorder identified by meta-analysis. *BMC psychiatry*, 8, p.51. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2453122&tool=pmcentrez&rendertype=abstract [Accessed March 4, 2016].

Faraone, S. V et al., 1999. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. *The American journal of psychiatry*, 156(5), pp.768–70. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10327912 [Accessed May 28, 2015].

Faraone, S. V et al., 2001. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. *The American journal of psychiatry*, 158(7), pp.1052–7. Available at:

http://www.ncbi.nlm.nih.gov/pubmed/11431226 [Accessed May 28, 2015].

Faraone, S. V et al., 2005. Molecular genetics of attention-deficit/hyperactivity disorder. *Biological psychiatry*, 57(11), pp.1313–23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15950004 [Accessed October 27, 2015].

Faraone, S. V et al., 2003. The worldwide prevalence of ADHD: is it an American condition? *World psychiatry : official journal of the World Psychiatric Association (WPA)*, 2(2), pp.104–13. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1525089&tool=pmcentrez&rendertype=abstract [Accessed November 3, 2015].

Faraone, S. V, Biederman, J. & Mick, E., 2006. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. *Psychological medicine*, 36(2), pp.159–65. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16420712 [Accessed September 3, 2014].

Fayyad, J. et al., 2007. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. *The British journal of psychiatry : the journal of mental science*, 190, pp.402–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17470954 [Accessed July 20, 2015].

Fischl, B. et al., 2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron*, 33(3), pp.341–55. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11832223 [Accessed January 6, 2015].

Fleckenstein, A.E. et al., 2007. New Insights into the Mechanism of Action of Amphetamines. *Annual Review of Pharmacology and Toxicology*, 47(1), pp.681–698. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17209801 [Accessed January 7, 2016].

Fosco, W.D. et al., 2015. Evaluating cognitive and motivational accounts of greater reinforcement effects among children with attention-deficit/hyperactivity disorder. *Behavioral and brain functions : BBF*, 11, p.20. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4438621&tool=pmcentrez&rendertype=abstract [Accessed January 24, 2016].

Fox, M.D. et al., 2006. Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. *Proceedings of the National Academy of Sciences of*

the United States of America, 103(26), pp.10046–51. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1480402&tool=pmce ntrez&rendertype=abstract [Accessed September 30, 2015].

Frank, M.J. et al., 2007. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 32(7), pp.1583–99. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17164816 [Accessed March 16, 2015].

Franke, B. et al., 2012. The genetics of attention deficit/hyperactivity disorder in adults, a review. *Molecular psychiatry*, 17(10), pp.960–87. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3449233&tool=pmce ntrez&rendertype=abstract [Accessed December 10, 2015].

Frodl, T. et al., 2010. Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers. *Acta psychiatrica Scandinavica*, 121(2), pp.111–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19878138 [Accessed March 4, 2016].

Frodl, T. & Skokauskas, N., 2012. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. *Acta Psychiatrica Scandinavica*, 125(2), pp.114–126. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22118249 [Accessed April 29, 2015].

Fusar-Poli, P. et al., 2012. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. *The American journal of psychiatry*, 169(3), pp.264–72. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22294258 [Accessed June 3, 2015].

Gervais, J. & Rouillard, C., 2000. Dorsal raphe stimulation differentially modulates dopaminergic neurons in the ventral tegmental area and substantia nigra. *Synapse (New York, N.Y.)*, 35(4), pp.281–91. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10657038 [Accessed October 13, 2015].

Ginsberg, Y. et al., 2014. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature. *The primary care companion for CNS disorders*, 16(3). Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4195639&tool=pmce ntrez&rendertype=abstract [Accessed December 14, 2015].

Gizer, I.R., Ficks, C. & Waldman, I.D., 2009. Candidate gene studies of ADHD: a meta-analytic review. *Human genetics*, 126(1), pp.51–90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19506906 [Accessed June 25, 2015].

Gizer, I.R. & Waldman, I.D., 2012. Double dissociation between lab measures of inattention and impulsivity and the dopamine transporter gene (DAT1) and dopamine D4 receptor gene (DRD4). *Journal of abnormal psychology*, 121(4), pp.1011–23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22564179 [Accessed May 12, 2015].

Gläscher, J., Hampton, A.N. & O'Doherty, J.P., 2009. Determining a role for ventromedial prefrontal cortex in encoding action-based value signals during reward-related decision making. *Cerebral cortex (New York, N.Y. : 1991)*, 19(2), pp.483–95. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2626172&tool=pmcentrez&rendertype=abstract [Accessed February 25, 2016].

Goldstein, J.M. & Litwin, L.C., 1988. Spontaneous activity of A9 and A10 dopamine neurons after acute and chronic administration of the selective dopamine D-1 receptor antagonist SCH 23390. *European journal of pharmacology*, 155(1-2), pp.175–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2907487 [Accessed November 3, 2015].

Grace, A.A., 2001. Psychostimulant actions on dopamine and limbic system function: Relevance to the pathophysiology and treatment of ADHD. In M. V Solanto, A. F. T. Arnsten, & F. X. Castellanos, eds. *Stimulant drugs and ADHD: Basic and clinical neuroscience*. New York, NY, US: Oxford University Press, pp. 134–157.

Gross, M.D., 1976. A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction. *Diseases of the nervous system*, 37(1), pp.14–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1106966 [Accessed March 21, 2016].

Haber, S.N., 2003. The primate basal ganglia: parallel and integrative networks. *Journal of chemical neuroanatomy*, 26(4), pp.317–30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14729134 [Accessed July 23, 2015].

Haber, S.N., Fudge, J.L. & McFarland, N.R., 2000. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 20(6),

pp.2369–82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10704511 [Accessed September 7, 2015].

Haber, S.N. & Knutson, B., 2010. The reward circuit: linking primate anatomy and human imaging. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 35(1), pp.4–26. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3055449&tool=pmce ntrez&rendertype=abstract [Accessed July 10, 2014].

Halmøy, A. et al., 2009. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. *Journal of attention disorders*, 13(2), pp.175–87. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19372500 [Accessed February 9, 2016].

Harpin, V.A., 2005. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. *Archives of Disease in Childhood*, 90(suppl_1), pp.i2–i7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1765272&tool=pmce ntrez&rendertype=abstract [Accessed September 27, 2015].

Hauser, T.U. et al., 2014. Role of the medial prefrontal cortex in impaired decision making in juvenile attention-deficit/hyperactivity disorder. *JAMA psychiatry*, 71(10), pp.1165–73. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25142296 [Accessed February 25, 2016].

Hawi, Z. et al., 2015. The molecular genetic architecture of attention deficit hyperactivity disorder. *Molecular psychiatry*, 20(3), pp.289–97. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25600112 [Accessed February 10, 2016].

Heimer, L., 2003. A new anatomical framework for neuropsychiatric disorders and drug abuse. *The American journal of psychiatry*, 160(10), pp.1726–39. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14514480 [Accessed February 11, 2016].

Helms, G., Dathe, H., Kallenberg, K., et al., 2008. High-resolution maps of magnetization transfer with inherent correction for RF inhomogeneity and T1 relaxation obtained from 3D FLASH MRI. *Magnetic resonance in medicine*, 60(6), pp.1396–407. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19025906 [Accessed December 3, 2015].

Helms, G. et al., 2009. Improved segmentation of deep brain grey matter structures using magnetization transfer (MT) parameter maps. *NeuroImage*, 47(1), pp.194–8. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2694257&tool=pmcentrez&rendertype=abstract [Accessed September 2, 2015].

Helms, G., Dathe, H. & Dechent, P., 2008. Quantitative FLASH MRI at 3T using a rational approximation of the Ernst equation. *Magnetic resonance in medicine*, 59(3), pp.667–72. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18306368 [Accessed February 3, 2016].

Henkelman, R.M., Stanisz, G.J. & Graham, S.J., 2001. Magnetization transfer in MRI: a review. *NMR in biomedicine*, 14(2), pp.57–64. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11320533 [Accessed February 17, 2016].

Hesslinger, B. et al., 2002. Frontoorbital volume reductions in adult patients with attention deficit hyperactivity disorder. *Neuroscience letters*, 328(3), pp.319–21. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12147334 [Accessed December 10, 2015].

Hollerman, J.R. & Schultz, W., 1998. Dopamine neurons report an error in the temporal prediction of reward during learning. *Nature neuroscience*, 1(4), pp.304–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10195164 [Accessed April 24, 2015].

Hoogman, M. et al., 2011. Nitric oxide synthase genotype modulation of impulsivity and ventral striatal activity in adult ADHD patients and healthy comparison subjects. *The American journal of psychiatry*, 168(10), pp.1099–106. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21724667 [Accessed May 11, 2015].

Horsfield, M.A. & Cercignani, M., 2015. Magnetization Transfer Imaging. In M. Filippi, ed. *Neuroimaging (Oxford Textbook in Clinical Neurology)*. Oxford: Oxford University Press.

Horvitz, J.C., Stewart, T. & Jacobs, B.L., 1997. Burst activity of ventral tegmental dopamine neurons is elicited by sensory stimuli in the awake cat. *Brain research*, 759(2), pp.251–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9221945 [Accessed May 18, 2015].

Hyman, C. et al., 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the

substantia nigra. *Nature*, 350(6315), pp.230–2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2005978 [Accessed September 28, 2015].

Iglesias, S. et al., 2013. Hierarchical prediction errors in midbrain and basal forebrain during sensory learning. *Neuron*, 80(2), pp.519–30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24139048 [Accessed January 27, 2016].

Ivanov, I. et al., 2010. Morphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder. *The American journal of psychiatry*, 167(4), pp.397–408. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4282161&tool=pmce ntrez&rendertype=abstract [Accessed December 10, 2015].

Jacob, C. et al., 2014. Internalizing and externalizing behavior in adult ADHD. *Attention deficit and hyperactivity disorders*, 6(2), pp.101–10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24557851 [Accessed May 28, 2015].

Jansons, K.M. & Alexander, D.C., 2003. Persistent angular structure: new insights from diffusion magnetic resonance imaging data. *Inverse Problems*, 19(5), pp.1031–1046. Available at: http://iopscience.iop.org/article/10.1088/0266-5611/19/5/303 [Accessed November 2, 2015].

Kakade, S. & Dayan, P., 2002. Dopamine: generalization and bonuses. *Neural Networks*, 15(4-6), pp.549–559. Available at: http://www.sciencedirect.com/science/article/pii/S0893608002000485 [Accessed May 6, 2015].

Kerr, A. & Zelazo, P.D., 2004. Development of "hot" executive function: the children's gambling task. *Brain and cognition*, 55(1), pp.148–57. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15134849 [Accessed January 12, 2016].

Kessler, R.C. et al., 2006. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. *The American journal of psychiatry*, 163(4), pp.716–23. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2859678&tool=pmce ntrez&rendertype=abstract [Accessed February 3, 2015].

Kim, Y. et al., 2009. Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens. *Proceedings of the National Academy of Sciences of the United States of America*, 106(8), pp.2915–20. Available at:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2650365&tool=pmce ntrez&rendertype=abstract [Accessed October 21, 2015].

Kimko, H.C., Cross, J.T. & Abernethy, D.R., 1999. Pharmacokinetics and clinical effectiveness of methylphenidate. *Clinical pharmacokinetics*, 37(6), pp.457–70. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10628897 [Accessed March 21, 2016].

Kiss, J.P., Zsilla, G. & Vizi, E.S., 2004. Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. *Neurochemistry international*, 45(4), pp.485–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15186914 [Accessed January 25, 2016].

Klink, R. et al., 2001. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 21(5), pp.1452–63. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11222635 [Accessed October 13, 2015].

Kluger, A.N., Siegfried, Z. & Ebstein, R.P., 2002. A meta-analysis of the association between DRD4 polymorphism and novelty seeking. *Molecular psychiatry*, 7(7), pp.712–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12192615 [Accessed May 28, 2015].

Kobel, M. et al., 2010. Structural and functional imaging approaches in attention deficit/hyperactivity disorder: does the temporal lobe play a key role? *Psychiatry research*, 183(3), pp.230–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20702071 [Accessed March 4, 2016].

Kollins, S.H., Lane, S.D. & Shapiro, S.K., 1997. Experimental analysis of childhood psychopathology: A laboratory matching analysis of the behaviour of children diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD). *The Psychological Record*, 47(), pp.25–44.

Konrad, K. & Eickhoff, S.B., 2010. Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. *Human brain mapping*, 31(6), pp.904–16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20496381 [Accessed September 2, 2015].

Kooij, S.J.J. et al., 2010. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. *BMC psychiatry*, 10, p.67.

Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2942810&tool=pmce ntrez&rendertype=abstract [Accessed January 26, 2016].

Kuczenski, R. & Segal, D.S., 1997. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. *Journal of neurochemistry*, 68(5), pp.2032–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9109529 [Accessed March 21, 2016].

LaHoste, G.J. et al., 1996. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. *Molecular psychiatry*, 1(2), pp.121–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9118321 [Accessed May 28, 2015].

Lammel, S. et al., 2012. Input-specific control of reward and aversion in the ventral tegmental area. *Nature*, 491(7423), pp.212–7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3493743&tool=pmce ntrez&rendertype=abstract [Accessed July 10, 2014].

Lange, M. et al., 2012. The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development. *Molecular psychiatry*, 17(9), pp.946–54. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22508465 [Accessed February 19, 2016].

Langkammer, C. et al., 2010. Quantitative MR imaging of brain iron: a postmortem validation study. *Radiology*, 257(2), pp.455–62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20843991 [Accessed March 17, 2016].

Larsson, H. et al., 2014. The heritability of clinically diagnosed attention deficit hyperactivity disorder across the lifespan. *Psychological medicine*, 44(10), pp.2223–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4071160&tool=pmce ntrez&rendertype=abstract [Accessed January 31, 2016].

Lasky-Su, J. et al., 2008. Family-based association analysis of a statistically derived quantitative traits for ADHD reveal an association in DRD4 with inattentive symptoms in ADHD individuals. *American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*, 147B(1), pp.100–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17579349 [Accessed September 22,

2015].

Lawes, I.N.C. et al., 2008. Atlas-based segmentation of white matter tracts of the human brain using diffusion tensor tractography and comparison with classical dissection. *NeuroImage*, 39(1), pp.62–79. Available at: http://www.sciencedirect.com/science/article/pii/S1053811907005411 [Accessed February 19, 2016].

Leemans, A. & Jones, D.K., 2009. The B-matrix must be rotated when correcting for subject motion in DTI data. *Magnetic resonance in medicine*, 61(6), pp.1336–49. Available at: http://doi.wiley.com/10.1002/mrm.21890 [Accessed September 28, 2015].

Levesque, I.R. & Pike, G.B., 2009. Characterizing healthy and diseased white matter using quantitative magnetization transfer and multicomponent T(2) relaxometry: A unified view via a four-pool model. *Magnetic resonance in medicine*, 62(6), pp.1487–96. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19859946 [Accessed March 3, 2016].

Liddle, E.B. et al., 2011. Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. *Journal of Child Psychology and Psychiatry*, 52(7), pp.761–771. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21073458 [Accessed March 23, 2015].

Lin, L.F. et al., 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science (New York, N.Y.)*, 260(5111), pp.1130–2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8493557 [Accessed May 9, 2015].

Liston, C. et al., 2006. Anterior cingulate and posterior parietal cortices are sensitive to dissociable forms of conflict in a task-switching paradigm. *Neuron*, 50(4), pp.643–53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16701213 [Accessed February 23, 2016].

Ljungberg, T., Apicella, P. & Schultz, W., 1992. Responses of monkey dopamine neurons during learning of behavioral reactions. *Journal of neurophysiology*, 67(1), pp.145–63. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1552316 [Accessed May 18, 2015].

Loos, M. et al., 2010. Inhibitory control and response latency differences between

C57BL/6J and DBA/2J mice in a Go/No-Go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine. *Behav Brain Res*, 214(2), pp.216–224. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20580749 [Accessed November 4, 2015].

Lopez-Larson, M.P. et al., 2012. Reduced insular volume in attention deficit hyperactivity disorder. *Psychiatry research*, 204(1), pp.32–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3998750&tool=pmce ntrez&rendertype=abstract [Accessed March 4, 2016].

Luman, M., Oosterlaan, J. & Sergeant, J.A., 2005. The impact of reinforcement contingencies on AD/HD: a review and theoretical appraisal. *Clinical psychology review*, 25(2), pp.183–213. Available at: http://www.sciencedirect.com/science/article/pii/S0272735804001527 [Accessed March 3, 2015].

Luman, M., Tripp, G. & Scheres, A., 2010. Identifying the neurobiology of altered reinforcement sensitivity in ADHD: a review and research agenda. *Neuroscience and biobehavioral reviews*, 34(5), pp.744–54. Available at: http://www.sciencedirect.com/science/article/pii/S0149763409001870 [Accessed May 12, 2015].

Lynn, D.E. et al., 2005. Temperament and character profiles and the dopamine D4 receptor gene in ADHD. *The American journal of psychiatry*, 162(5), pp.906–13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15863792 [Accessed April 29, 2015].

Makris, N. et al., 2007. Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. *Cerebral cortex (New York, N.Y. : 1991)*, 17(6), pp.1364–75. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16920883 [Accessed March 4, 2016].

Makris, N. et al., 2015. Toward Defining the Neural Substrates of ADHD: A Controlled Structural MRI Study in Medication-Naive Adults. *Journal of Attention Disorders*, 19(11), pp.944–953. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24189200 [Accessed January 27, 2017].

Makris, N. et al., 2015. Toward Defining the Neural Substrates of ADHD: A Controlled Structural MRI Study in Medication-Naïve Adults. *Journal of attention disorders*, 19(11), pp.944–53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24189200

[Accessed January 31, 2016].

Mannuzza, S. et al., 2008. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. *The American journal of psychiatry*, 165(5), pp.604–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2967384&tool=pmce ntrez&rendertype=abstract [Accessed May 20, 2015].

Mannuzza, S., Klein, R.G. & Moulton, J.L., 2003. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. *Journal of child and adolescent psychopharmacology*, 13(3), pp.273–82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14642015 [Accessed June 9, 2015].

Martin, W.R., Ye, F.Q. & Allen, P.S., 1998. Increasing striatal iron content associated with normal aging. *Movement disorders : official journal of the Movement Disorder Society*, 13(2), pp.281–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9539342 [Accessed December 7, 2015].

Martinez, D. et al., 2003. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*, 23(3), pp.285–300. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12621304 [Accessed September 2, 2015].

Mathys, C. et al., 2011. A bayesian foundation for individual learning under uncertainty. *Frontiers in human neuroscience*, 5, p.39. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3096853&tool=pmce ntrez&rendertype=abstract [Accessed November 25, 2015].

McCarthy, H. et al., 2013. Attention network hypoconnectivity with default and affective network hyperconnectivity in adults diagnosed with attention-deficit/hyperactivity disorder in childhood. *JAMA psychiatry*, 70(12), pp.1329–37. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24132732 [Accessed January 18, 2016].

McClure, S.M., Berns, G.S. & Montague, P.R., 2003. Temporal Prediction Errors in a Passive Learning Task Activate Human Striatum. *Neuron*, 38(2), pp.339–346. Available at:

http://www.sciencedirect.com/science/article/pii/S0896627303001545 [Accessed May 11, 2015].

Mehta, M.A. et al., 2000. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 20(6), p.RC65. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10704519 [Accessed January 16, 2016].

Mehta, M.A., Goodyer, I.M. & Sahakian, B.J., 2004. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. *Journal of child psychology and psychiatry, and allied disciplines*, 45(2), pp.293–305. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14982243 [Accessed January 16, 2016].

Mejías-Aponte, C.A., Drouin, C. & Aston-Jones, G., 2009. Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: prominent inputs from medullary homeostatic centers. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 29(11), pp.3613–26. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2731794&tool=pmcentrez&rendertype=abstract [Accessed November 3, 2015].

Menke, R.A. et al., 2010. Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease. *NeuroImage*, 52(4), pp.1175–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20677376 [Accessed February 12, 2016].

Menon, V., 2011. Large-scale brain networks and psychopathology: a unifying triple network model. *Trends in cognitive sciences*, 15(10), pp.483–506. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21908230 [Accessed July 11, 2014].

Mereu, G. et al., 1987. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. *European journal of pharmacology*, 141(3), pp.395–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3666033 [Accessed October 13, 2015].

Mevorach, C., Humphreys, G.W. & Shalev, L., 2009. Reflexive and Preparatory Selection and Suppression of Salient Information in the Right and Left Posterior Parietal Cortex. *Journal of Cognitive Neuroscience*, 21(6), pp.1204–1214.

Available at: http://www.ncbi.nlm.nih.gov/pubmed/18752407 [Accessed February 12, 2017].

Mills, K.L. et al., 2012. Altered cortico-striatal-thalamic connectivity in relation to spatial working memory capacity in children with ADHD. *Frontiers in psychiatry*, 3, p.2. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3265767&tool=pmcentrez&rendertype=abstract [Accessed December 10, 2015].

Montague, P.R., Dayan, P. & Sejnowski, T.J., 1996. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 16(5), pp.1936–47. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8774460 [Accessed June 2, 2015].

Monuteaux, M.C. et al., 2008. A preliminary study of dopamine D4 receptor genotype and structural brain alterations in adults with ADHD. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 147B(8), pp.1436–1441. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18951431 [Accessed January 23, 2017].

Mori, S. et al., 1999. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. *Annals of neurology*, 45(2), pp.265–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9989633 [Accessed February 22, 2016].

Moseley, M.E. et al., 1990. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. *Radiology*, 176(2), pp.439–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2367658 [Accessed February 18, 2016].

Mostofsky, S.H. et al., 2002. Smaller prefrontal and premotor volumes in boys with attention-deficit/hyperactivity disorder. *Biological psychiatry*, 52(8), pp.785–94. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12372650 [Accessed March 4, 2016].

Mugler, J.P. & Brookeman, J.R., 1990. Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). *Magnetic resonance in medicine*, 15(1), pp.152–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2374495 [Accessed January 8, 2016].

Munafò, M.R. et al., 2008. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data. *Biological*

psychiatry, 63(2), pp.197–206. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17574217 [Accessed May 28, 2015].

Murray, G.K. et al., 2008. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. *Molecular psychiatry*, 13(3), pp.239, 267–76. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2564111&tool=pmce ntrez&rendertype=abstract [Accessed June 2, 2015].

Nakao, T. et al., 2011. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. *The American journal of psychiatry*, 168(11), pp.1154–63. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21865529 [Accessed July 20, 2015].

Narr, K.L. et al., 2009. Widespread cortical thinning is a robust anatomical marker for attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 48(10), pp.1014–22. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2891193&tool=pmce ntrez&rendertype=abstract [Accessed March 4, 2016].

Navarra, R. et al., 2008. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. *Progress in neuro-psychopharmacology & biological psychiatry*, 32(1), pp.34–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17714843 [Accessed September 4, 2015].

Ni, H.-C. et al., 2013. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)*, 16(9), pp.1959–73. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23672818 [Accessed February 21, 2016].

Niv, Y. et al., 2007. Tonic dopamine: opportunity costs and the control of response vigor. *Psychopharmacology*, 191(3), pp.507–20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17031711 [Accessed February 24, 2016].

O'Doherty, J.P. et al., 2003. Temporal difference models and reward-related learning in the human brain. *Neuron*, 38(2), pp.329–37. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12718865 [Accessed May 30, 2015].

Ogawa, S. et al., 1990. Brain magnetic resonance imaging with contrast dependent on

blood oxygenation. *Proceedings of the National Academy of Sciences of the United States of America*, 87(24), pp.9868–72. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=55275&tool=pmcentrez&rendertype=abstract [Accessed April 10, 2015].

Okuyama, Y. et al., 2000. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. *Molecular psychiatry*, 5(1), pp.64–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10673770 [Accessed May 28, 2015].

Parker, M.O. et al., 2014. Atomoxetine reduces anticipatory responding in a 5-choice serial reaction time task for adult zebrafish. *Psychopharmacology*, 231(13), pp.2671–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4167589&tool=pmcentrez&rendertype=abstract [Accessed November 16, 2015].

Paterson, N.E. et al., 2011. Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone. *Neuroscience research*, 69(1), pp.41–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20934466 [Accessed November 16, 2015].

Patrick, K.S. & Markowitz, J.S., 1997. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. *Human Psychopharmacology: Clinical and Experimental*, 12(6), pp.527–546. Available at: http://doi.wiley.com/10.1002/%28SICI%291099-1077%28199711/12%2912%3A6%3C527%3A%3AAID-HUP932%3E3.0.CO%3B2-U [Accessed March 21, 2016].

Perlov, E. et al., 2008. Hippocampus and amygdala morphology in adults with attention-deficit hyperactivity disorder. *Journal of psychiatry & neuroscience : JPN*, 33(6), pp.509–15. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2575764&tool=pmcentrez&rendertype=abstract [Accessed March 4, 2016].

Perry, J.L., Stairs, D.J. & Bardo, M.T., 2008. Impulsive choice and environmental enrichment: effects of d-amphetamine and methylphenidate. *Behavioural brain research*, 193(1), pp.48–54. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2681296&tool=pmce

ntrez&rendertype=abstract [Accessed May 6, 2015].

Pessiglione, M. et al., 2006. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. *Nature*, 442(7106), pp.1042–5. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2636869&tool=pmce ntrez&rendertype=abstract [Accessed May 11, 2015].

Peters, J. & Büchel, C., 2011. The neural mechanisms of inter-temporal decision-making: understanding variability. *Trends in cognitive sciences*, 15(5), pp.227–39. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21497544 [Accessed September 5, 2015].

Petersen, S.E. & Posner, M.I., 2012. The Attention System of the Human Brain: 20 Years After. *Annual Review of Neuroscience*, 35(1), pp.73–89. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22524787 [Accessed January 24, 2017].

Pizzagalli, D.A. et al., 2008. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. *Psychopharmacology*, 196(2), pp.221–32. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2268635&tool=pmce ntrez&rendertype=abstract [Accessed May 28, 2015].

Plessen, K.J. et al., 2006. Hippocampus and amygdala morphology in attention-deficit/hyperactivity disorder. *Archives of general psychiatry*, 63(7), pp.795–807. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2367150&tool=pmce ntrez&rendertype=abstract [Accessed February 10, 2016].

Plichta, M.M. & Scheres, A., 2014. Ventral-striatal responsiveness during reward anticipation in ADHD and its relation to trait impulsivity in the healthy population: a meta-analytic review of the fMRI literature. *Neuroscience and biobehavioral reviews*, 38, pp.125–34. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3989497&tool=pmce ntrez&rendertype=abstract [Accessed May 11, 2015].

Polanczyk, G. et al., 2007. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. *The American journal of psychiatry*, 164(6), pp.942–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17541055 [Accessed July 20, 2015].

Poser, B.A. et al., 2006. BOLD contrast sensitivity enhancement and artifact reduction with multiecho EPI: parallel-acquired inhomogeneity-desensitized fMRI. *Magnetic resonance in medicine*, 55(6), pp.1227–35. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16680688 [Accessed March 18, 2016].

Posner, J. et al., 2011. The attenuation of dysfunctional emotional processing with stimulant medication: An fMRI study of adolescents with ADHD. *Psychiatry Research: Neuroimaging*, 193(3), pp.151–160. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21778039 [Accessed February 22, 2017].

Proal, E. et al., 2011. Brain Gray Matter Deficits at 33-Year Follow-up in Adults With Attention-Deficit/Hyperactivity Disorder Established in Childhood. *Archives of General Psychiatry*, 68(11), pp.1122–1134. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3554238&tool=pmcentrez&rendertype=abstract [Accessed May 8, 2015].

Robbins, T., 2002. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. *Psychopharmacology*, 163(3-4), pp.362–380. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12373437 [Accessed February 20, 2017].

Robinson, E.S.J. et al., 2009. Behavioural characterisation of high impulsivity on the 5-choice serial reaction time task: specific deficits in "waiting" versus "stopping". *Behavioural brain research*, 196(2), pp.310–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18940201 [Accessed November 2, 2015].

Roeding, R.L. et al., 2014. Sex differences in adolescent methylphenidate sensitization: effects on glial cell-derived neurotrophic factor and brain-derived neurotrophic factor. *Behavioural brain research*, 273, pp.139–43. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25036427 [Accessed October 16, 2015].

Romanos, M. et al., 2010. Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. *Journal of psychiatry & neuroscience : JPN*, 35(1), pp.55–8. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2799505&tool=pmcentrez&rendertype=abstract [Accessed November 3, 2015].

Rosa Neto, P. et al., 2002. Methylphenidate-evoked potentiation of extracellular dopamine in the brain of adolescents with premature birth: correlation with attentional deficit. *Annals of the New York Academy of Sciences*, 965, pp.434–9.

Available at: http://www.ncbi.nlm.nih.gov/pubmed/12105118 [Accessed January 8, 2016].

Rosenblad, C., Kirik, D. & Björklund, A., 2000. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. *Experimental neurology*, 161(2), pp.503–16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10686072 [Accessed August 4, 2015].

Rösler, M. et al., 2004. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. *European archives of psychiatry and clinical neuroscience*, 254(6), pp.365–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15538605 [Accessed December 10, 2015].

Rossi, M.A. et al., 2013. Bidirectional modulation of substantia nigra activity by motivational state. *PloS one*, 8(8), p.e71598. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0071598 [Accessed November 16, 2015].

Roussos, P., Giakoumaki, S.G. & Bitsios, P., 2009. Cognitive and emotional processing in high novelty seeking associated with the L-DRD4 genotype. *Neuropsychologia*, 47(7), pp.1654–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19397860 [Accessed April 28, 2015].

Rowe, D.C. et al., 1998. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. *Molecular psychiatry*, 3(5), pp.419–26. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9774775 [Accessed September 22, 2015].

Rubia, K., 2011. "Cool" inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus "hot" ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review. *Biological psychiatry*, 69(12), pp.e69–87. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21094938 [Accessed February 23, 2016].

Rubia, K. et al., 2009. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task. *Neuropharmacology*, 57(7-8), pp.640–52. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19715709 [Accessed June 3, 2015].

Rushworth, M.F., Paus, T. & Sipila, P.K., 2001. Attention systems and the organization of the human parietal cortex. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 21(14), pp.5262–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11438601 [Accessed February 12, 2017].

Rutledge, R.B. et al., 2009. Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 29(48), pp.15104–14. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3376711&tool=pmcentrez&rendertype=abstract [Accessed October 22, 2015].

Sagvolden, T. et al., 2005. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. *The Behavioral and brain sciences*, 28(3), pp.397–419; discussion 419–68. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16209748 [Accessed December 28, 2015].

Sahakian, B.J. & Morein-Zamir, S., 2015. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. *The lancet. Psychiatry*, 2(4), pp.357–62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26360089 [Accessed November 17, 2015].

Scheres, A. et al., 2006. Temporal and probabilistic discounting of rewards in children and adolescents: effects of age and ADHD symptoms. *Neuropsychologia*, 44(11), pp.2092–103. Available at: http://www.sciencedirect.com/science/article/pii/S0028393205003374 [Accessed May 12, 2015].

Scheres, A. et al., 2010. Temporal reward discounting in attention-deficit/hyperactivity disorder: the contribution of symptom domains, reward magnitude, and session length. *Biological psychiatry*, 67(7), pp.641–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20034616 [Accessed May 12, 2015].

Scheres, A. et al., 2007. Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder. *Biological psychiatry*, 61(5), pp.720–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16950228 [Accessed March 11, 2015].

Scheres, A., Lee, A. & Sumiya, M., 2008. Temporal reward discounting and ADHD:

task and symptom specific effects. *Journal of neural transmission (Vienna, Austria : 1996)*, 115(2), pp.221–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17876680 [Accessed May 29, 2015].

Schiemann, J. et al., 2012. K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration. *Nature neuroscience*, 15(9), pp.1272–80. Available at: http://www.nature.com/neuro/journal/v15/n9/full/nn.3185.html#ref2 [Accessed January 13, 2016].

Schneider, M. et al., 2006. Anatomical and functional brain imaging in adult attention-deficit/hyperactivity disorder (ADHD)--a neurological view. *European archives of psychiatry and clinical neuroscience*, 256 Suppl , pp.i32–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16977550 [Accessed December 21, 2015].

Schultz, W., 1998. Predictive reward signal of dopamine neurons. *Journal of neurophysiology*, 80(1), pp.1–27. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9658025 [Accessed July 24, 2015].

Schultz, W., Dayan, P. & Montague, P.R., 1997. A neural substrate of prediction and reward. *Science (New York, N.Y.)*, 275(5306), pp.1593–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9054347 [Accessed January 5, 2015].

Schultz, W. & Dickinson, A., 2000. Neuronal coding of prediction errors. *Annual review of neuroscience*, 23, pp.473–500. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10845072 [Accessed December 7, 2014].

Schulz, K.P. et al., 2004. Response inhibition in adolescents diagnosed with attention deficit hyperactivity disorder during childhood: an event-related FMRI study. *The American journal of psychiatry*, 161(9), pp.1650–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15337656 [Accessed February 21, 2016].

Seeman, P. & Madras, B., 2002. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. *Behavioural brain research*, 130(1-2), pp.79–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11864721 [Accessed January 12, 2016].

Seeman, P. & Madras, B.K., 1998. Anti-hyperactivity medication: methylphenidate and amphetamine. *Molecular psychiatry*, 3(5), pp.386–96. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9774771 [Accessed February 9, 2016].

Seidman, L.J. et al., 2006. Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. *Biological psychiatry*, 60(10), pp.1071–80. Available at: http://www.sciencedirect.com/science/article/pii/S0006322306005658 [Accessed January 31, 2016].

Seidman, L.J. et al., 2011. Gray matter alterations in adults with attention-deficit/hyperactivity disorder identified by voxel based morphometry. *Biological psychiatry*, 69(9), pp.857–66. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3940267&tool=pmcentrez&rendertype=abstract [Accessed November 11, 2015].

Seidman, L.J., Valera, E.M. & Makris, N., 2005. Structural brain imaging of attention-deficit/hyperactivity disorder. *Biological psychiatry*, 57(11), pp.1263–72. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15949998 [Accessed June 22, 2015].

Semrud-Clikeman, M. et al., 2006. Volumetric MRI differences in treatment-naïve vs chronically treated children with ADHD. *Neurology*, 67(6), pp.1023–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17000972 [Accessed March 4, 2016].

Shaw, M. et al., 2012. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC medicine*, 10(1), p.99. Available at: http://www.biomedcentral.com/1741-7015/10/99 [Accessed October 1, 2015].

Shaw, P. et al., 2006. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. *Archives of general psychiatry*, 63(5), pp.540–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16651511 [Accessed March 4, 2016].

Shaw, P. et al., 2007. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. *Archives of general psychiatry*, 64(8), pp.921–31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17679637 [Accessed March 23, 2015].

Shaw, R., Grayson, A. & Lewis, V., 2005. Inhibition, ADHD, and computer games: the inhibitory performance of children with ADHD on computerized tasks and games. *Journal of attention disorders*, 8(4), pp.160–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16110046 [Accessed February 3, 2016].

Shim, S.-H. et al., 2008. Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). *Progress in neuro-psychopharmacology & biological psychiatry*, 32(8), pp.1824–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18760321 [Accessed October 16, 2015].

Shim, S.-H. et al., 2015. Increased levels of plasma glial-derived neurotrophic factor in children with attention deficit hyperactivity disorder. *Nordic journal of psychiatry*, pp.1–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25753832 [Accessed October 16, 2015].

Silvetti, M. et al., 2013. Deficient reinforcement learning in medial frontal cortex as a model of dopamine-related motivational deficits in ADHD. *Neural networks : the official journal of the International Neural Network Society*, 46, pp.199–209. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23811383 [Accessed May 8, 2015].

Simchon-Tenenbaum, Y., Weizman, A. & Rehavi, M., 2015. Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. *Behavioural brain research*, 282, pp.125–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25576963 [Accessed August 30, 2015].

Simon, V. et al., 2009. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *The British journal of psychiatry : the journal of mental science*, 194(3), pp.204–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19252145 [Accessed August 18, 2015].

Sled, J.G. & Pike, G.B., 2000. Quantitative interpretation of magnetization transfer in spoiled gradient echo MRI sequences. *Journal of magnetic resonance (San Diego, Calif. : 1997)*, 145(1), pp.24–36. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10873494 [Accessed March 2, 2016].

Smalley, S.L. et al., 1998. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. *Molecular psychiatry*, 3(5), pp.427–30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9774776 [Accessed May 28, 2015].

Smith, A.B. et al., 2008. Reduced activation in right lateral prefrontal cortex and anterior cingulate gyrus in medication-naïve adolescents with attention deficit hyperactivity disorder during time discrimination. *Journal of child psychology and*

psychiatry, and allied disciplines, 49(9), pp.977–85. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18759938 [Accessed February 23, 2016].

Sonuga-Barke, E.J.S. et al., 2008. Executive dysfunction and delay aversion in attention deficit hyperactivity disorder: nosologic and diagnostic implications. *Child and adolescent psychiatric clinics of North America*, 17(2), pp.367–84, ix. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18295151 [Accessed April 11, 2015].

Sonuga-Barke, E.J.S. & Castellanos, F.X., 2007. Spontaneous attentional fluctuations in impaired states and pathological conditions: a neurobiological hypothesis. *Neuroscience and biobehavioral reviews*, 31(7), pp.977–86. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17445893 [Accessed February 24, 2016].

Sonuga-Barke, E.J.S., Dalen, L. & Remington, B., 2003. Do executive deficits and delay aversion make independent contributions to preschool attention-deficit/hyperactivity disorder symptoms? *Journal of the American Academy of Child and Adolescent Psychiatry*, 42(11), pp.1335–42. Available at: http://www.sciencedirect.com/science/article/pii/S0890856709621079 [Accessed May 12, 2015].

Spencer, T.J. et al., 2013. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. *The Journal of clinical psychiatry*, 74(9), pp.902–17. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3801446&tool=pmcentrez&rendertype=abstract [Accessed January 7, 2016].

Spielberger, C., 1983. *State-Trait Anxiety Inventory*, Palo Alto, CA: Consulting Psychologists Press.

Stanley, J.A. et al., 2008. Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. *Archives of general psychiatry*, 65(12), pp.1419–28. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4446574&tool=pmcentrez&rendertype=abstract [Accessed November 26, 2015].

Steinberg, E.E. et al., 2013. A causal link between prediction errors, dopamine neurons and learning. *Nature neuroscience*, 16(7), pp.966–73. Available at:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3705924&tool=pmce ntrez&rendertype=abstract [Accessed June 2, 2015].

Steinfels, G.F. et al., 1983. Response of dopaminergic neurons in cat to auditory stimuli presented across the sleep-waking cycle. *Brain Research*, 277(1), pp.150–154. Available at: http://www.sciencedirect.com/science/article/pii/0006899383909174 [Accessed May 18, 2015].

Stoodley, C.J., 2014. Distinct regions of the cerebellum show gray matter decreases in autism, ADHD, and developmental dyslexia. *Frontiers in systems neuroscience*, 8, p.92. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4033133&tool=pmce ntrez&rendertype=abstract [Accessed March 4, 2016].

Strobel, A. et al., 1999. Association between the dopamine D4 receptor (DRD4) exon III polymorphism and measures of Novelty Seeking in a German population. *Molecular psychiatry*, 4(4), pp.378–84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10483056 [Accessed April 24, 2015].

Sutton, R.S. & Barto, A.G., 1998. Introduction to Reinforcement Learning. Available at: http://dl.acm.org/citation.cfm?id=551283 [Accessed May 6, 2015].

Tellegen, A. & Waller, N.G., 2008. Exploring personality through test construction: Development of the Multidimensional Personality Questionnaire. In G. Boyle, G. Matthew, & D. Saklofske, eds. *Handbook of Personality Theory and Testing: Vol. II. Personality Measurement and Assessment*. Greenwich, CT: JAI Press.

Thoma, P. et al., 2015. Probabilistic reward learning in adults with Attention Deficit Hyperactivity Disorder--an electrophysiological study. *Psychiatry research*, 225(1-2), pp.133–44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25467706 [Accessed January 8, 2016].

Thorell, L.B., 2007. Do delay aversion and executive function deficits make distinct contributions to the functional impact of ADHD symptoms? A study of early academic skill deficits. *Journal of Child Psychology and Psychiatry*, 48(11), pp.1061–1070. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17995481 [Accessed April 10, 2015].

Tomac, A. et al., 1995. Protection and repair of the nigrostriatal dopaminergic system

by GDNF in vivo. *Nature*, 373(6512), pp.335–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7830766 [Accessed August 26, 2015].

Tomer, R. et al., 2008. Incentive motivation is associated with striatal dopamine asymmetry. *Biological psychology*, 77(1), pp.98–101. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2413324&tool=pmce ntrez&rendertype=abstract [Accessed July 31, 2015].

Tomitaka, M. et al., 1999. Association between novelty seeking and dopamine receptor D4 (DRD4) exon III polymorphism in Japanese subjects. *American journal of medical genetics*, 88(5), pp.469–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10490700 [Accessed May 28, 2015].

Tournier, J.-D., Calamante, F. & Connelly, A., 2013. Determination of the appropriate *b* value and number of gradient directions for high-angular-resolution diffusion-weighted imaging. *NMR in Biomedicine*, 26(12), pp.1775–1786. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24038308 [Accessed January 26, 2017].

Tripp, G. & Wickens, J.R., 2008. Research Review: Dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. *Journal of Child Psychology and Psychiatry*, 49(7), pp.691–704. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18081766 [Accessed January 12, 2016].

United States Food and Drug Administration, 2013. *Adderall XR Prescribing Information*,

Vaidya, C.J. & Stollstorff, M., 2008. Cognitive neuroscience of Attention Deficit Hyperactivity Disorder: current status and working hypotheses. *Developmental disabilities research reviews*, 14(4), pp.261–7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4437560&tool=pmce ntrez&rendertype=abstract [Accessed February 23, 2016].

Vaillancourt, D.E. et al., 2009. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. *Neurology*, 72(16), pp.1378–84. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2677508&tool=pmce ntrez&rendertype=abstract [Accessed October 30, 2015].

Valera, E.M. et al., 2007. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. *Biological psychiatry*, 61(12), pp.1361–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16950217 [Accessed July 1, 2015].

Vincent, J.L. et al., 2008. Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. *Journal of neurophysiology*, 100(6), pp.3328–42. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2604839&tool=pmce ntrez&rendertype=abstract [Accessed February 23, 2016].

Volkow, N.D. et al., 2007. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. *Archives of general psychiatry*, 64(8), pp.932–40. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17679638 [Accessed May 6, 2015].

Volkow, N.D. et al., 1998. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *The American journal of psychiatry*, 155(10), pp.1325–31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9766762 [Accessed April 29, 2015].

Volkow, N.D. et al., 2009. Evaluating dopamine reward pathway in ADHD: clinical implications. *JAMA*, 302(10), pp.1084–91. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2958516&tool=pmce ntrez&rendertype=abstract [Accessed June 3, 2015].

Volkow, N.D. et al., 2005. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. *Biological psychiatry*, 57(11), pp.1410–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15950015 [Accessed December 17, 2015].

Volkow, N.D. et al., 2012. Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder. *Journal of Neuroscience*, 32(3), pp.841–849. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3350870&tool=pmce ntrez&rendertype=abstract [Accessed March 17, 2015].

Volkow, N.D. et al., 2011. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. *Molecular psychiatry*, 16(11), pp.1147–54. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3010326&tool=pmce ntrez&rendertype=abstract [Accessed June 25, 2015].

Volkow, N.D. et al., 2002. "Nonhedonic" food motivation in humans involves dopamine

in the dorsal striatum and methylphenidate amplifies this effect. *Synapse (New York, N.Y.)*, 44(3), pp.175–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11954049 [Accessed March 2, 2015].

Volkow, N.D. et al., 2001. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 21(2), p.RC121. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11160455 [Accessed May 8, 2015].

Voon, V. et al., 2014. Measuring "waiting" impulsivity in substance addictions and binge eating disorder in a novel analogue of rodent serial reaction time task. *Biological psychiatry*, 75(2), pp.148–55. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3988873&tool=pmcentrez&rendertype=abstract [Accessed May 8, 2015].

Voon, V. et al., 2015. Waiting Impulsivity: The Influence of Acute Methylphenidate and Feedback. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)*. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26136351 [Accessed September 4, 2015].

Vossel, S., Thiel, C.M. & Fink, G.R., 2006. Cue validity modulates the neural correlates of covert endogenous orienting of attention in parietal and frontal cortex. *NeuroImage*, 32(3), pp.1257–1264. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16846742 [Accessed February 12, 2017].

Waelti, P., Dickinson, A. & Schultz, W., 2001. Dopamine responses comply with basic assumptions of formal learning theory. *Nature*, 412(6842), pp.43–8. Available at: http://dx.doi.org/10.1038/35083500 [Accessed June 2, 2015].

Wall, S.C., Gu, H. & Rudnick, G., 1995. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. *Molecular pharmacology*, 47(3), pp.544–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7700252 [Accessed February 9, 2016].

Wang, G.-J. et al., 2013. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. *PloS one*, 8(5), p.e63023. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3655054&tool=pmcentrez&rendertype=abstract [Accessed October 21, 2015].

Wang, L. et al., 2009. Altered small-world brain functional networks in children with attention-deficit/hyperactivity disorder. *Human brain mapping*, 30(2), pp.638–49. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18219621 [Accessed February 23, 2016].

Weiskopf, N. & Helms, G., 2008. Multi-parameter mapping of the human brain at 1mm resolution in less than 20 minutes. In *Proceedings of the International Society for Magnetic Resonance in Medicine*.

Weyandt, L.L. et al., 2003. The internal restlessness scale: performance of college students with and without ADHD. *Journal of learning disabilities*, 36(4), pp.382–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15490909 [Accessed February 16, 2016].

Wilbertz, G. et al., 2012. Orbitofrontal reward sensitivity and impulsivity in adult attention deficit hyperactivity disorder. *NeuroImage*, 60(1), pp.353–61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22197790 [Accessed May 11, 2015].

Wilens, T.E. et al., 2003. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. *Pediatrics*, 111(1), pp.179–85. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12509574 [Accessed June 9, 2015].

Willcutt, E.G., 2012. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 9(3), pp.490–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3441936&tool=pmcentrez&rendertype=abstract [Accessed October 15, 2014].

Willcutt, E.G. et al., 2005. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. *Biological psychiatry*, 57(11), pp.1336–46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15950006 [Accessed July 10, 2014].

Williams, J. & Dayan, P., 2005. Dopamine, learning, and impulsivity: a biological account of attention-deficit/hyperactivity disorder. *Journal of child and adolescent psychopharmacology*, 15(2), pp.160–79; discussion 157–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15910202 [Accessed December 16, 2015].

Wills, T.A., Vaccaro, D. & McNamara, G., 1994. Novelty seeking, risk taking, and

related constructs as predictors of adolescent substance use: An application of Cloninger's theory. *Journal of Substance Abuse*, 6(1), pp.1–20. Available at: http://www.sciencedirect.com/science/article/pii/S0899328994900396 [Accessed September 18, 2015].

Wittmann, B.C. et al., 2008. Striatal activity underlies novelty-based choice in humans. *Neuron*, 58(6), pp.967–73. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2535823&tool=pmcentrez&rendertype=abstract [Accessed May 8, 2015].

Wodka, E.L. et al., 2007. Evidence that response inhibition is a primary deficit in ADHD. *Journal of clinical and experimental neuropsychology*, 29(4), pp.345–56. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17497558 [Accessed February 21, 2016].

Xia, S. et al., 2012. Thalamic shape and connectivity abnormalities in children with attention-deficit/hyperactivity disorder. *Psychiatry research*, 204(2-3), pp.161–7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3518751&tool=pmcentrez&rendertype=abstract [Accessed December 10, 2015].

Yeo, B.T.T. et al., 2011. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *Journal of neurophysiology*, 106(3), pp.1125–65. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3174820&tool=pmcentrez&rendertype=abstract [Accessed July 13, 2014].

Youdim, M.B. et al., 1983. Brain iron and dopamine receptor function. *Advances in biochemical psychopharmacology*, 37, pp.309–21. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6138953 [Accessed April 19, 2015].

Yu-Feng, Z. et al., 2007. Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI. *Brain and Development*, 29(2), pp.83–91. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16919409 [Accessed September 3, 2015].

Zald, D.H. et al., 2008. Midbrain Dopamine Receptor Availability Is Inversely Associated with Novelty-Seeking Traits in Humans. *Journal of Neuroscience*, 28(53), pp.14372–14378. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2748420&tool=pmce

ntrez&rendertype=abstract [Accessed October 14, 2015].

Zhang, H. et al., 2012. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage*, 61(4), pp.1000–16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22484410 [Accessed March 3, 2015].